{"253965e58c9ce706e1978988ae8fad6e5b86276f": [["In fact, this is a staple subject of social psychology that addresses the influence of loneliness or, more generally, of mood on human cognitive function, often with discrepant findings (see, e.g., [2, 3] ).", [["loneliness", "DISEASE", 87, 97], ["human", "ORGANISM", 129, 134], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134]]], ["Recent lockdowns and social restriction measures that isolated workers from their peers have placed these issues at the forefront of public attention, with news outlets reminding their customers that they do not need to be productive, and to expect a reduction in overall productivity during this time.", [["Recent lockdowns and social restriction measures", "TREATMENT", 0, 48], ["reduction", "OBSERVATION_MODIFIER", 251, 260], ["overall", "OBSERVATION_MODIFIER", 264, 271], ["productivity", "OBSERVATION", 272, 284]]], ["But why is it that productivity would decrease during a period that one would think people have more time on their hands than ever before?", [["people", "ORGANISM", 84, 90], ["people", "SPECIES", 84, 90]]]], "d934fd82446990b7be622f8be1c9a505b47f0b56": [["It is generated by electrocautery used in virtually all standard surgical facilities as a means of performing surgical dissection of various tissues.", [["tissues", "ANATOMY", 141, 148], ["tissues", "TISSUE", 141, 148], ["electrocautery", "TREATMENT", 19, 33], ["surgical dissection of various tissues", "TREATMENT", 110, 148], ["electrocautery", "OBSERVATION", 19, 33], ["surgical dissection", "OBSERVATION", 110, 129], ["various tissues", "ANATOMY", 133, 148]]], ["Electrocautery is a process in which an electrical current is passed through a resistant metal wire electrode.", [["Electrocautery", "TREATMENT", 0, 14], ["a resistant metal wire electrode", "TREATMENT", 77, 109], ["metal wire", "OBSERVATION", 89, 99]]], ["The heated electrode is then applied to the tissue for dissection or hemostasis (Pollock et al., 2008) .", [["tissue", "ANATOMY", 44, 50], ["tissue", "TISSUE", 44, 50], ["The heated electrode", "TREATMENT", 0, 20], ["dissection", "PROBLEM", 55, 65], ["electrode", "OBSERVATION_MODIFIER", 11, 20], ["tissue", "ANATOMY", 44, 50], ["dissection", "OBSERVATION", 55, 65]]], ["Given the positioning of surgical personnel over and around the surgical patient, surgical smoke is often directly in the path of their respiratory field.", [["respiratory", "ANATOMY", 136, 147], ["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["surgical personnel", "TREATMENT", 25, 43], ["surgical", "OBSERVATION", 25, 33], ["surgical smoke", "OBSERVATION", 82, 96]]], ["The Occupational Safety and Health Administration (OSHA) estimates that 500,000 workers are exposed to laser and electrocautery smoke each year (OSHA, 2007) .IN TROD UCTIONThere have been significant concerns about exposure to surgical smoke, and about the adequacy of standard surgical masks (SMs) to protect personnel in the OR.", [["standard surgical masks", "TREATMENT", 269, 292], ["significant", "OBSERVATION_MODIFIER", 188, 199]]], ["Surgical smoke contains known carcinogens as well as viable biologic particles (Barrett and Garber, 2003) .", [["carcinogens", "OBSERVATION", 30, 41]]], ["Carcinogenic and neurotoxic compounds were found in surgical smoke aerosols generated from porcine tissue as well as during human surgical procedures (Krones et al., 2007; Sahaf et al., 2007) .", [["tissue", "ANATOMY", 99, 105], ["neurotoxic", "DISEASE", 17, 27], ["porcine", "ORGANISM", 91, 98], ["tissue", "TISSUE", 99, 105], ["human", "ORGANISM", 124, 129], ["porcine", "SPECIES", 91, 98], ["human", "SPECIES", 124, 129], ["porcine", "SPECIES", 91, 98], ["human", "SPECIES", 124, 129], ["Carcinogenic and neurotoxic compounds", "PROBLEM", 0, 37], ["human surgical procedures", "TREATMENT", 124, 149], ["neurotoxic compounds", "OBSERVATION", 17, 37], ["surgical smoke", "OBSERVATION", 52, 66], ["porcine tissue", "OBSERVATION", 91, 105]]], ["A review by Biggins and Renfree (2002) reported the failure of SMs to provide appropriate protection to healthcare personnel and suggested establishing new standards to reduce the risks.", [["the failure of SMs", "PROBLEM", 48, 66]]], ["Other studies have revealed that SMs are insufficient for providing adequate protection against surgical smoke (Barrett and Garber, 2003; Alp et al., 2006) .IN TROD UCTIONExposure to surgical smoke aerosol has relevance to public health settings due to the presence of small particles.", [["Other studies", "TEST", 0, 13], ["surgical smoke aerosol", "TREATMENT", 183, 205], ["small particles", "PROBLEM", 269, 284], ["small", "OBSERVATION_MODIFIER", 269, 274], ["particles", "OBSERVATION", 275, 284]]], ["Weber et al. (1993) tested eight SMs and found that for fine particles (<1,000 nm) the penetration through these masks ranged from 20% to nearly 100%.", [["these masks", "TEST", 107, 118]]], ["Studies conducted with two SMs sealed on a manikin headform indicated that for particles of 10-80 nm in diameter (including MS2 virions), the filter penetration was 20.5-84.5% (Balazy et al., 2006a, b) .", [["Studies", "TEST", 0, 7], ["a manikin headform", "TREATMENT", 41, 59], ["MS2 virions", "TREATMENT", 124, 135], ["the filter penetration", "TEST", 138, 160]]], ["Since SMs have a comparatively poor fit, faceseal (FS) leakage represents a prominent penetration pathway.", [["SMs", "CELL", 6, 9], ["a comparatively poor fit", "PROBLEM", 15, 39], ["faceseal (FS) leakage", "PROBLEM", 41, 62], ["a prominent penetration pathway", "PROBLEM", 74, 105], ["prominent", "OBSERVATION_MODIFIER", 76, 85], ["penetration pathway", "OBSERVATION", 86, 105]]], ["This is especially true for small particles, e.g. those in the size range of influenza A virions (Booth et al., 2013) as well as virions causing Human Papilloma Virus (HPV), Severe Acute Respiratory Syndrome (SARS), and Middle East Respiratory Syndrome (MERS).IN TROD UCTIONAlthough N95 filtering facepiece respirators (FFRs) are more efficient than SMs [their N95 filter is certified by the National Institute of Occupational Safety and Health (NIOSH) to allow no more than 5% penetration], penetration of ultrafine particles (<100 nm) through some N95 FFRs may exceed this threshold (Balazy et al., 2006a) .", [["Human Papilloma Virus (HPV)", "DISEASE", 145, 172], ["Acute Respiratory Syndrome", "DISEASE", 181, 207], ["SARS", "DISEASE", 209, 213], ["Middle East Respiratory Syndrome", "DISEASE", 220, 252], ["MERS", "DISEASE", 254, 258], ["influenza A virions", "ORGANISM", 77, 96], ["Human Papilloma Virus", "ORGANISM", 145, 166], ["HPV", "ORGANISM", 168, 171], ["Human Papilloma Virus", "SPECIES", 145, 166], ["Human Papilloma Virus", "SPECIES", 145, 166], ["HPV", "SPECIES", 168, 171], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 174, 214], ["Middle East Respiratory Syndrome (MERS)", "SPECIES", 220, 259], ["small particles", "PROBLEM", 28, 43], ["influenza A virions", "PROBLEM", 77, 96], ["Human Papilloma Virus (HPV)", "PROBLEM", 145, 172], ["Severe Acute Respiratory Syndrome", "PROBLEM", 174, 207], ["SARS)", "PROBLEM", 209, 214], ["Middle East Respiratory Syndrome", "PROBLEM", 220, 252], ["their N95 filter", "TREATMENT", 355, 371], ["penetration of ultrafine particles", "TREATMENT", 492, 526], ["some N95 FFRs", "TREATMENT", 545, 558], ["small", "OBSERVATION_MODIFIER", 28, 33], ["particles", "OBSERVATION", 34, 43], ["size", "OBSERVATION_MODIFIER", 63, 67], ["influenza", "OBSERVATION", 77, 86], ["Papilloma Virus", "OBSERVATION", 151, 166], ["Severe", "OBSERVATION_MODIFIER", 174, 180], ["Acute", "OBSERVATION_MODIFIER", 181, 186], ["Respiratory Syndrome", "OBSERVATION", 187, 207], ["Middle", "ANATOMY_MODIFIER", 220, 226], ["Respiratory Syndrome", "OBSERVATION", 232, 252]]], ["The highest filter penetration values were observed for particles of 30-70 nm in diameter, which includes the size of several respiratory pathogenic virions (Zheng and Baker, 2006; Mettenleiter and Sobrino, 2008) , as well as a substantial fraction of surgical smoke particles (Bruske-Hohlfeld et al., 2008; Andreasson et al., 2009) .IN TROD UCTIONNIOSH recommends combining general room ventilation with local exhaust ventilation (LEV) to control the airborne particles generated by surgical smoke (NIOSH, 1996) .", [["LEV", "CHEMICAL", 432, 435], ["The highest filter penetration values", "TEST", 0, 37], ["particles", "TEST", 56, 65], ["several respiratory pathogenic virions", "PROBLEM", 118, 156], ["combining general room ventilation", "TREATMENT", 365, 399], ["local exhaust ventilation (LEV", "TREATMENT", 405, 435], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["filter penetration", "OBSERVATION", 12, 30], ["size", "OBSERVATION_MODIFIER", 110, 114], ["several", "OBSERVATION_MODIFIER", 118, 125], ["respiratory pathogenic virions", "OBSERVATION", 126, 156], ["surgical smoke", "OBSERVATION", 252, 266]]], ["However, due to the variability of surgical smoke and its potential hazards, the implementation of personal protective equipment (PPE) is also needed to protect healthcare workers in ORs.", [["personal protective equipment (PPE)", "TREATMENT", 99, 134]]], ["The Association for periOperative Registered Nurses (AORN) recognizes the hazard of the surgical smoke.", [["surgical smoke", "OBSERVATION", 88, 102]]], ["AORN also urges the use of PPE and evacuation and filtration of smoke through an appropriate system (AORN, 2016a,b,c) .", [["PPE", "TREATMENT", 27, 30], ["evacuation", "TREATMENT", 35, 45], ["filtration", "TREATMENT", 50, 60]]], ["They recommend using fit-tested surgical N95 FFRs or high-filtration masks to protect against surgical smoke (AORN, 2008; Benson et al., 2013) .", [["surgical N95 FFRs", "TREATMENT", 32, 49], ["high-filtration masks", "TREATMENT", 53, 74]]], ["However these recommendations are not regulatory requirements, and presently the use of N95 FFRs in ORs is primarily limited to procedures involving HPV.", [["HPV", "ORGANISM", 149, 152], ["HPV", "SPECIES", 149, 152], ["N95 FFRs", "TREATMENT", 88, 96], ["HPV", "PROBLEM", 149, 152]]], ["Overall, SMs remains the standard protection devices in ORs.", [["the standard protection devices", "TREATMENT", 21, 52]]], ["Recently, so-called 'N95 surgical mask respirators' (SMRs) have been introduced.", [["surgical mask respirators", "TREATMENT", 25, 50]]], ["Rozzi et al. (2012) investigated the absorption capabilities of organic vapor FFRs against the aromatic hydrocarbons generated in surgical smoke, but neither this nor similar investigations addressed the particulate matter component.", [["aromatic hydrocarbons", "CHEMICAL", 95, 116], ["aromatic hydrocarbons", "CHEMICAL", 95, 116], ["organic vapor FFRs", "SIMPLE_CHEMICAL", 64, 82], ["aromatic hydrocarbons", "SIMPLE_CHEMICAL", 95, 116], ["organic vapor FFRs", "TREATMENT", 64, 82], ["surgical smoke", "OBSERVATION", 130, 144], ["particulate matter", "OBSERVATION_MODIFIER", 204, 222]]], ["A higher grade FFR (N100) was pilot-studied against surgical smoke from porcine tissue (Koehler et al., 2014) .", [["tissue", "ANATOMY", 80, 86], ["porcine", "ORGANISM", 72, 79], ["tissue", "TISSUE", 80, 86], ["A higher grade FFR", "PROBLEM", 0, 18], ["pilot", "TEST", 30, 35], ["porcine tissue", "OBSERVATION", 72, 86]]], ["One of these facepieces was modified by creating a FS made of ethylene vinyl acetate foam that was affixed to the inner perimeter of the respirator, replacing the stock face seal.", [["inner perimeter", "ANATOMY", 114, 129], ["ethylene vinyl acetate", "CHEMICAL", 62, 84], ["ethylene vinyl acetate", "CHEMICAL", 62, 84], ["facepieces", "CANCER", 13, 23], ["ethylene vinyl acetate", "SIMPLE_CHEMICAL", 62, 84], ["ethylene vinyl acetate foam", "TREATMENT", 62, 89], ["the respirator", "TREATMENT", 133, 147], ["the stock face seal", "TREATMENT", 159, 178], ["respirator", "ANATOMY", 137, 147], ["stock", "OBSERVATION", 163, 168], ["face seal", "OBSERVATION", 169, 178]]], ["The modification significantly improved the respirator performance by minimizing the FS leakage.", [["the FS leakage", "PROBLEM", 81, 95], ["significantly", "OBSERVATION_MODIFIER", 17, 30], ["improved", "OBSERVATION_MODIFIER", 31, 39], ["leakage", "OBSERVATION", 88, 95]]], ["It is acknowledged that N100 FFRs have limitations for deployment in ORs due to their exhalation valve component.", [["deployment in ORs", "TREATMENT", 55, 72], ["their exhalation valve component", "PROBLEM", 80, 112], ["exhalation valve", "OBSERVATION", 86, 102]]], ["However, it is still important to generate data about the efficiency of these highest grade facepieces against surgical smoke because it will help determine the feasibility of making appropriate design modifications to other respirators, e.g. N95 SMRs (that have no exhalation valves), in order to maximize their performance.IN TROD UCTIONThe protection provided by a respirator at a workplace is typically assessed by determining its workplace protection factor (WPF) measured under specific conditions.", [["workplace protection factor", "PROTEIN", 435, 462], ["WPF", "PROTEIN", 464, 467], ["these highest grade facepieces", "PROBLEM", 72, 102], ["exhalation valves", "TREATMENT", 266, 283]]], ["One way to quantify the WPF is through the simulated workplace protection factor (SWPF).", [["WPF", "DNA", 24, 27]]], ["SWPF is measured in a controlled laboratory setting while the wearer performs exercises mimicking the actual work procedures.IN TROD UCTIONThe purpose of our study was to determine the SWPFs against surgical smoke for two SMs and two N95 SMRs (both currently approved for OR use), as well as for a conventional and newly developed N100 FFR.Respirator selectionCommercially available SMs (Model 1800NL, 3M, St. Paul, MN, and Model 14683, Kimberly Clark, Neenah, WI, USA) and N95 FFRs marketed as SMRs (Model 1860 and Model 1870, 3M, St. Paul, MN, USA) were selected for this study.", [["our study", "TEST", 154, 163], ["N100 FFR", "TEST", 331, 339], ["this study", "TEST", 569, 579]]], ["The above devices were labeled as SM1, SM2, N95 SMR1, and N95 SMR2, respectively.", [["SM1", "GENE_OR_GENE_PRODUCT", 34, 37], ["SM1", "PROTEIN", 34, 37], ["SM2", "PROTEIN", 39, 42], ["SMR1", "PROTEIN", 48, 52], ["N95 SMR2", "PROTEIN", 58, 66], ["The above devices", "TREATMENT", 0, 17], ["above devices", "OBSERVATION", 4, 17], ["SM2", "ANATOMY", 39, 42], ["N95 SMR2", "OBSERVATION", 58, 66]]], ["The SM1 and SM2 were originally designed to reduce the contamination of others in the wearer's surrounding to airborne pathogens that he/she may aerosolize during exhalation; SMs are also used to reduce the potential exposure of the wearer to blood and body fluids.", [["blood", "ANATOMY", 243, 248], ["body fluids", "ANATOMY", 253, 264], ["SM1", "GENE_OR_GENE_PRODUCT", 4, 7], ["SM2", "GENE_OR_GENE_PRODUCT", 12, 15], ["blood", "ORGANISM_SUBSTANCE", 243, 248], ["body", "ORGANISM_SUBDIVISION", 253, 257], ["fluids", "ORGANISM_SUBSTANCE", 258, 264], ["SM1", "PROTEIN", 4, 7], ["SM2", "PROTEIN", 12, 15], ["airborne pathogens", "PROBLEM", 110, 128], ["SMs", "PROBLEM", 175, 178], ["blood and body fluids", "TREATMENT", 243, 264], ["SM1", "ANATOMY", 4, 7], ["SM2", "ANATOMY", 12, 15], ["contamination", "OBSERVATION", 55, 68], ["airborne pathogens", "OBSERVATION", 110, 128]]], ["The N95 SMR1 and N95 SMR2 are intended to be deployed during laser surgery, electrocautery and other procedures which utilize powered medical instruments.", [["N95 SMR2", "GENE_OR_GENE_PRODUCT", 17, 25], ["N95 SMR1", "PROTEIN", 4, 12], ["N95 SMR2", "PROTEIN", 17, 25], ["N95 SMR2", "TREATMENT", 17, 25], ["laser surgery", "TREATMENT", 61, 74], ["electrocautery", "TREATMENT", 76, 90], ["other procedures", "TREATMENT", 95, 111], ["powered medical instruments", "TREATMENT", 126, 153]]], ["All four selected SMs and SMRs (see Table 1 ) are equipped with a malleable metallic nosepiece to form the bridge of the nose.Respirator selectionAdditionally, two higher-grade FFRs were evaluated in this study.", [["nose", "ANATOMY", 121, 125], ["nose", "ORGANISM_SUBDIVISION", 121, 125], ["a malleable metallic nosepiece", "TREATMENT", 64, 94], ["Respirator selectionAdditionally", "TEST", 126, 158], ["this study", "TEST", 200, 210], ["bridge", "ANATOMY_MODIFIER", 107, 113], ["nose", "ANATOMY", 121, 125], ["higher", "OBSERVATION_MODIFIER", 164, 170]]], ["One was an original commercially available N100 FFR (Model 8233, 3M, St. Paul, MN, USA); the other was the same FFR modified with a novel FS, labeled as FS Prototype N100 (Koehler et al., 2014) .", [["a novel FS", "TEST", 130, 140]]], ["The model of the selected N100 FFR was also shown in Table 1 .Challenge aerosolThe surgical smoke was generated by electrocautery dissection of porcine muscle tissue, as described previously by several investigators (Hensman et al., 1998; Weld et al., 2007) .", [["muscle tissue", "ANATOMY", 152, 165], ["porcine", "ORGANISM", 144, 151], ["muscle tissue", "TISSUE", 152, 165], ["N100", "DNA", 26, 30], ["Challenge aerosol", "TREATMENT", 62, 79], ["electrocautery dissection of porcine muscle tissue", "TREATMENT", 115, 165], ["surgical smoke", "OBSERVATION", 83, 97], ["electrocautery", "OBSERVATION_MODIFIER", 115, 129], ["dissection", "OBSERVATION", 130, 140], ["porcine muscle tissue", "OBSERVATION", 144, 165]]], ["A standard electrosurgical generator was used as the energy source for the cautery procedures (Valleylab Force FX, Covidien, Boulder, CO, USA).", [["A standard electrosurgical generator", "TREATMENT", 0, 36], ["the cautery procedures", "TREATMENT", 71, 93], ["Valleylab Force FX", "TREATMENT", 95, 113], ["cautery", "OBSERVATION", 75, 82]]], ["Electrocautery dissection was performed utilizing a standard electrosurgical pencil (Valleylab E2516, Covidien, Boulder, CO, USA) at a setting of 40 watts for both cutting and coagulation, using a blend mode.Challenge aerosolHuman subject selection Ten human subjects representing healthcare workers were recruited for this study: five adult males and five adult females.", [["human", "ORGANISM", 253, 258], ["human", "SPECIES", 253, 258], ["human", "SPECIES", 253, 258], ["Electrocautery dissection", "TREATMENT", 0, 25], ["a standard electrosurgical pencil", "TREATMENT", 50, 83], ["a blend mode", "TREATMENT", 195, 207], ["this study", "TEST", 319, 329], ["dissection", "OBSERVATION", 15, 25]]], ["All of the subjects except one experienced surgeon were recruited from research staff and Fit testing Prior to evaluating the respirator/mask performance in the exposure chamber with surgical smoke, the subjects underwent fit testing while wearing the two N95 SMRs and two N100 FFRs according to the OSHA fit testing protocol (OSHA 29 CFR 1910.134 ).", [["Fit testing", "TEST", 90, 101], ["the respirator/mask performance", "TREATMENT", 122, 153], ["fit testing", "TEST", 222, 233]]], ["An SM is not subject for the OSHA fit testing.", [["the OSHA fit testing", "TEST", 25, 45], ["SM", "OBSERVATION", 3, 5]]], ["After the fit testing, the subjects were introduced into the chamber for the SWPF study immediately.Challenge aerosolSodium chloride (NaCl) particles were generated using a particle generator (Model 8026, TSI Inc., Shoreview, MN, USA) to create a sufficient ambient concentration to obtain measurable protection factors with highly efficient respirators.", [["aerosolSodium chloride", "CHEMICAL", 110, 132], ["NaCl", "CHEMICAL", 134, 138], ["aerosolSodium chloride", "CHEMICAL", 110, 132], ["NaCl", "CHEMICAL", 134, 138], ["aerosolSodium chloride", "SIMPLE_CHEMICAL", 110, 132], ["NaCl) particles", "SIMPLE_CHEMICAL", 134, 149], ["the fit testing", "TEST", 6, 21], ["the SWPF study", "TEST", 73, 87], ["Challenge aerosolSodium chloride (NaCl) particles", "TREATMENT", 100, 149], ["a particle generator", "TREATMENT", 171, 191], ["a sufficient ambient concentration", "TREATMENT", 245, 279]]], ["The FF is calculated as the aerosol concentration outside of the respirator divided by its concentration inside of the respirator when a subject is performing a specific set of procedures (OSHA29 CFR 1910.134) .", [["the aerosol concentration", "TREATMENT", 24, 49], ["the respirator", "TREATMENT", 61, 75]]], ["The passing criterion of FF is 100.Experimental setupThe experimental setup is presented in Fig. 1 .", [["Experimental setup", "TREATMENT", 35, 53], ["The experimental setup", "TREATMENT", 53, 75], ["experimental setup", "OBSERVATION", 57, 75]]], ["While inside the exposure chamber (volume = 3.6 \u00d7 2.4 \u00d7 2.6 m 3 ), a subject wearing a tested respirator or SM under the test performed electrocautery dissection on a section of animal muscle tissue located on a surgical table mimicking a conventional surgical procedure.", [["muscle tissue", "ANATOMY", 185, 198], ["muscle tissue", "TISSUE", 185, 198], ["volume", "TEST", 35, 41], ["a tested respirator", "TREATMENT", 85, 104], ["electrocautery dissection", "TREATMENT", 136, 161], ["animal muscle tissue", "PROBLEM", 178, 198], ["a surgical table", "TREATMENT", 210, 226], ["a conventional surgical procedure", "TREATMENT", 237, 270], ["dissection", "OBSERVATION", 151, 161], ["muscle tissue", "ANATOMY", 185, 198]]], ["The height of the surgical table was approximately 1 m above the ground, a typical height in ORs.", [["height", "OBSERVATION_MODIFIER", 4, 10], ["surgical", "OBSERVATION", 18, 26]]], ["The choice of the surgical equipment utilized, the distance from the cautery to the test subject, and the cautery settings, were all determined by an experienced board-certified surgeon with over 10,000 h of surgical electrocautery experience.", [["the surgical equipment", "TREATMENT", 14, 36], ["the cautery", "TREATMENT", 65, 76], ["the cautery settings", "TREATMENT", 102, 122], ["surgical electrocautery experience", "TREATMENT", 208, 242], ["cautery", "OBSERVATION", 69, 76]]], ["The subjects were trained in the techniques of electrocautery dissection by the same surgeon, who was also a subject in the study.Experimental setupThe surgical smoke aerosol generated during this procedure was sampled in the breathing zone directly outside the respirator/mask (representing the inhalation exposure of an unprotected individual) as well as inside the respirator/mask (representing the inhalation exposure of a wearer).", [["electrocautery dissection", "TREATMENT", 47, 72], ["the study", "TEST", 120, 129], ["Experimental setup", "TREATMENT", 130, 148], ["The surgical smoke aerosol", "TREATMENT", 148, 174], ["this procedure", "TREATMENT", 192, 206], ["the respirator/mask", "TREATMENT", 258, 277], ["the respirator/mask", "TREATMENT", 364, 383], ["electrocautery", "OBSERVATION_MODIFIER", 47, 61], ["dissection", "OBSERVATION", 62, 72], ["surgical smoke", "OBSERVATION", 152, 166]]], ["The inrespirator sampling line was connected to the probe located inside the respirator; the ambient air sampling line was connected to the probe located at the breathing zone (Fig. 1B) .", [["The inrespirator sampling line", "TREATMENT", 0, 30], ["the respirator", "TREATMENT", 73, 87], ["the ambient air sampling line", "TREATMENT", 89, 118], ["respirator", "OBSERVATION_MODIFIER", 77, 87], ["ambient", "OBSERVATION_MODIFIER", 93, 100], ["air", "OBSERVATION", 101, 104], ["sampling line", "OBSERVATION", 105, 118], ["breathing", "ANATOMY", 161, 170], ["zone", "ANATOMY_MODIFIER", 171, 175]]], ["The inlets of the two respective sampling lines were located 6 cm from each other.", [["the two respective sampling lines", "TREATMENT", 14, 47], ["inlets", "OBSERVATION_MODIFIER", 4, 10], ["two", "OBSERVATION_MODIFIER", 18, 21], ["respective", "OBSERVATION_MODIFIER", 22, 32], ["sampling lines", "OBSERVATION", 33, 47], ["6 cm", "OBSERVATION_MODIFIER", 61, 65]]], ["The same sampling configuration was used in fit testing.", [["fit testing", "TEST", 44, 55]]], ["The aerosol concentrations and particle size distributions of the inside-and outside-sampled aerosol (C in and C out respectively) were measured by a particle size spectrometer (Nanoparticle Aerosol Monitor/ Mini Wide Range Aerosol Spectrometer, Model 1320, Grimm Technologies, Inc., Ainring, Germany) in combination with an optical particle counter (OPC) (Model 1.108, Grimm Technologies, Inc.).", [["The aerosol concentrations", "TREATMENT", 0, 26], ["a particle size spectrometer", "TREATMENT", 148, 176], ["Mini Wide Range Aerosol Spectrometer", "TREATMENT", 208, 244], ["an optical particle counter (OPC", "TREATMENT", 322, 354], ["aerosol concentrations", "OBSERVATION", 4, 26], ["particle", "OBSERVATION_MODIFIER", 31, 39], ["size", "OBSERVATION_MODIFIER", 40, 44], ["distributions", "OBSERVATION_MODIFIER", 45, 58]]], ["The inside and outside concentration measurements were controlled by a high speed two-way electromagnetic valve.", [["outside concentration measurements", "TEST", 15, 49], ["a high speed two-way electromagnetic valve", "TREATMENT", 69, 111], ["electromagnetic valve", "OBSERVATION", 90, 111]]], ["The average concentration of the two 6-min outside concentration measurements was calculated and recorded as C out .", [["concentration measurements", "TEST", 51, 77], ["average", "OBSERVATION_MODIFIER", 4, 11], ["concentration", "OBSERVATION_MODIFIER", 12, 25]]], ["The average concentration of the continuous 12-min inside concentration measurement was calculated and recorded as C in .", [["concentration measurement", "TEST", 58, 83], ["average", "OBSERVATION_MODIFIER", 4, 11], ["concentration", "OBSERVATION_MODIFIER", 12, 25]]], ["The SWPF was determined as C out /C in .", [["SWPF", "SIMPLE_CHEMICAL", 4, 8]]], ["The data were recorded in a particle size range of 25-1,150 nm.", [["The data", "TEST", 0, 8]]], ["Based on the total aerosol concentrations measured across this size range, the total protection factor (SWPF total ) was calculated.", [["total protection factor", "PROTEIN", 79, 102], ["the total aerosol concentrations", "TREATMENT", 9, 41], ["the total protection factor", "TREATMENT", 75, 102], ["size", "OBSERVATION_MODIFIER", 63, 67]]], ["Additionally, the particle size selectivity of the aerosol measurement allowed determining SWPFs for different particle sizes (SWPF dp ).", [["SWPFs", "SIMPLE_CHEMICAL", 91, 96], ["SWPFs", "PROTEIN", 91, 96], ["the aerosol measurement", "TEST", 47, 70], ["particle", "OBSERVATION_MODIFIER", 18, 26], ["size", "OBSERVATION_MODIFIER", 27, 31], ["selectivity", "OBSERVATION_MODIFIER", 32, 43], ["particle", "OBSERVATION_MODIFIER", 111, 119], ["sizes", "OBSERVATION_MODIFIER", 120, 125]]], ["These were recorded within a narrower range of 25-290 nm because the particle concentrations inside of the tested N95 and N100 FFRs were almost zero for particles larger than 290 nm.", [["N100 FFRs", "TEST", 122, 131]]], ["The corresponding mean sizes for the 10 selected channels were 25, 35, 45, 60, 85, 115, 145, 180, 265, and 290 nm.", [["The corresponding mean sizes", "TEST", 0, 28], ["mean", "OBSERVATION_MODIFIER", 18, 22], ["sizes", "OBSERVATION_MODIFIER", 23, 28], ["290 nm", "OBSERVATION_MODIFIER", 107, 113]]], ["During the smoke generation process, the exposure chamber was ventilated using a preinstalled ventilation and high-efficiency particulate air (HEPA) filtration system operating at an air exchange rate of five Air Exchanges per hour (AEH).", [["the exposure chamber", "TREATMENT", 37, 57], ["a preinstalled ventilation", "TREATMENT", 79, 105], ["high-efficiency particulate air (HEPA) filtration system", "TREATMENT", 110, 166], ["an air exchange rate", "TREATMENT", 180, 200], ["chamber", "OBSERVATION_MODIFIER", 50, 57]]], ["At the same time, some ORs operate at lower air exchange rates.", [["air exchange", "OBSERVATION", 44, 56]]], ["We have intentionally chosen a relatively low exchange rate to establish the most conservative assessment with the highest feasible concentration level of smoke particles.Data analysisThe data analysis was performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).", [["conservative assessment", "TEST", 82, 105], ["Data analysis", "TEST", 171, 184], ["The data analysis", "TEST", 184, 201], ["SAS version", "TEST", 222, 233]]], ["For each respiratory protective device (RPD), geometric mean (GM) and geometric standard deviation (GSD) of SWPF were calculated.", [["respiratory", "ANATOMY", 9, 20], ["each respiratory protective device", "TREATMENT", 4, 38], ["geometric mean (GM", "TEST", 46, 64], ["geometric standard deviation (GSD) of SWPF", "PROBLEM", 70, 112], ["standard deviation", "OBSERVATION", 80, 98]]], ["The statistical analyses were applied after performing a log-transformation of the data.", [["The statistical analyses", "TEST", 0, 24]]], ["Paired t-test was used to test the difference between different RPDs.", [["Paired t-test", "TEST", 0, 13]]], ["Two-way ANOVA was deployed to evaluate the effects of subjects and particle sizes on the size-selective SWPFs.", [["particle", "OBSERVATION_MODIFIER", 67, 75], ["sizes", "OBSERVATION_MODIFIER", 76, 81], ["size", "OBSERVATION_MODIFIER", 89, 93], ["selective", "OBSERVATION_MODIFIER", 94, 103], ["SWPFs", "OBSERVATION", 104, 109]]], ["P values below 0.05 represented a significant difference.R E SULTS A ND DISCUSS IONConcentration and particle size distribution of the surgical smoke in the breathing zone The total aerosol particle concentration measured in the breathing zone of the experienced surgeon who was exposed to the surgical smoke level ranged from 0.708 \u00d7 10 6 to 1.080 \u00d7 10 6 particles cm \u22123 (mean = 0.946 \u00d7 10 6 particles cm \u22123 and SD = 0.111 \u00d7 10 6 ), which was around 1,000 times higher than the background level.", [["P values", "TEST", 0, 8], ["a significant difference", "PROBLEM", 32, 56], ["the surgical smoke", "PROBLEM", 131, 149], ["The total aerosol particle concentration", "TREATMENT", 172, 212], ["mean", "TEST", 373, 377], ["SD", "TEST", 413, 415], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["difference", "OBSERVATION", 46, 56], ["particle", "OBSERVATION_MODIFIER", 101, 109], ["size", "OBSERVATION_MODIFIER", 110, 114], ["surgical smoke", "OBSERVATION", 135, 149], ["breathing", "ANATOMY", 157, 166], ["zone", "ANATOMY_MODIFIER", 167, 171], ["total", "OBSERVATION_MODIFIER", 176, 181], ["aerosol particle", "OBSERVATION", 182, 198]]], ["At the same time, the size-specific concentration levels were substantially below the upper threshold limits of the aerosol instrument.", [["specific concentration levels", "TEST", 27, 56], ["the aerosol instrument", "TREATMENT", 112, 134], ["size", "OBSERVATION_MODIFIER", 22, 26], ["concentration", "OBSERVATION_MODIFIER", 36, 49], ["upper threshold", "OBSERVATION_MODIFIER", 86, 101], ["aerosol instrument", "OBSERVATION", 116, 134]]], ["The particle size distributions generated in five experiments (Tests I through V) are presented in Fig. 2 .", [["particle", "OBSERVATION_MODIFIER", 4, 12], ["size", "OBSERVATION_MODIFIER", 13, 17]]], ["The curves have a similar shape; four of them peak at a particle size of 115 nm observed and one at 145 nm.", [["similar", "OBSERVATION_MODIFIER", 18, 25], ["shape", "OBSERVATION_MODIFIER", 26, 31], ["particle size", "OBSERVATION_MODIFIER", 56, 69], ["115 nm", "OBSERVATION_MODIFIER", 73, 79], ["145 nm", "OBSERVATION_MODIFIER", 100, 106]]], ["The tests with other subjects generally generated similar particle size distribution curves although the total particle concentration levels were lower, which can be attributed to their limited experience in operating the electrocautery equipment.", [["The tests", "TEST", 0, 9], ["the total particle concentration levels", "TEST", 101, 140], ["the electrocautery equipment", "TREATMENT", 218, 246], ["particle", "OBSERVATION_MODIFIER", 58, 66], ["size", "OBSERVATION_MODIFIER", 67, 71]]], ["It was noticed that some subjects did not apply the electrocautery pencil to the tissue as frequently as it was demonstrated by surgeon, which could produce a lower level of smoke.", [["tissue", "ANATOMY", 81, 87], ["tissue", "TISSUE", 81, 87], ["the electrocautery pencil", "TREATMENT", 48, 73], ["tissue", "ANATOMY", 81, 87], ["smoke", "OBSERVATION", 174, 179]]], ["With regard to the above between-subject variability and other factors influencing the aerosol concentration and particle size distribution in the breathing zone, it should be acknowledged that in an actual operating setting, electrocautery use in different surgical procedures involving various tissues would likewise have an effect on the concentration and particle size distribution of the generated surgical smoke.R E SULTS A ND DISCUSS IONThe surgical smoke particle concentration measured in this study was relatively high compared to the levels found by Hohlfeld et al. (2008) .", [["tissues", "ANATOMY", 296, 303], ["tissues", "TISSUE", 296, 303], ["other factors", "PROBLEM", 57, 70], ["the aerosol concentration", "TREATMENT", 83, 108], ["particle size distribution in the breathing zone", "PROBLEM", 113, 161], ["electrocautery", "TREATMENT", 226, 240], ["different surgical procedures", "TREATMENT", 248, 277], ["this study", "TEST", 498, 508], ["particle", "OBSERVATION_MODIFIER", 113, 121], ["size", "OBSERVATION_MODIFIER", 122, 126], ["distribution", "OBSERVATION_MODIFIER", 127, 139], ["breathing zone", "OBSERVATION", 147, 161], ["particle", "OBSERVATION_MODIFIER", 359, 367], ["size", "OBSERVATION_MODIFIER", 368, 372], ["surgical smoke", "OBSERVATION", 403, 417], ["surgical smoke", "OBSERVATION", 448, 462], ["particle", "OBSERVATION_MODIFIER", 463, 471]]], ["One explanation for the difference may be that the measurements were conducted during different surgical procedures utilizing different aerosol instruments (Hohlfeld et al. used a condensation particle counter).", [["the measurements", "TEST", 47, 63], ["different surgical procedures", "TREATMENT", 86, 115], ["different aerosol instruments", "TREATMENT", 126, 155], ["a condensation particle counter", "TREATMENT", 178, 209]]], ["Additionally, the higher concentration measured in the present study may be attributed to lower air exchange rate established in our chamber.", [["the higher concentration", "PROBLEM", 14, 38], ["lower air exchange rate", "PROBLEM", 90, 113], ["higher", "OBSERVATION_MODIFIER", 18, 24], ["concentration", "OBSERVATION_MODIFIER", 25, 38], ["may be attributed to", "UNCERTAINTY", 69, 89], ["lower", "ANATOMY_MODIFIER", 90, 95], ["air exchange", "OBSERVATION", 96, 108]]], ["It is also noted that in the quoted study the aerosol sampling was performed at the side of the anesthetist, rather than directly in front of the surgeon's mask, as in our OR setup.", [["the aerosol sampling", "TEST", 42, 62], ["the surgeon's mask", "TREATMENT", 142, 160]]], ["This greater distance from the surgeon's breathing zone may explain their findings of lower particle concentrations.", [["lower particle concentrations", "PROBLEM", 86, 115], ["greater", "OBSERVATION_MODIFIER", 5, 12], ["lower", "OBSERVATION_MODIFIER", 86, 91], ["particle concentrations", "OBSERVATION", 92, 115]]], ["While acknowledging the above differences, it is recognized that the ambient aerosol concentration level does not affect the outcome of this effort because SWPF is a non-dimensional parameter.R E SULTS A ND DISCUSS IONSimulated workplace protection factor (SWPF total ) Figure 3 presents the values of SWPF total for the six tested RPDs.", [["SWPF", "SIMPLE_CHEMICAL", 156, 160], ["the ambient aerosol concentration level", "TREATMENT", 65, 104]]], ["The SWPF total values for SM1 and SM2 were close to 1 with GM = 1.49, GSD = 1.95 (SM1), Figure 2 Particle size distribution of surgical smoke measured in the breathing zone of the board-certified surgeon (the most experienced subject). and GM = 1.76, GSD = 1.71 (SM2), indicating essentially no protection.", [["GM", "CHEMICAL", 59, 61], ["GM", "CHEMICAL", 240, 242], ["SWPF", "PROTEIN", 4, 8], ["SM1", "PROTEIN", 26, 29], ["SM2", "PROTEIN", 34, 37], ["The SWPF total values", "TEST", 0, 21], ["SM1", "TEST", 26, 29], ["SM2", "TEST", 34, 37], ["GM", "TEST", 59, 61], ["GSD", "TEST", 70, 73], ["surgical smoke", "PROBLEM", 127, 141], ["GM", "TEST", 240, 242], ["GSD", "TEST", 251, 254], ["SM2", "ANATOMY", 34, 37], ["Particle", "OBSERVATION_MODIFIER", 97, 105], ["size", "OBSERVATION_MODIFIER", 106, 110], ["distribution", "OBSERVATION_MODIFIER", 111, 123], ["surgical smoke", "OBSERVATION", 127, 141], ["no", "UNCERTAINTY", 292, 294], ["protection", "OBSERVATION", 295, 305]]], ["The difference in SWPF total between SM1 and SM2 was not significant (P > 0.05, Table 2 ).", [["SWPF", "CANCER", 18, 22], ["SM1", "GENE_OR_GENE_PRODUCT", 37, 40], ["SWPF", "PROTEIN", 18, 22], ["SM1", "PROTEIN", 37, 40], ["The difference in SWPF total between SM1", "PROBLEM", 0, 40], ["P", "TEST", 70, 71], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["SM2", "ANATOMY", 45, 48], ["not", "UNCERTAINTY", 53, 56], ["significant", "OBSERVATION_MODIFIER", 57, 68]]], ["Some particle size-selective SWPF values obtained for SMs were actually below 1, indicating that the aerosol concentrations inside the SMs were higher than outside.", [["selective SWPF values", "TEST", 19, 40], ["SMs", "TEST", 54, 57], ["the aerosol concentrations", "TREATMENT", 97, 123], ["particle", "OBSERVATION_MODIFIER", 5, 13], ["size", "OBSERVATION_MODIFIER", 14, 18], ["selective", "OBSERVATION_MODIFIER", 19, 28], ["higher", "OBSERVATION_MODIFIER", 144, 150]]], ["This counter-intuitive finding can be attributed to the fact that the same aerosol instrument was deployed alternating between the inside and outside measurements, which were conducted at different time points introducing an uncertainty, which affects the SWPF.", [["the same aerosol instrument", "TREATMENT", 66, 93]]], ["The uncertainty is particularly apparent when the SWPF is close to 1.", [["SWPF", "DNA", 50, 54]]], ["Overall, a very low efficiency of SMs observed in this study is consistent with previous reports (Dixon and Nelson, 1984; Zhuang et al., 2003; Reponen et al., 2011) .R E SULTS A ND DISCUSS IONThe SWPF total of both N95 SMRs were significantly higher than the values of SMs (P < 0.01, Table 2 ).", [["a very low efficiency of SMs", "PROBLEM", 9, 37], ["this study", "TEST", 50, 60], ["N95 SMRs", "TEST", 215, 223], ["SMs", "TEST", 269, 272], ["very", "OBSERVATION_MODIFIER", 11, 15], ["low efficiency", "OBSERVATION_MODIFIER", 16, 30], ["consistent with", "UNCERTAINTY", 64, 79]]], ["Both N95 SMRs offered a measurable level of protection: GM = 263, GSD = 2.17, and GM = 208, GSD = 2.31, respectively.", [["GM", "CHEMICAL", 56, 58], ["GM", "CHEMICAL", 82, 84], ["GM", "TEST", 56, 58], ["GSD", "TEST", 66, 69], ["GM", "TEST", 82, 84], ["GSD", "TEST", 92, 95]]], ["Their SWPF total values exceeded 100 (the fit test passing level) and, by far, exceeded 10 (the OSHA's assigned protection factor).", [["Their SWPF total values", "TEST", 0, 23]]], ["It is noted that the protection factors offered by these N95 respirators are higher than the minimum requirement for their filter material alone.", [["the protection factors", "TREATMENT", 17, 39], ["these N95 respirators", "TREATMENT", 51, 72], ["their filter material", "TREATMENT", 117, 138]]], ["The difference between SWPF total values obtained for the two N95 SMRs was not significant (P > 0.05, Table 2 ).R E SULTS A ND DISCUSS IONThe two N100 FFRs demonstrated significantlyabout an order of magnitude-higher protection compared to N95 SMRs (P < 0.01, see Table 2 ): GM = 1,089 and GSD = 2.08 for the control N100 FFR and GM = 2,199 and GSD = 2.05 for the FS Prototype N100 FFR.", [["GM", "CHEMICAL", 275, 277], ["GM", "CHEMICAL", 330, 332], ["SWPF", "CANCER", 23, 27], ["SWPF", "PROTEIN", 23, 27], ["N100 FFRs", "DNA", 146, 155], ["SWPF total values", "TEST", 23, 40], ["the two N95 SMRs", "TEST", 54, 70], ["P", "TEST", 92, 93], ["magnitude", "TEST", 200, 209], ["N95 SMRs", "TEST", 240, 248], ["GM", "TEST", 275, 277], ["GSD", "TEST", 290, 293], ["FFR", "TEST", 322, 325], ["GM", "TEST", 330, 332], ["GSD", "TEST", 345, 348], ["the FS Prototype", "TEST", 360, 376]]], ["The difference between SWPF total values obtained for the two N100 FFRs was also significant (P < 0.05, Table 2 ).", [["SWPF", "PROTEIN", 23, 27], ["SWPF total values", "TEST", 23, 40], ["the two N100 FFRs", "TEST", 54, 71], ["significant", "OBSERVATION_MODIFIER", 81, 92]]], ["Thus, the modified FS component of the N100 FFR (FS Prototype N100 FFR) was capable of significantly improving the protection provided by a highly efficient N100 FFR.", [["FS Prototype N100 FFR", "TREATMENT", 49, 70]]], ["Since the N100 FFR's design modification was concerned exclusively with the peripheral area, the difference in SWPF total can be attributed solely to the improved fit of the respirator to the user's face.R E SULTS A ND DISCUSS IONIn summary, the SWPF total results suggest that, in contrast to the NIOSH certified respiratory protection devices such as N95 and N100, SMs could not protect healthcare workers against surgical smoke in ORs.", [["peripheral area", "ANATOMY", 76, 91], ["peripheral area", "MULTI-TISSUE_STRUCTURE", 76, 91], ["N100", "DNA", 10, 14], ["respiratory protection devices", "TREATMENT", 314, 344], ["SMs", "TREATMENT", 367, 370], ["peripheral", "ANATOMY_MODIFIER", 76, 86], ["area", "ANATOMY", 87, 91]]], ["While we recognize that conventional N100 FFRs (equipped with exhalation valves) are not practical for human OR use, the data obtained with the FS prototype demonstrate the potential of the new FS technology for implementation on various types of respirators.R E SULTS A ND DISCUSS IONCorrelation between SWPF total and FF determined for N95 SMRs Two out of 10 subjects (20%) did not pass the fit test with SMR1, and 8 out of 10 (80%) did not pass it with SMR2 (FF < 100).", [["human", "ORGANISM", 103, 108], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["conventional N100 FFRs", "TREATMENT", 24, 46], ["exhalation valves", "TREATMENT", 62, 79], ["N95 SMRs", "TEST", 338, 346], ["the fit test", "TEST", 389, 401], ["SMR1", "TEST", 407, 411]]], ["In three cases out of 20 (15%), Figure 3 SWPF total for commercially available SMs and N95 SMRs widely used in ORs as well as for the new FS prototype N100 and a conventional N100 FFR (control).", [["N95 SMRs", "TREATMENT", 87, 95], ["the new FS prototype N100", "TREATMENT", 130, 155], ["a conventional N100 FFR", "TREATMENT", 160, 183]]], ["Asterisk denotes statistically significant difference (P < 0.05).", [["statistically", "OBSERVATION_MODIFIER", 17, 30], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["difference", "OBSERVATION_MODIFIER", 43, 53]]], ["Note: SM and N95 SMR data represent the GMs of 10 subjects (n = 10) while the FS Prototype N100 and Control N100 data represent the GMs of nine subjects (n = 9) since one subject did not wear the N100 FFRs appropriately. the SWPF total was below 100 (including two cases in which the subjects failed the fit test).", [["N95 SMR data", "TEST", 13, 25], ["the GMs", "TEST", 36, 43], ["the FS Prototype N100", "TREATMENT", 74, 95], ["N100 data", "TEST", 108, 117], ["the SWPF total", "TEST", 221, 235]]], ["The relationship between SWPF total and FF is presented in Fig. 4 .", [["SWPF", "PROTEIN", 25, 29], ["SWPF total and FF", "TREATMENT", 25, 42]]], ["None of the correlations (either for SMR1, or for SMR2, or for both data sets combined) were significant (P > 0.05).", [["SMR1", "PROTEIN", 37, 41], ["SMR2", "PROTEIN", 50, 54], ["SMR1", "TEST", 37, 41], ["SMR2", "TEST", 50, 54]]], ["The slopes of log(SWPF total ) against log(FF) were as follows: 0.19 for SMR1, 1.01 for SMR2, and 0.35 for the two combined; all had rather low coefficient of correlation R 2 .R E SULTS A ND DISCUSS IONAll 10 subjects wearing SMR2, and 7 out of 10 subjects wearing SMR1 produced data points above the 1:1 line, indicating that the SWPF exceeded the corresponding FF in the majority of the tests.", [["SMR1", "PROTEIN", 265, 269], ["log(SWPF total )", "TREATMENT", 14, 30], ["log(FF)", "TEST", 39, 46], ["SMR1", "TEST", 73, 77], ["SMR2", "TEST", 88, 92], ["the SWPF", "PROBLEM", 327, 335], ["the tests", "TEST", 385, 394], ["slopes", "OBSERVATION_MODIFIER", 4, 10]]], ["This suggests that while no significant correlation was found between the two factors, the FF can serve as a conservative estimate of the SWPF.R E SULTS A ND DISCUSS IONThe relationship between FF and SWPF total obtained in this study confirms the observations of Zhuang et al., who conducted fit testing on 15 workers and then assigned them, with the same respirators, to their routine jobs while measuring the WPFs.", [["this study", "TEST", 224, 234]]], ["The investigators reported lack of correlation between FF and WPF for FFs \u2265 500 (P > 0.05) (Dixon and Nelson, 1984) .", [["FF", "TEST", 55, 57], ["FFs", "TEST", 70, 73]]], ["One reason may be that the OSHA Figure 4 Correlation between SWPF total and the FF for 10 subjects wearing N95 SMRs: the lines in red and green are the regression lines fit for the corresponding data points (SMR1 and SMR2, respectively); the line in black is the regression line fit for all the data points (red and green combined).R E SULTS A ND DISCUSS IONfit testing protocol requires very specific body movements, which may not fully represent actual workplace activities.", [["body", "ANATOMY", 402, 406], ["body", "ORGANISM_SUBDIVISION", 402, 406], ["the lines", "TREATMENT", 117, 126], ["testing protocol", "TEST", 362, 378], ["regression lines", "OBSERVATION", 152, 168], ["line", "OBSERVATION_MODIFIER", 242, 246], ["black", "OBSERVATION_MODIFIER", 250, 255], ["regression line", "OBSERVATION", 263, 278]]], ["Likewise, the breathing rates may be different when a worker performs fit testing versus when he/she conducts the workplace activities.R E SULTS A ND DISCUSS IONParticle size specific simulated workplace protection factor (SWPF dp ) The protection factors offered by the six tested RPDs worn on 10 subjects are plotted in Fig. 5 against the particle sizes.", [["protection factors", "PROTEIN", 237, 255], ["The protection factors", "TREATMENT", 233, 255], ["particle", "OBSERVATION_MODIFIER", 341, 349], ["sizes", "OBSERVATION_MODIFIER", 350, 355]]], ["Each curve represents the SWPF dp data obtained for a subject wearing a specific RPD.", [["the SWPF dp data", "TEST", 22, 38], ["a specific RPD", "PROBLEM", 70, 84]]], ["A clear trend representing the effect of particle size was observed only on the two N100 FFRs.", [["clear", "OBSERVATION", 2, 7], ["particle", "OBSERVATION_MODIFIER", 41, 49], ["size", "OBSERVATION_MODIFIER", 50, 54]]], ["Statistical analysis shows that between-subject variability was a strongly significant factor affecting their SWPF dp (P < 0.01), indicating the SWPF dp varies significantly depending on the subject regardless of the type of RPDs (see Table 3 ).R E SULTS A ND DISCUSS IONIf the dominant particle penetration pathway was a filter, the SWPF would be dependent on the particle size since the filter penetration is generally sizedependent (Kulkarni et al., 2011) .", [["SWPF dp", "GENE_OR_GENE_PRODUCT", 145, 152], ["SWPF", "SIMPLE_CHEMICAL", 334, 338], ["R", "SPECIES", 245, 246], ["Statistical analysis", "TEST", 0, 20], ["the SWPF dp varies", "PROBLEM", 141, 159], ["the dominant particle penetration pathway", "TREATMENT", 274, 315], ["a filter", "TREATMENT", 320, 328], ["the filter penetration", "PROBLEM", 385, 407], ["filter", "OBSERVATION", 322, 328], ["particle size", "OBSERVATION_MODIFIER", 365, 378], ["filter penetration", "OBSERVATION", 389, 407]]], ["Electret filters used in high-efficiency respirators offer very high protection against very small particles (20-30 nm) as well as against much larger particles (>200 nm) leaving the room for the most penetrating particle size (MPPS) in-between; the exact MPPS value depends on the filter characteristics and face velocity.", [["Electret filters", "TREATMENT", 0, 16], ["high-efficiency respirators", "TREATMENT", 25, 52], ["very small particles", "PROBLEM", 88, 108], ["the exact MPPS value", "TEST", 246, 266], ["face velocity", "TEST", 309, 322], ["particle", "OBSERVATION_MODIFIER", 213, 221], ["size", "OBSERVATION_MODIFIER", 222, 226], ["filter", "OBSERVATION", 282, 288], ["face velocity", "OBSERVATION", 309, 322]]], ["This is consistent with the SWPF data shown for FS100 and N100 FFRs for which the particle size had a significant effect, indicating that an appreciable percentage of particles measured inside the respirator penetrated through the filter (relative to penetration through the FS leakage).", [["FS100", "SIMPLE_CHEMICAL", 48, 53], ["the SWPF data", "TEST", 24, 37], ["FS100", "TEST", 48, 53], ["N100 FFRs", "TEST", 58, 67], ["an appreciable percentage of particles", "PROBLEM", 138, 176], ["the filter", "TREATMENT", 227, 237], ["the FS leakage", "TREATMENT", 271, 285], ["consistent with", "UNCERTAINTY", 8, 23], ["size", "OBSERVATION_MODIFIER", 91, 95], ["significant effect", "OBSERVATION", 102, 120], ["appreciable", "OBSERVATION_MODIFIER", 141, 152], ["percentage", "OBSERVATION_MODIFIER", 153, 163], ["particles", "OBSERVATION", 167, 176], ["respirator penetrated", "OBSERVATION", 197, 218], ["filter", "OBSERVATION", 231, 237], ["leakage", "OBSERVATION", 278, 285]]], ["In contrast, if the FS leakage served as the major penetration pathway, the penetration may not be significantly affected by the particle size, at least for the essentially inertialess surgical smoke particles.", [["the FS leakage", "PROBLEM", 16, 30], ["the penetration", "PROBLEM", 72, 87], ["leakage", "OBSERVATION", 23, 30], ["particle size", "OBSERVATION_MODIFIER", 129, 142], ["surgical smoke", "OBSERVATION", 185, 199]]], ["Particle size selective SWPFs. the data suggest that most of the particles, which penetrated through an SM or an N95 SMR, utilize the FS leakage pathway.R E SULTS A ND DISCUSS IONFinally, although the present investigation specifically addressed surgical smoke, as was noted earlier, the particle sizes involved are in the same range as virions causing influenza, HPV, SARS, and MERS (Rota et al., 2003; Zheng and Baker, 2006; Zaki et al., 2012) .", [["influenza", "DISEASE", 353, 362], ["SARS", "DISEASE", 369, 373], ["HPV", "ORGANISM", 364, 367], ["HPV", "SPECIES", 364, 367], ["the data", "TEST", 31, 39], ["the FS leakage pathway", "TREATMENT", 130, 152], ["influenza", "PROBLEM", 353, 362], ["size", "OBSERVATION_MODIFIER", 9, 13], ["selective", "OBSERVATION_MODIFIER", 14, 23], ["SWPFs", "OBSERVATION", 24, 29]]], ["Since the RPDs studied here are frequently incorporated for public health use, the findings herein may have application to various public health scenarios, e.g. those involving infectious aerosols.CON CLUS IONSOur study results strongly suggest that SMs do not provide measurable protection to OR workers against surgical smoke.", [["the RPDs", "TEST", 6, 14], ["CON CLUS IONSOur study", "TEST", 197, 219]]], ["More efficient N95 SMRs are capable of reducing the inhalation exposure to surgical smoke by over two orders of magnitude (SWPF total = 208-263).", [["N95", "SIMPLE_CHEMICAL", 15, 18]]], ["Given the fact that the particle size was not a significant factor affecting the performance of SMs and SMRs, we concluded that the FS leakage was the main penetration pathway for the surgical smoke particles to enter into the tested SMs and the N95 SMRs.CON CLUS IONSThe N100 FFRs, both the control and FS Prototype versions, offered the highest protection against surgical smoke (SWPF total = 1, 199) .", [["the FS leakage", "PROBLEM", 128, 142], ["the surgical smoke particles", "TREATMENT", 180, 208], ["FS Prototype versions", "TREATMENT", 304, 325], ["particle", "OBSERVATION_MODIFIER", 24, 32], ["size", "OBSERVATION_MODIFIER", 33, 37], ["leakage", "OBSERVATION", 135, 142]]], ["In contrast to SMs and the N95 SMRs, the particle size was a significant factor affecting the performance of these N100 FFRs, which suggest that the filter penetration pathway likely dominated over the FS leakage component.CON CLUS IONSThe SWPF total obtained for the newly developed FS Prototype N100 FFR significantly exceeded that of the control N100 FFR, the difference being due to the improved fit of the FFR to the user's face.", [["the filter penetration pathway", "PROBLEM", 145, 175], ["the FS leakage component", "PROBLEM", 198, 222], ["particle", "OBSERVATION_MODIFIER", 41, 49], ["size", "OBSERVATION_MODIFIER", 50, 54], ["significant", "OBSERVATION_MODIFIER", 61, 72], ["filter penetration", "OBSERVATION", 149, 167], ["leakage", "OBSERVATION", 205, 212]]], ["This finding may have relevance to the design of N95 SMRs, as well as other RPDs, since FS leakage was the predominant pathway of smoke particle penetration in the SMRs we tested.", [["N95", "SIMPLE_CHEMICAL", 49, 52], ["RPDs", "PATHOLOGICAL_FORMATION", 76, 80], ["N95 SMRs", "PROBLEM", 49, 57], ["other RPDs", "PROBLEM", 70, 80], ["FS leakage", "PROBLEM", 88, 98], ["leakage", "OBSERVATION", 91, 98], ["smoke particle", "OBSERVATION", 130, 144]]], ["If the improvements demonstrated herein on the N100 FFRs are achievable on N95 SMRs, it would represent an important advance in the design of RPDs for OR personnel.", [["N100 FFRs", "DNA", 47, 56]]]], "4218c8d3a97c7c88653a308a055eb89b7642eba6": [["Anakinra in COVID-19: important considerations for clinical trialsThe COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 320 000 deaths as of May 19, 2020.", [["Anakinra", "CHEMICAL", 0, 8], ["acute respiratory syndrome coronavirus", "DISEASE", 109, 147], ["deaths", "DISEASE", 192, 198], ["Anakinra", "CHEMICAL", 0, 8], ["Anakinra", "SIMPLE_CHEMICAL", 0, 8], ["SARS-CoV-2", "ORGANISM", 151, 161], ["severe acute respiratory syndrome coronavirus", "SPECIES", 102, 147], ["SARS-CoV-2", "SPECIES", 151, 161], ["Anakinra in COVID", "TREATMENT", 0, 17], ["clinical trials", "TREATMENT", 51, 66], ["The COVID", "TEST", 66, 75], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 98, 147], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["respiratory syndrome", "OBSERVATION", 115, 135]]], ["COVID-19 deaths are primarily caused by acute respiratory distress syndrome (ARDS) and by a cytokine storm syndrome-ie, a state of hyperinflammation leading to multiorgan failure.", [["respiratory", "ANATOMY", 46, 57], ["multiorgan", "ANATOMY", 160, 170], ["deaths", "DISEASE", 9, 15], ["acute respiratory distress syndrome", "DISEASE", 40, 75], ["ARDS", "DISEASE", 77, 81], ["hyperinflammation", "DISEASE", 131, 148], ["multiorgan failure", "DISEASE", 160, 178], ["multiorgan", "ORGAN", 160, 170], ["cytokine", "PROTEIN", 92, 100], ["acute respiratory distress syndrome", "PROBLEM", 40, 75], ["ARDS", "PROBLEM", 77, 81], ["a cytokine storm syndrome", "PROBLEM", 90, 115], ["hyperinflammation", "PROBLEM", 131, 148], ["multiorgan failure", "PROBLEM", 160, 178], ["primarily caused", "UNCERTAINTY", 20, 36], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["respiratory distress", "OBSERVATION", 46, 66], ["ARDS", "OBSERVATION", 77, 81], ["multiorgan failure", "OBSERVATION", 160, 178]]], ["1 A recent Lancet letter 2 suggested that screening patients with COVID-19 for hyperinflammation and treating them with immunosuppressive drugs could improve mortality.", [["hyperinflammation", "DISEASE", 79, 96], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["screening", "TEST", 42, 51], ["COVID", "TEST", 66, 71], ["hyperinflammation", "PROBLEM", 79, 96], ["immunosuppressive drugs", "TREATMENT", 120, 143]]], ["Cytokine storm complicating macrophage activation syndrome associated with rheumatic disease shares considerable biochemical overlap with the hyperinflammation observed in patients with COVID-19.", [["macrophage", "ANATOMY", 28, 38], ["rheumatic disease", "DISEASE", 75, 92], ["hyperinflammation", "DISEASE", 142, 159], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["macrophage", "CELL", 28, 38], ["patients", "ORGANISM", 172, 180], ["Cytokine", "PROTEIN", 0, 8], ["patients", "SPECIES", 172, 180], ["Cytokine storm", "PROBLEM", 0, 14], ["macrophage activation syndrome", "PROBLEM", 28, 58], ["rheumatic disease", "PROBLEM", 75, 92], ["considerable biochemical overlap", "PROBLEM", 100, 132], ["the hyperinflammation", "PROBLEM", 138, 159], ["COVID", "TEST", 186, 191], ["macrophage activation syndrome", "OBSERVATION", 28, 58], ["rheumatic disease", "OBSERVATION", 75, 92], ["biochemical overlap", "OBSERVATION", 113, 132]]], ["1, 3 At the time of writing, there are ten ongoing clinical trials in COVID-19 with the drug anakinra (table).", [["anakinra", "CHEMICAL", 93, 101], ["anakinra", "SIMPLE_CHEMICAL", 93, 101], ["COVID", "TEST", 70, 75], ["the drug anakinra", "TREATMENT", 84, 101]]], ["Anakinra inhibits the proinflammatory cytokines interleukin (IL)-1\u03b1 and IL-1\u03b2 and has been used with some success to treat macrophage activation syndrome caused by various inflammatory conditions, 4, 5 and in several small studies in patients with COVID-19.", [["macrophage", "ANATOMY", 123, 133], ["Anakinra", "CHEMICAL", 0, 8], ["macrophage activation syndrome", "DISEASE", 123, 153], ["Anakinra", "CHEMICAL", 0, 8], ["Anakinra", "SIMPLE_CHEMICAL", 0, 8], ["interleukin (IL)-1\u03b1", "GENE_OR_GENE_PRODUCT", 48, 67], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 72, 77], ["macrophage", "CELL", 123, 133], ["patients", "ORGANISM", 234, 242], ["proinflammatory cytokines", "PROTEIN", 22, 47], ["interleukin (IL)-1\u03b1 and IL-1\u03b2", "PROTEIN", 48, 77], ["patients", "SPECIES", 234, 242], ["Anakinra", "TREATMENT", 0, 8], ["the proinflammatory cytokines interleukin (IL)", "TREATMENT", 18, 64], ["IL", "TREATMENT", 72, 74], ["macrophage activation syndrome", "PROBLEM", 123, 153], ["various inflammatory conditions", "PROBLEM", 164, 195], ["COVID", "TEST", 248, 253], ["proinflammatory", "OBSERVATION_MODIFIER", 22, 37], ["macrophage activation syndrome", "OBSERVATION", 123, 153], ["various", "OBSERVATION_MODIFIER", 164, 171], ["inflammatory", "OBSERVATION", 172, 184]]], ["6, 7 Here we support the rationale for targeting hyperinflammation in COVID-19 with anakinra and comment on different aspects of its use, patient selection, dosing, and outcome measures.Anakinra in COVID-19: important considerations for clinical trialsAnakinra is an immunosuppressive drug that carries the theoretical risk of harm in the wrong patient group by potentially targeting beneficial inflammation; however, positive effects might also be missed if the correct patient group is not ascertained.", [["hyperinflammation", "DISEASE", 49, 66], ["anakinra", "CHEMICAL", 84, 92], ["Anakinra", "CHEMICAL", 186, 194], ["Anakinra", "CHEMICAL", 252, 260], ["inflammation", "DISEASE", 395, 407], ["Anakinra", "CHEMICAL", 186, 194], ["Anakinra", "CHEMICAL", 252, 260], ["anakinra", "SIMPLE_CHEMICAL", 84, 92], ["patient", "ORGANISM", 138, 145], ["Anakinra", "SIMPLE_CHEMICAL", 186, 194], ["Anakinra", "SIMPLE_CHEMICAL", 252, 260], ["patient", "ORGANISM", 345, 352], ["patient", "ORGANISM", 471, 478], ["patient", "SPECIES", 138, 145], ["patient", "SPECIES", 345, 352], ["patient", "SPECIES", 471, 478], ["targeting hyperinflammation in COVID", "TREATMENT", 39, 75], ["anakinra", "TREATMENT", 84, 92], ["Anakinra in COVID", "TREATMENT", 186, 203], ["clinical trials", "TREATMENT", 237, 252], ["Anakinra", "TREATMENT", 252, 260], ["an immunosuppressive drug", "TREATMENT", 264, 289], ["beneficial inflammation", "PROBLEM", 384, 407], ["harm", "OBSERVATION", 327, 331], ["beneficial", "OBSERVATION_MODIFIER", 384, 394], ["inflammation", "OBSERVATION", 395, 407]]], ["It is important, therefore, to target treatment to individuals considered to have hyperinflammation.", [["hyperinflammation", "DISEASE", 82, 99], ["hyperinflammation", "PROBLEM", 82, 99], ["hyperinflammation", "OBSERVATION", 82, 99]]], ["Diagnostic criteria in this patient group are poorly developed and there is no consensus, as seen from the inclusion criteria listed for the ongoing anakinra trials (table) .", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["Diagnostic criteria", "TEST", 0, 19], ["the ongoing anakinra trials", "TREATMENT", 137, 164], ["no", "UNCERTAINTY", 76, 78]]], ["Although serum ferritin and IL-6 concentrations are highly specific to hyperinflammation and have been shown to be associated with a need for ventilation in patients with COVID-19, 8 they are not routinely measured in the clinical setting, a short coming that is highly relevant given the requirement to identify as many patients as possible that might benefit.", [["serum", "ANATOMY", 9, 14], ["hyperinflammation", "DISEASE", 71, 88], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["ferritin", "GENE_OR_GENE_PRODUCT", 15, 23], ["IL-6", "GENE_OR_GENE_PRODUCT", 28, 32], ["patients", "ORGANISM", 157, 165], ["patients", "ORGANISM", 321, 329], ["serum ferritin", "PROTEIN", 9, 23], ["patients", "SPECIES", 157, 165], ["patients", "SPECIES", 321, 329], ["serum ferritin", "TEST", 9, 23], ["IL", "TEST", 28, 30], ["hyperinflammation", "PROBLEM", 71, 88], ["ventilation", "TREATMENT", 142, 153], ["COVID", "TEST", 171, 176]]], ["We suggest a pragmatic approach to patient selection based on identifying patients with progressive disease and evidence of increasing inflammation.", [["inflammation", "DISEASE", 135, 147], ["patient", "ORGANISM", 35, 42], ["patients", "ORGANISM", 74, 82], ["patient", "SPECIES", 35, 42], ["patients", "SPECIES", 74, 82], ["a pragmatic approach", "TREATMENT", 11, 31], ["patient selection", "TREATMENT", 35, 52], ["progressive disease", "PROBLEM", 88, 107], ["increasing inflammation", "PROBLEM", 124, 147], ["progressive", "OBSERVATION_MODIFIER", 88, 99], ["disease", "OBSERVATION", 100, 107], ["evidence of", "UNCERTAINTY", 112, 123], ["increasing", "OBSERVATION_MODIFIER", 124, 134], ["inflammation", "OBSERVATION", 135, 147]]], ["Therefore, we pro pose using worsening lymphopenia, a marker of disease progression and severity in COVID-19, and increas ing C-reactive protein as evidence of worsening inflammation.", [["lymphopenia", "DISEASE", 39, 50], ["inflammation", "DISEASE", 170, 182], ["COVID-19", "CELL", 100, 108], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 126, 144], ["C-reactive protein", "PROTEIN", 126, 144], ["worsening lymphopenia", "PROBLEM", 29, 50], ["disease progression", "PROBLEM", 64, 83], ["severity", "TEST", 88, 96], ["COVID", "TEST", 100, 105], ["increas ing C-reactive protein", "PROBLEM", 114, 144], ["worsening inflammation", "PROBLEM", 160, 182], ["worsening", "OBSERVATION_MODIFIER", 29, 38], ["lymphopenia", "OBSERVATION", 39, 50], ["severity", "OBSERVATION_MODIFIER", 88, 96], ["reactive protein", "OBSERVATION", 128, 144], ["evidence of", "UNCERTAINTY", 148, 159], ["worsening", "OBSERVATION_MODIFIER", 160, 169], ["inflammation", "OBSERVATION", 170, 182]]], ["The dose and route of administration of anakinra is especially relevant given its short plasma half-life, with both intravenous and subcutaneous routes being considered.", [["plasma", "ANATOMY", 88, 94], ["intravenous", "ANATOMY", 116, 127], ["subcutaneous", "ANATOMY", 132, 144], ["anakinra", "CHEMICAL", 40, 48], ["anakinra", "SIMPLE_CHEMICAL", 40, 48], ["plasma", "ORGANISM_SUBSTANCE", 88, 94], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 116, 127], ["anakinra", "TREATMENT", 40, 48], ["both intravenous and subcutaneous routes", "TREATMENT", 111, 151]]], ["6, 7 While a short half-life is beneficial in limiting the drug's duration of action in case of adverse events, it also leads to large peak-trough fluctuations with an intravenous formulation.", [["intravenous", "ANATOMY", 168, 179], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 168, 179], ["adverse events", "PROBLEM", 96, 110], ["large peak-trough fluctuations", "PROBLEM", 129, 159], ["an intravenous formulation", "TREATMENT", 165, 191]]], ["Variation in dosing needs to be minimised to ensure constant and adequate bioavailability, and to avoid a detrimental rebound increase of inflammation.", [["inflammation", "DISEASE", 138, 150], ["Variation in dosing", "TREATMENT", 0, 19], ["a detrimental rebound increase of inflammation", "PROBLEM", 104, 150], ["inflammation", "OBSERVATION", 138, 150]]], ["Pharmacokinetic studies in vari ous disease states have shown that subcutaneous anakinra might ensure adequate and consistent plasma concentrations, with bioavailability ranging from 80-95%.", [["subcutaneous", "ANATOMY", 67, 79], ["plasma", "ANATOMY", 126, 132], ["anakinra", "CHEMICAL", 80, 88], ["anakinra", "SIMPLE_CHEMICAL", 80, 88], ["plasma", "ORGANISM_SUBSTANCE", 126, 132], ["Pharmacokinetic studies", "TEST", 0, 23], ["vari ous disease states", "PROBLEM", 27, 50], ["subcutaneous anakinra", "TREATMENT", 67, 88], ["bioavailability", "TEST", 154, 169], ["subcutaneous", "ANATOMY", 67, 79], ["anakinra", "OBSERVATION", 80, 88]]], ["9 to the development of peripheral oedema and poor skin perfusion.", [["skin", "ANATOMY", 51, 55], ["peripheral oedema", "DISEASE", 24, 41], ["peripheral oedema", "PATHOLOGICAL_FORMATION", 24, 41], ["skin", "ORGAN", 51, 55], ["peripheral oedema", "PROBLEM", 24, 41], ["poor skin perfusion", "PROBLEM", 46, 65], ["peripheral", "ANATOMY_MODIFIER", 24, 34], ["oedema", "OBSERVATION", 35, 41], ["poor", "OBSERVATION_MODIFIER", 46, 50], ["skin perfusion", "OBSERVATION", 51, 65]]], ["Repeated subcutaneous injections might also lead to patient discomfort.", [["subcutaneous", "ANATOMY", 9, 21], ["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["Repeated subcutaneous injections", "TREATMENT", 0, 32], ["patient discomfort", "PROBLEM", 52, 70]]], ["However, these downsides should be weighed against the considerable benefits of subcutaneous administration in the context of this pandemic, which include easy administration by any health-care professional, increased cost-effectiveness with no need for infusion pumps or equivalent, and reduced fluid load.", [["subcutaneous", "ANATOMY", 80, 92], ["fluid", "ANATOMY", 296, 301], ["subcutaneous administration", "TREATMENT", 80, 107], ["this pandemic", "PROBLEM", 126, 139], ["infusion pumps", "TREATMENT", 254, 268], ["reduced fluid load", "PROBLEM", 288, 306], ["fluid load", "OBSERVATION", 296, 306]]], ["Reduced fluid load is important as current guidelines for management of severe ARDS recommend a nega tive fluid balance of 0\u00b75-1\u00b70 L per day, 11 and the most commonly adopted mode of intravenous anakinra results in infusion of a minimum of 400 mL of fluid.", [["fluid", "ANATOMY", 8, 13], ["intravenous", "ANATOMY", 183, 194], ["ARDS", "DISEASE", 79, 83], ["anakinra", "CHEMICAL", 195, 203], ["fluid", "ORGANISM_SUBSTANCE", 8, 13], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 183, 194], ["anakinra", "SIMPLE_CHEMICAL", 195, 203], ["fluid", "ORGANISM_SUBSTANCE", 250, 255], ["Reduced fluid load", "PROBLEM", 0, 18], ["management", "TREATMENT", 58, 68], ["severe ARDS", "PROBLEM", 72, 83], ["a nega tive fluid balance", "TEST", 94, 119], ["intravenous anakinra", "TREATMENT", 183, 203], ["fluid", "PROBLEM", 250, 255], ["fluid load", "OBSERVATION", 8, 18], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["ARDS", "OBSERVATION", 79, 83]]], ["Another important consideration is the choice of how to record the success (or otherwise) of the intervention.", [["the intervention", "TREATMENT", 93, 109]]], ["It is rare for single trials to provide definitive answers, so a core set of outcomes that are reported by all trials of a given intervention are important to allow systematic reviewers to combine results in similar patient populations.", [["patient", "ORGANISM", 216, 223], ["patient", "SPECIES", 216, 223], ["a given intervention", "TREATMENT", 121, 141]]], ["12 Of the ten identified trials (table), six trials consider patients with a severe condition.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["a severe condition", "PROBLEM", 75, 93]]], ["These trials are dominated by the REMAP-CAP trial (NCT02735707), which has an open-ended recruitment and a target of 7100 patients.", [["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130]]], ["The other five trials have a total of fewer than 400 participants receiving anakinra, with no outcome common to all.", [["anakinra", "CHEMICAL", 76, 84], ["anakinra", "SIMPLE_CHEMICAL", 76, 84], ["participants", "SPECIES", 53, 65], ["anakinra", "TREATMENT", 76, 84]]], ["The other four trials include patients with less severe disease but who are hospitalised, with total recruitment around 250 participants.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["participants", "SPECIES", 124, 136], ["less severe disease", "PROBLEM", 44, 63], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["disease", "OBSERVATION", 56, 63]]], ["Only five trials explicitly mention ferritin as an outcome, which is regarded as an important parameter for assessing hyperinflammation, and these trials will report data in different ways that will preclude pooling.", [["hyperinflammation", "DISEASE", 118, 135], ["ferritin", "GENE_OR_GENE_PRODUCT", 36, 44], ["ferritin", "PROTEIN", 36, 44], ["ferritin", "TEST", 36, 44], ["hyperinflammation", "PROBLEM", 118, 135]]], ["Even without the clinical heterogeneity inherent in the range of eligibility criteria and dosing regimens under study (table), power for meaningful meta-analysis will be low.Anakinra in COVID-19: important considerations for clinical trialsAnakinra is a highly plausible drug candidate in COVID-19, but we encourage trialists to consider patient selection, dosing, and outcome measures, and, impor tantly, to ensure collection of core outcome measures for current and future trials.", [["Anakinra", "CHEMICAL", 174, 182], ["Anakinra", "CHEMICAL", 240, 248], ["Anakinra", "CHEMICAL", 174, 182], ["Anakinra", "CHEMICAL", 240, 248], ["Anakinra", "SIMPLE_CHEMICAL", 174, 182], ["Anakinra", "SIMPLE_CHEMICAL", 240, 248], ["COVID-19", "CELL", 289, 297], ["patient", "ORGANISM", 338, 345], ["patient", "SPECIES", 338, 345], ["the clinical heterogeneity", "PROBLEM", 13, 39], ["dosing regimens", "TREATMENT", 90, 105], ["meaningful meta-analysis", "TEST", 137, 161], ["Anakinra in COVID", "TREATMENT", 174, 191], ["clinical trials", "TREATMENT", 225, 240], ["Anakinra", "TREATMENT", 240, 248], ["core outcome measures", "TREATMENT", 430, 451]]]], "17ec06b3cba19451bc6ff5e399e4a46bce07e04f": [["s COVID-19 reaches every part and level of the United States (U.S.), our society's widespread inequalities will be intensely highlighted and further exacerbated.", [["s COVID", "TEST", 0, 7]]], ["The outbreak's impact will also be acutely felt by disadvantaged and underprivileged children.", [["children", "ORGANISM", 85, 93], ["children", "SPECIES", 85, 93]]], ["1 Those effects will prominently emerge in our oral healthcare system, where they will further widen glaring child oral health disparities.", [["oral", "ANATOMY", 47, 51], ["oral", "ANATOMY", 115, 119], ["oral", "ORGANISM_SUBDIVISION", 47, 51], ["oral", "ORGANISM_SUBDIVISION", 115, 119]]]], "64c4deefdb2d0fd84c18022b7212eb12abcdd47a": [["that \"herd immunity\" strategies will both compromise population health and result in cumulative burden with associated long-term complications.", [["associated long-term complications", "PROBLEM", 108, 142], ["long-term", "OBSERVATION_MODIFIER", 119, 128]]], ["At this time, consistent and persistent immune response across the entire population is speculative, and vaccine approaches have a likelihood of proving to be inadequate long-term solutions without immunomodulators and therapeutics to offset infection.", [["infection", "DISEASE", 242, 251], ["persistent immune response", "PROBLEM", 29, 55], ["vaccine", "TREATMENT", 105, 112], ["inadequate long-term solutions", "TREATMENT", 159, 189], ["immunomodulators", "TREATMENT", 198, 214], ["therapeutics", "TREATMENT", 219, 231], ["infection", "PROBLEM", 242, 251], ["persistent", "OBSERVATION_MODIFIER", 29, 39], ["immune response", "OBSERVATION", 40, 55], ["infection", "OBSERVATION", 242, 251]]], ["Additionally, considerations of appropriate epitope display, glycosylations, T cell responses, antibody responses, innate immune responses, and immune evasive techniques of the virus must be taken into account across various demographics, both with and without vaccination.", [["T cell", "ANATOMY", 77, 83], ["T cell", "CELL", 77, 83], ["glycosylations", "TEST", 61, 75], ["T cell responses", "TEST", 77, 93], ["antibody responses", "TEST", 95, 113], ["immune evasive techniques", "TREATMENT", 144, 169], ["the virus", "PROBLEM", 173, 182], ["vaccination", "TREATMENT", 261, 272]]], ["13, 14, 15, 16, 17 An ideal therapeutic strategy must take into account the root cause of infection, rather than attempting to treat specific downstream symptoms, given the measurable effects of various portions of the virus on extensive and specific cascades of physiological, intracellular and biological systems, as has been suggested with whole-interactome mass cytometry studies.", [["root", "ANATOMY", 76, 80], ["intracellular", "ANATOMY", 278, 291], ["infection", "DISEASE", 90, 99], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 278, 291], ["An ideal therapeutic strategy", "TREATMENT", 19, 48], ["infection", "PROBLEM", 90, 99], ["specific downstream symptoms", "PROBLEM", 133, 161], ["the virus", "PROBLEM", 215, 224], ["cytometry studies", "TEST", 366, 383], ["infection", "OBSERVATION", 90, 99], ["virus", "OBSERVATION", 219, 224], ["mass", "OBSERVATION", 361, 365]]], ["18 SARS-CoV-2 has evolved numerous mechanisms for cloaking itself from the innate and adaptive immune systems.", [["SARS", "DISEASE", 3, 7], ["CoV-2", "ORGANISM", 8, 13], ["cloaking itself", "PROBLEM", 50, 65]]]], "7618648cbebee253c3e4b91afde90332babffc0e": [["IntroductionThe novel coronavirus disease 2019 , caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2), that was first reported in China has quickly spread globally achieving a pandemic status, accounting for more than 1.5 million cases and close to 100,000 deaths worldwide [1, 2] .", [["coronavirus disease", "DISEASE", 22, 41], ["acute respiratory syndrome-coronavirus", "DISEASE", 66, 104], ["SARS-CoV2)", "DISEASE", 108, 118], ["deaths", "DISEASE", 274, 280], ["coronavirus", "ORGANISM", 22, 33], ["severe acute respiratory syndrome-coronavirus 2", "ORGANISM", 59, 106], ["SARS-CoV2", "ORGANISM", 108, 117], ["-coronavirus", "SPECIES", 92, 104], ["severe acute respiratory syndrome-coronavirus", "SPECIES", 59, 104], ["SARS-CoV2)", "SPECIES", 108, 118], ["The novel coronavirus disease", "PROBLEM", 12, 41], ["severe acute respiratory syndrome", "PROBLEM", 59, 92], ["coronavirus", "PROBLEM", 93, 104], ["coronavirus disease", "OBSERVATION", 22, 41], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["respiratory syndrome", "OBSERVATION", 72, 92]]], ["Viral illnesses are known to be associated with significant physical morbidity and mortality but also have significant impact on mental health.", [["Viral illnesses", "DISEASE", 0, 15], ["Viral illnesses", "PROBLEM", 0, 15], ["significant physical morbidity", "PROBLEM", 48, 78], ["illnesses", "OBSERVATION", 6, 15], ["morbidity", "OBSERVATION", 69, 78], ["significant", "OBSERVATION_MODIFIER", 107, 118]]], ["Coronavirus and influenza seropositivity has been previously shown to be associated with psychiatric findings including suicidality [3] .", [["Coronavirus", "CHEMICAL", 0, 11], ["influenza seropositivity", "DISEASE", 16, 40], ["psychiatric", "DISEASE", 89, 100], ["suicidality", "DISEASE", 120, 131], ["Coronavirus", "PROBLEM", 0, 11], ["influenza seropositivity", "PROBLEM", 16, 40], ["suicidality", "PROBLEM", 120, 131]]], ["However, the impact of COVID-19 infection on suicidal tendency has not been reported.", [["COVID-19", "CHEMICAL", 23, 31], ["infection", "DISEASE", 32, 41], ["suicidal tendency", "DISEASE", 45, 62], ["COVID-19", "ORGANISM", 23, 31], ["COVID", "TREATMENT", 23, 28], ["suicidal tendency", "PROBLEM", 45, 62], ["infection", "OBSERVATION", 32, 41]]], ["We report a case of a patient with suicidality in a patient infected with COVID-19.Case ReportA 38-year-old American man with past medical history significant for hypertension, diabetes mellitus, obesity, and cervical spine disk bulge and a past psychiatric history significant for anxiety and depression self-presented to our hospital's emergency department (ED) after a suicide attempt.", [["cervical spine disk", "ANATOMY", 209, 228], ["suicidality", "DISEASE", 35, 46], ["hypertension", "DISEASE", 163, 175], ["diabetes mellitus", "DISEASE", 177, 194], ["obesity", "DISEASE", 196, 203], ["cervical spine disk bulge", "DISEASE", 209, 234], ["psychiatric", "DISEASE", 246, 257], ["anxiety", "DISEASE", 282, 289], ["depression", "DISEASE", 294, 304], ["patient", "ORGANISM", 22, 29], ["patient", "ORGANISM", 52, 59], ["man", "ORGANISM", 117, 120], ["cervical spine", "MULTI-TISSUE_STRUCTURE", 209, 223], ["patient", "SPECIES", 22, 29], ["patient", "SPECIES", 52, 59], ["man", "SPECIES", 117, 120], ["suicidality", "PROBLEM", 35, 46], ["COVID", "TEST", 74, 79], ["hypertension", "PROBLEM", 163, 175], ["diabetes mellitus", "PROBLEM", 177, 194], ["obesity", "PROBLEM", 196, 203], ["cervical spine disk bulge", "PROBLEM", 209, 234], ["anxiety", "PROBLEM", 282, 289], ["depression", "PROBLEM", 294, 304], ["a suicide attempt", "TREATMENT", 370, 387], ["significant for", "UNCERTAINTY", 147, 162], ["hypertension", "OBSERVATION", 163, 175], ["diabetes mellitus", "OBSERVATION", 177, 194], ["obesity", "OBSERVATION", 196, 203], ["cervical spine", "ANATOMY", 209, 223], ["disk bulge", "OBSERVATION", 224, 234]]], ["He ingested 10-15 tablets of baclofen 10 mg each prior to arrival.", [["baclofen", "CHEMICAL", 29, 37], ["baclofen", "CHEMICAL", 29, 37], ["He", "ORGANISM", 0, 2], ["baclofen", "SIMPLE_CHEMICAL", 29, 37], ["baclofen", "TREATMENT", 29, 37]]], ["The patient reported suicidal ideation with intent after suicidal behavior with possible injuries.", [["suicidal ideation", "DISEASE", 21, 38], ["suicidal behavior", "DISEASE", 57, 74], ["injuries", "DISEASE", 89, 97], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["suicidal ideation", "PROBLEM", 21, 38], ["suicidal behavior", "PROBLEM", 57, 74], ["injuries", "PROBLEM", 89, 97]]], ["Apart from worsening depression and active suicidal ideation with intent, he complained of recent worsening of headaches, neck pain, \"feeling warm,\" and mild nausea.", [["neck", "ANATOMY", 122, 126], ["depression", "DISEASE", 21, 31], ["suicidal ideation", "DISEASE", 43, 60], ["headaches", "DISEASE", 111, 120], ["neck pain", "DISEASE", 122, 131], ["nausea", "DISEASE", 158, 164], ["neck", "ORGANISM_SUBDIVISION", 122, 126], ["worsening depression", "PROBLEM", 11, 31], ["active suicidal ideation", "PROBLEM", 36, 60], ["headaches", "PROBLEM", 111, 120], ["neck pain", "PROBLEM", 122, 131], ["warm", "PROBLEM", 142, 146], ["mild nausea", "PROBLEM", 153, 164], ["worsening", "OBSERVATION_MODIFIER", 11, 20], ["depression", "OBSERVATION", 21, 31], ["active", "OBSERVATION_MODIFIER", 36, 42], ["worsening", "OBSERVATION_MODIFIER", 98, 107], ["headaches", "OBSERVATION", 111, 120], ["neck", "ANATOMY", 122, 126], ["pain", "OBSERVATION", 127, 131], ["mild", "OBSERVATION_MODIFIER", 153, 157], ["nausea", "OBSERVATION", 158, 164]]], ["Patient denied prior history of any suicide attempts, homicidal ideation, psychosis, or manic symptoms.", [["homicidal ideation", "DISEASE", 54, 72], ["psychosis", "DISEASE", 74, 83], ["manic", "DISEASE", 88, 93], ["Patient", "SPECIES", 0, 7], ["any suicide attempts", "PROBLEM", 32, 52], ["homicidal ideation", "PROBLEM", 54, 72], ["psychosis", "PROBLEM", 74, 83], ["manic symptoms", "PROBLEM", 88, 102]]], ["The patient had seen a psychiatrist two months prior and denied depressive symptoms at that time.", [["depressive symptoms", "DISEASE", 64, 83], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["depressive symptoms", "PROBLEM", 64, 83]]], ["He reported three prior psychiatric hospitalizations for worsening mood symptoms, once requiring electroconvulsive therapy (ECT).", [["psychiatric", "DISEASE", 24, 35], ["mood symptoms", "DISEASE", 67, 80], ["worsening mood symptoms", "PROBLEM", 57, 80], ["electroconvulsive therapy", "TREATMENT", 97, 122]]], ["The patient reported medication adherence that providers confirmed with pharmacy.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["The patient recently moved in with his cousin in Iowa and was single.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Liabilities included recent move, physical illness complaints, living situation, and chronic mental illness.", [["physical illness complaints", "DISEASE", 34, 61], ["chronic mental illness", "DISEASE", 85, 107], ["physical illness complaints", "PROBLEM", 34, 61], ["chronic mental illness", "PROBLEM", 85, 107], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["mental illness", "OBSERVATION", 93, 107]]], ["Of note, the patient reported two paternal family members who completed suicide as well as maternal and paternal family history of depression.Case ReportIn the emergency department, the patient's vitals were temperature 99.5\u00b0F (37.5\u00b0C), blood pressure 107/60, respiratory rate 18 breaths/min, and oxygen saturation 97%.", [["blood", "ANATOMY", 237, 242], ["depression", "DISEASE", 131, 141], ["oxygen", "CHEMICAL", 297, 303], ["oxygen", "CHEMICAL", 297, 303], ["patient", "ORGANISM", 13, 20], ["patient", "ORGANISM", 186, 193], ["blood", "ORGANISM_SUBSTANCE", 237, 242], ["oxygen", "SIMPLE_CHEMICAL", 297, 303], ["patient", "SPECIES", 13, 20], ["patient", "SPECIES", 186, 193], ["depression", "PROBLEM", 131, 141], ["the patient's vitals", "TEST", 182, 202], ["temperature", "TEST", 208, 219], ["C", "TEST", 233, 234], ["blood pressure", "TEST", 237, 251], ["respiratory rate", "TEST", 260, 276], ["breaths/min", "TEST", 280, 291], ["oxygen saturation", "TEST", 297, 314], ["depression", "OBSERVATION", 131, 141]]], ["He was tachycardic with HR 123 beats per minute.", [["He", "ORGANISM", 0, 2], ["tachycardic", "PROBLEM", 7, 18], ["HR", "TEST", 24, 26]]], ["The patient's physical exam was normal both in the emergency department and during the initial history and physical except tachycardia.", [["tachycardia", "DISEASE", 123, 134], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["The patient's physical exam", "TEST", 0, 27], ["tachycardia", "PROBLEM", 123, 134], ["normal", "OBSERVATION", 32, 38]]], ["Significant laboratory data in the ED showed thrombocytopenia with platelets 11 \u00d7 10 3 A few hours after admission, the patient was noted to be febrile with temperature measured 101.3\u00b0F (38.5\u00b0C).", [["platelets", "ANATOMY", 67, 76], ["thrombocytopenia", "DISEASE", 45, 61], ["febrile", "DISEASE", 144, 151], ["platelets", "CELL", 67, 76], ["patient", "ORGANISM", 120, 127], ["platelets", "CELL_TYPE", 67, 76], ["patient", "SPECIES", 120, 127], ["Significant laboratory data", "TEST", 0, 27], ["thrombocytopenia", "PROBLEM", 45, 61], ["platelets", "TEST", 67, 76], ["febrile", "PROBLEM", 144, 151], ["temperature", "TEST", 157, 168], ["thrombocytopenia", "OBSERVATION", 45, 61], ["febrile", "OBSERVATION", 144, 151]]], ["On repeat questioning, he admitted to a mild dry cough over the last 12 hours.", [["dry cough", "DISEASE", 45, 54], ["a mild dry cough", "PROBLEM", 38, 54], ["mild", "OBSERVATION_MODIFIER", 40, 44], ["dry", "OBSERVATION_MODIFIER", 45, 48], ["cough", "OBSERVATION", 49, 54]]], ["Medicine service was consulted, and the patient was transferred to the general medical floor.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47]]], ["Given his symptoms, a nasopharyngeal swab was sent as part of COVID-19 surveillance, which came back positive for SARS-CoV-2 on polymerase chain reaction (PCR) assay.", [["nasopharyngeal swab", "ANATOMY", 22, 41], ["nasopharyngeal swab", "CANCER", 22, 41], ["SARS-CoV", "SPECIES", 114, 122], ["his symptoms", "PROBLEM", 6, 18], ["a nasopharyngeal swab", "TEST", 20, 41], ["COVID", "TEST", 62, 67], ["surveillance", "TEST", 71, 83], ["SARS", "PROBLEM", 114, 118], ["CoV", "TEST", 119, 122], ["polymerase chain reaction", "TEST", 128, 153], ["PCR", "TEST", 155, 158], ["nasopharyngeal", "ANATOMY", 22, 36]]], ["The patient was put in an isolation room, and proper precautions were taken to prevent spread to healthcare workers.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["proper precautions", "TREATMENT", 46, 64]]], ["However, the situation was challenging due to inability to perform comforting measures like hand holding and engage in conversations from close distance.", [["hand", "ANATOMY", 92, 96], ["hand", "ORGANISM_SUBDIVISION", 92, 96], ["comforting measures", "TREATMENT", 67, 86]]], ["The patient was discharged on day 5 for self-quarantine at home.DiscussionThis case describes a patient with known anxiety and depression who was admitted for a suicide attempt and was diagnosed with COVID-19 infection during the same hospitalization.", [["anxiety", "DISEASE", 115, 122], ["depression", "DISEASE", 127, 137], ["infection", "DISEASE", 209, 218], ["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 96, 103], ["known anxiety", "PROBLEM", 109, 122], ["depression", "PROBLEM", 127, 137], ["a suicide attempt", "PROBLEM", 159, 176], ["COVID-19 infection", "PROBLEM", 200, 218], ["infection", "OBSERVATION", 209, 218]]], ["The patient had no prior history of suicide attempt prior to this encounter.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["suicide attempt", "PROBLEM", 36, 51]]], ["To the best of our knowledge, this is among the first reports of suicidal ideation in a patient with COVID-19 infection from the United States.DiscussionCOVID-19 has been demonstrated to be associated with high morbidity and mortality.", [["suicidal ideation", "DISEASE", 65, 82], ["COVID-19 infection", "DISEASE", 101, 119], ["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["suicidal ideation", "PROBLEM", 65, 82], ["COVID-19 infection", "PROBLEM", 101, 119], ["high morbidity and mortality", "PROBLEM", 206, 234], ["infection", "OBSERVATION", 110, 119]]], ["The three most common symptoms reported by patients infected with COVID-19 are fever, cough, and dyspnea.", [["fever", "DISEASE", 79, 84], ["cough", "DISEASE", 86, 91], ["dyspnea", "DISEASE", 97, 104], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["common symptoms", "PROBLEM", 15, 30], ["COVID", "TEST", 66, 71], ["fever", "PROBLEM", 79, 84], ["cough", "PROBLEM", 86, 91], ["dyspnea", "PROBLEM", 97, 104], ["cough", "OBSERVATION", 86, 91], ["dyspnea", "OBSERVATION", 97, 104]]], ["Less common symptoms are myalgia, anorexia, malaise, sore throat, nasal congestion, and headache.", [["nasal", "ANATOMY", 66, 71], ["myalgia", "DISEASE", 25, 32], ["anorexia", "DISEASE", 34, 42], ["sore throat", "DISEASE", 53, 64], ["nasal congestion", "DISEASE", 66, 82], ["headache", "DISEASE", 88, 96], ["nasal", "ORGANISM_SUBDIVISION", 66, 71], ["Less common symptoms", "PROBLEM", 0, 20], ["myalgia", "PROBLEM", 25, 32], ["anorexia", "PROBLEM", 34, 42], ["malaise", "PROBLEM", 44, 51], ["sore throat", "PROBLEM", 53, 64], ["nasal congestion", "PROBLEM", 66, 82], ["headache", "PROBLEM", 88, 96], ["myalgia", "OBSERVATION", 25, 32], ["anorexia", "OBSERVATION", 34, 42], ["malaise", "OBSERVATION", 44, 51], ["sore throat", "ANATOMY", 53, 64], ["nasal", "ANATOMY", 66, 71], ["congestion", "OBSERVATION", 72, 82], ["headache", "OBSERVATION", 88, 96]]], ["Symptoms may appear in as few as two days or can take as long as 14 days after exposure.", [["Symptoms", "PROBLEM", 0, 8]]], ["Anecdotally, mental disorders have been linked to infection with common respiratory viruses [4] .", [["infection", "DISEASE", 50, 59], ["respiratory viruses", "DISEASE", 72, 91], ["mental disorders", "PROBLEM", 13, 29], ["infection", "PROBLEM", 50, 59], ["common respiratory viruses", "PROBLEM", 65, 91], ["infection", "OBSERVATION", 50, 59], ["respiratory viruses", "OBSERVATION", 72, 91]]], ["However, only influenza B has been reported to be associated with suicide attempt in patients with coexisting mood disorders [3] .DiscussionCoronaviruses are negatively stranded RNA viruses, with the capacity of rapid mutation and recombination.", [["influenza B", "DISEASE", 14, 25], ["mood disorders", "DISEASE", 110, 124], ["influenza B", "ORGANISM", 14, 25], ["patients", "ORGANISM", 85, 93], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 140, 153], ["patients", "SPECIES", 85, 93], ["influenza B", "PROBLEM", 14, 25], ["coexisting mood disorders", "PROBLEM", 99, 124], ["Coronaviruses", "PROBLEM", 140, 153], ["negatively stranded RNA viruses", "PROBLEM", 158, 189], ["rapid mutation", "PROBLEM", 212, 226], ["RNA viruses", "OBSERVATION", 178, 189]]], ["Generally, two proposed pathophysiologic mechanisms explain the bidirectional relationship between viral illness and psychiatric illness.", [["viral illness", "DISEASE", 99, 112], ["psychiatric illness", "DISEASE", 117, 136], ["viral illness", "PROBLEM", 99, 112], ["psychiatric illness", "PROBLEM", 117, 136]]], ["First, the virus can be directly toxic to the brain.", [["brain", "ANATOMY", 46, 51], ["brain", "ORGAN", 46, 51], ["the virus", "PROBLEM", 7, 16], ["virus", "OBSERVATION", 11, 16], ["brain", "ANATOMY", 46, 51]]], ["They are capable of replication within the nervous system; the presence of viral RNA has been previously demonstrated in the brain tissue of patients with multiple sclerosis [5, 6] .", [["nervous system", "ANATOMY", 43, 57], ["brain tissue", "ANATOMY", 125, 137], ["multiple sclerosis", "DISEASE", 155, 173], ["nervous system", "ANATOMICAL_SYSTEM", 43, 57], ["brain tissue", "TISSUE", 125, 137], ["patients", "ORGANISM", 141, 149], ["viral RNA", "RNA", 75, 84], ["patients", "SPECIES", 141, 149], ["viral RNA", "PROBLEM", 75, 84], ["multiple sclerosis", "PROBLEM", 155, 173], ["replication", "OBSERVATION", 20, 31], ["nervous system", "ANATOMY", 43, 57], ["viral RNA", "OBSERVATION", 75, 84], ["brain tissue", "ANATOMY", 125, 137], ["multiple", "OBSERVATION_MODIFIER", 155, 163], ["sclerosis", "OBSERVATION", 164, 173]]], ["Common respiratory viruses such coronaviruses and influenza viruses are neurotropic and have also been isolated from the central nervous system [7] .DiscussionSecondly, the immune response generated by the host in response to viral illness can also affect mood disorders through indirect neurological effects [8] .", [["central nervous system", "ANATOMY", 121, 143], ["neurological", "ANATOMY", 288, 300], ["influenza viruses", "DISEASE", 50, 67], ["viral illness", "DISEASE", 226, 239], ["mood disorders", "DISEASE", 256, 270], ["coronaviruses", "ORGANISM", 32, 45], ["influenza viruses", "ORGANISM", 50, 67], ["central nervous system", "ANATOMICAL_SYSTEM", 121, 143], ["Common respiratory viruses", "PROBLEM", 0, 26], ["coronaviruses", "PROBLEM", 32, 45], ["influenza viruses", "PROBLEM", 50, 67], ["viral illness", "PROBLEM", 226, 239], ["mood disorders", "PROBLEM", 256, 270], ["indirect neurological effects", "PROBLEM", 279, 308], ["respiratory viruses", "OBSERVATION", 7, 26], ["influenza viruses", "OBSERVATION", 50, 67], ["central nervous", "ANATOMY", 121, 136]]], ["Most of the symptoms are thought to be related to the effect of specific cytokines, including tumor necrosis factor alpha, interleukin 6 and 8, and interferon alpha.", [["tumor", "DISEASE", 94, 99], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 94, 121], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 123, 136], ["8", "GENE_OR_GENE_PRODUCT", 141, 142], ["interferon alpha", "GENE_OR_GENE_PRODUCT", 148, 164], ["cytokines", "PROTEIN", 73, 82], ["tumor necrosis factor alpha", "PROTEIN", 94, 121], ["interleukin 6 and 8", "PROTEIN", 123, 142], ["interferon alpha", "PROTEIN", 148, 164], ["the symptoms", "PROBLEM", 8, 20], ["specific cytokines", "PROBLEM", 64, 82], ["tumor necrosis factor alpha", "PROBLEM", 94, 121], ["interleukin", "TEST", 123, 134], ["interferon alpha", "PROBLEM", 148, 164], ["tumor", "OBSERVATION_MODIFIER", 94, 99], ["necrosis", "OBSERVATION", 100, 108]]], ["These immune responses ultimately result in a systemic inflammatory process like the physiological consequences of stress and mood disorders.", [["mood disorders", "DISEASE", 126, 140], ["a systemic inflammatory process", "PROBLEM", 44, 75], ["stress", "PROBLEM", 115, 121], ["mood disorders", "PROBLEM", 126, 140], ["systemic", "OBSERVATION_MODIFIER", 46, 54], ["inflammatory", "OBSERVATION", 55, 67]]], ["The immune response to coronavirus involves cellmediated and humoral-mediated immunities, with production of antibodies, interferon, and cytokines.", [["coronavirus", "ORGANISM", 23, 34], ["interferon", "GENE_OR_GENE_PRODUCT", 121, 131], ["antibodies", "PROTEIN", 109, 119], ["interferon", "PROTEIN", 121, 131], ["cytokines", "PROTEIN", 137, 146], ["coronavirus", "PROBLEM", 23, 34], ["production of antibodies", "PROBLEM", 95, 119], ["interferon", "TREATMENT", 121, 131], ["cytokines", "TREATMENT", 137, 146]]], ["Increased level of antibodies to prior existing strains of coronavirus has been described in a case report in a patient with recent onset of mental illness [9] .DiscussionSymptoms such fatigue, lack of appetite, decrease of social interaction, and loss of interest can be seen in both scenarios [10] .", [["coronavirus", "DISEASE", 59, 70], ["mental illness", "DISEASE", 141, 155], ["fatigue", "DISEASE", 185, 192], ["coronavirus", "ORGANISM", 59, 70], ["patient", "ORGANISM", 112, 119], ["antibodies", "PROTEIN", 19, 29], ["patient", "SPECIES", 112, 119], ["Increased level of antibodies", "PROBLEM", 0, 29], ["coronavirus", "PROBLEM", 59, 70], ["mental illness", "PROBLEM", 141, 155], ["fatigue", "PROBLEM", 185, 192], ["lack of appetite", "PROBLEM", 194, 210], ["coronavirus", "OBSERVATION", 59, 70]]], ["However, the common symptoms of depression such as hopelessness, worthlessness, guilt, and suicidal ideation are typically not seen in infectious processes alone.", [["depression", "DISEASE", 32, 42], ["hopelessness", "DISEASE", 51, 63], ["worthlessness", "DISEASE", 65, 78], ["guilt", "DISEASE", 80, 85], ["suicidal ideation", "DISEASE", 91, 108], ["the common symptoms", "PROBLEM", 9, 28], ["depression", "PROBLEM", 32, 42], ["hopelessness", "PROBLEM", 51, 63], ["worthlessness", "PROBLEM", 65, 78], ["guilt", "PROBLEM", 80, 85], ["suicidal ideation", "PROBLEM", 91, 108], ["depression", "OBSERVATION", 32, 42], ["infectious", "OBSERVATION", 135, 145]]], ["High stress, negative affect, and depression reduce cellmediated immunity, ultimately predisposing to other illnesses such as viral illness.", [["depression", "DISEASE", 34, 44], ["viral illness", "DISEASE", 126, 139], ["High stress", "PROBLEM", 0, 11], ["depression", "PROBLEM", 34, 44], ["other illnesses", "PROBLEM", 102, 117], ["viral illness", "PROBLEM", 126, 139], ["stress", "OBSERVATION", 5, 11], ["negative affect", "OBSERVATION_MODIFIER", 13, 28]]], ["This creates concern of selfperpetuating illness during the current COVID-19 pandemic.DiscussionRecent Chinese publications have expressed concerns regarding clusters of COVID-19 breakouts among those with mental illness [11] .", [["illness", "DISEASE", 213, 220], ["selfperpetuating illness", "PROBLEM", 24, 48], ["the current COVID", "TEST", 56, 73], ["pandemic", "PROBLEM", 77, 85], ["concern of", "UNCERTAINTY", 13, 23], ["selfperpetuating", "OBSERVATION_MODIFIER", 24, 40], ["illness", "OBSERVATION", 41, 48]]], ["China has also found increased rates of negative emotions such as anxiety and depression and decreased positive emotion during the country's epidemic [12] .", [["anxiety", "DISEASE", 66, 73], ["depression", "DISEASE", 78, 88], ["increased rates of negative emotions", "PROBLEM", 21, 57], ["anxiety", "PROBLEM", 66, 73], ["depression", "PROBLEM", 78, 88], ["decreased positive emotion", "PROBLEM", 93, 119], ["increased", "OBSERVATION_MODIFIER", 21, 30]]], ["Social isolation, stress over the pandemic, and negative emotions make individuals more susceptible to COVID-19 infection by enhancing a stress-related immunocompromised state, which can further contribute to worsening mood symptoms.", [["pandemic", "DISEASE", 34, 42], ["infection", "DISEASE", 112, 121], ["COVID-19", "ORGANISM", 103, 111], ["COVID-19", "SPECIES", 103, 111], ["COVID-19 infection", "PROBLEM", 103, 121], ["a stress-related immunocompromised state", "PROBLEM", 135, 175], ["worsening mood symptoms", "PROBLEM", 209, 232]]], ["Financial burden, unemployment, and domestic abuse can be some of the reasons related to increase in suicidal tendencies with COVID-19 [13] .", [["domestic abuse", "DISEASE", 36, 50], ["COVID-19", "CHEMICAL", 126, 134], ["increase in suicidal tendencies", "PROBLEM", 89, 120], ["COVID", "TEST", 126, 131]]], ["Also, the infodemic of fake news and misinformation can make people fearful of symptoms and increase stress.", [["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["symptoms", "PROBLEM", 79, 87], ["increase stress", "PROBLEM", 92, 107]]], ["Our patient had multiple life stressors prior to worsening depressive symptoms and suicide attempt as well as prior to emergence of COVID-19 symptoms.", [["depressive symptoms", "DISEASE", 59, 78], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["worsening depressive symptoms", "PROBLEM", 49, 78], ["suicide attempt", "PROBLEM", 83, 98], ["COVID-19 symptoms", "PROBLEM", 132, 149]]], ["In the first reported case in literature, a male from Bangladesh was deemed to have committed suicide due to concerns that he had COVID-19 infection and social ostracization [14] .", [["COVID-19", "CHEMICAL", 130, 138], ["infection", "DISEASE", 139, 148], ["COVID-19 infection", "PROBLEM", 130, 148], ["infection", "OBSERVATION", 139, 148]]], ["Since then, other reports have surfaced from Asia and Europe demonstrating suicidal tendency in patients with COVID-19 infection [15] [16] [17] [18] .", [["COVID-19", "CHEMICAL", 110, 118], ["infection", "DISEASE", 119, 128], ["COVID-19", "CHEMICAL", 110, 118], ["patients", "ORGANISM", 96, 104], ["COVID-19", "SIMPLE_CHEMICAL", 110, 118], ["[15] [16] [17] [18]", "SIMPLE_CHEMICAL", 129, 148], ["patients", "SPECIES", 96, 104], ["suicidal tendency", "PROBLEM", 75, 92], ["COVID-19 infection", "PROBLEM", 110, 128]]], ["Women and racial minority groups have been shown to be at higher risk for such behavior.", [["Women", "ORGANISM", 0, 5], ["Women", "SPECIES", 0, 5], ["such behavior", "PROBLEM", 74, 87]]], ["The only other report from United States has been from New York where command hallucinations were found to be the first manifestation of COVID-19 [19] .DiscussionWith the ongoing COVID-19 pandemic, health care providers must recognize the relationship between mental illness and viral illness to better treat patients.", [["hallucinations", "DISEASE", 78, 92], ["viral illness", "DISEASE", 279, 292], ["COVID-19", "CHEMICAL", 137, 145], ["patients", "ORGANISM", 309, 317], ["patients", "SPECIES", 309, 317], ["hallucinations", "PROBLEM", 78, 92], ["COVID", "TEST", 137, 142], ["mental illness", "PROBLEM", 260, 274], ["viral illness", "PROBLEM", 279, 292]]], ["Although this case cannot support causation, it does stress the bidirectional 2DiscussionCase Reports in Psychiatry effects that physical and mental illness share.", [["physical and mental illness", "DISEASE", 129, 156]]], ["Certainly, this patient had social stressors prior to his suicide attempt; however, coexisting COVID-19 infection could have exacerbated the effects of these social stressors on his mental health and vice versa.", [["infection", "DISEASE", 104, 113], ["patient", "ORGANISM", 16, 23], ["patient", "SPECIES", 16, 23], ["his suicide attempt", "PROBLEM", 54, 73], ["coexisting COVID-19 infection", "PROBLEM", 84, 113], ["infection", "OBSERVATION", 104, 113]]], ["Health care professionals and society should take note of these associations with the current pandemic and its ramifications.ConclusionWe present a case of 38-year-old male who presented with his first suicidal attempt and was subsequently diagnosed to have COVID-19 infection.", [["infection", "DISEASE", 267, 276], ["male", "ORGANISM", 168, 172], ["his first suicidal attempt", "PROBLEM", 192, 218], ["COVID-19 infection", "PROBLEM", 258, 276], ["infection", "OBSERVATION", 267, 276]]], ["Factors underlying this association need to be further evaluated.Data AvailabilityNot applicable.ConsentThe patient has given consent for publication of his case details.Conflicts of InterestThere are no competing interests or disclosures.", [["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["no", "UNCERTAINTY", 201, 203]]]], "bff257c88477638e5f141c36a42207798de12d0b": [], "f43b9c2ef313d334140f5e5297d5c1a31bb2d21c": [["Introductionl-Carnitine is a key component of the so-called carnitine shuttle, a multienzyme transport system that is required to transfer activated long-chain fatty acids (acyl-CoAs) into the mitochondrial matrix, where they are degraded via \u03b2-oxidation (Violante et al. 2013) .", [["mitochondrial matrix", "ANATOMY", 193, 213], ["Carnitine", "CHEMICAL", 14, 23], ["carnitine", "CHEMICAL", 60, 69], ["fatty acids", "CHEMICAL", 160, 171], ["acyl-CoAs", "CHEMICAL", 173, 182], ["Carnitine", "CHEMICAL", 14, 23], ["carnitine", "CHEMICAL", 60, 69], ["fatty acids", "CHEMICAL", 160, 171], ["acyl-CoAs", "CHEMICAL", 173, 182], ["Introductionl-Carnitine", "SIMPLE_CHEMICAL", 0, 23], ["carnitine", "SIMPLE_CHEMICAL", 60, 69], ["long-chain fatty acids", "SIMPLE_CHEMICAL", 149, 171], ["acyl-CoAs", "SIMPLE_CHEMICAL", 173, 182], ["mitochondrial matrix", "CELLULAR_COMPONENT", 193, 213], ["Carnitine", "TREATMENT", 14, 23], ["the so-called carnitine shuttle", "TREATMENT", 46, 77], ["a multienzyme transport system", "TREATMENT", 79, 109], ["mitochondrial matrix", "ANATOMY", 193, 213]]], ["In the course of this process, l-carnitine is conjugated to acyl-CoAs by carnitine palmitoyltransferase 1 (CPT1) yielding acylcarnitines, which are then transported to the inner mitochondrial compartment by the carnitine acylcarnitine translocase (CACT) in exchange for free carnitine (Houten and Wanders 2010) .", [["inner mitochondrial compartment", "ANATOMY", 172, 203], ["l-carnitine", "CHEMICAL", 31, 42], ["acyl-CoAs", "CHEMICAL", 60, 69], ["carnitine", "CHEMICAL", 73, 82], ["acylcarnitines", "CHEMICAL", 122, 136], ["carnitine", "CHEMICAL", 211, 220], ["acylcarnitine", "CHEMICAL", 221, 234], ["carnitine", "CHEMICAL", 275, 284], ["l-carnitine", "CHEMICAL", 31, 42], ["acyl-CoAs", "CHEMICAL", 60, 69], ["carnitine", "CHEMICAL", 73, 82], ["acylcarnitines", "CHEMICAL", 122, 136], ["carnitine acylcarnitine", "CHEMICAL", 211, 234], ["carnitine", "CHEMICAL", 275, 284], ["l-carnitine", "SIMPLE_CHEMICAL", 31, 42], ["acyl-CoAs", "SIMPLE_CHEMICAL", 60, 69], ["carnitine palmitoyltransferase 1", "GENE_OR_GENE_PRODUCT", 73, 105], ["CPT1", "GENE_OR_GENE_PRODUCT", 107, 111], ["acylcarnitines", "SIMPLE_CHEMICAL", 122, 136], ["inner", "TISSUE", 172, 177], ["mitochondrial compartment", "CELLULAR_COMPONENT", 178, 203], ["carnitine", "SIMPLE_CHEMICAL", 211, 220], ["acylcarnitine", "SIMPLE_CHEMICAL", 221, 234], ["carnitine", "SIMPLE_CHEMICAL", 275, 284], ["carnitine palmitoyltransferase 1", "PROTEIN", 73, 105], ["CPT1", "PROTEIN", 107, 111], ["carnitine acylcarnitine translocase", "PROTEIN", 211, 246], ["CACT", "PROTEIN", 248, 252], ["l-carnitine", "TREATMENT", 31, 42], ["carnitine palmitoyltransferase", "TEST", 73, 103], ["acylcarnitines", "TREATMENT", 122, 136], ["the carnitine acylcarnitine translocase", "TREATMENT", 207, 246]]], ["Thereafter, carnitine palmitoyltransferase 2 (CPT2) retransforms acylcarnitines to acyl-CoA esters, which are then degraded to acyl-CoA subunits, thus generating substrates for the citric acid cycle and reducing equivalents for the electron transport chain (Houten and Wanders 2010) .IntroductionAlthough l-carnitine is present in plants, the main nutritional sources for humans are foodstuffs of animal origin (Mitchell 1978) .", [["carnitine", "CHEMICAL", 12, 21], ["acylcarnitines", "CHEMICAL", 65, 79], ["acyl-CoA esters", "CHEMICAL", 83, 98], ["acyl-CoA", "CHEMICAL", 127, 135], ["citric acid", "CHEMICAL", 181, 192], ["l-carnitine", "CHEMICAL", 305, 316], ["carnitine", "CHEMICAL", 12, 21], ["acylcarnitines", "CHEMICAL", 65, 79], ["acyl-CoA esters", "CHEMICAL", 83, 98], ["acyl-CoA", "CHEMICAL", 127, 135], ["citric acid", "CHEMICAL", 181, 192], ["l-carnitine", "CHEMICAL", 305, 316], ["carnitine palmitoyltransferase 2", "GENE_OR_GENE_PRODUCT", 12, 44], ["CPT2", "GENE_OR_GENE_PRODUCT", 46, 50], ["acylcarnitines", "SIMPLE_CHEMICAL", 65, 79], ["acyl-CoA esters", "SIMPLE_CHEMICAL", 83, 98], ["acyl-CoA", "SIMPLE_CHEMICAL", 127, 135], ["citric acid", "SIMPLE_CHEMICAL", 181, 192], ["electron", "SIMPLE_CHEMICAL", 232, 240], ["l-carnitine", "SIMPLE_CHEMICAL", 305, 316], ["humans", "ORGANISM", 372, 378], ["carnitine palmitoyltransferase 2", "PROTEIN", 12, 44], ["CPT2", "PROTEIN", 46, 50], ["acyl-CoA subunits", "PROTEIN", 127, 144], ["humans", "SPECIES", 372, 378], ["humans", "SPECIES", 372, 378], ["carnitine palmitoyltransferase 2 (CPT2)", "TREATMENT", 12, 51], ["acylcarnitines to acyl-CoA esters", "TREATMENT", 65, 98], ["acyl-CoA subunits", "TREATMENT", 127, 144], ["the citric acid cycle", "TREATMENT", 177, 198], ["l-carnitine", "TREATMENT", 305, 316], ["main", "OBSERVATION_MODIFIER", 343, 347]]], ["Depending on dietary habits, daily intake from food sources ranges from <0.16 to 2.4 mg/kg body weight (bw), the bioavailability being generally lower in humans that regularly consume a diet high in l-carnitine (e.g., abundant consumption of red meat) and even lower when high amounts of this compound are supplemented exogenously (Harper et al. 1988; Rebouche 2004; Sahajwalla et al. 1995) .", [["body", "ANATOMY", 91, 95], ["red meat", "ANATOMY", 242, 250], ["l-carnitine", "CHEMICAL", 199, 210], ["l-carnitine", "CHEMICAL", 199, 210], ["body", "ORGANISM_SUBDIVISION", 91, 95], ["humans", "ORGANISM", 154, 160], ["l-carnitine", "SIMPLE_CHEMICAL", 199, 210], ["meat", "ORGANISM_SUBDIVISION", 246, 250], ["humans", "SPECIES", 154, 160], ["humans", "SPECIES", 154, 160]]], ["The body concentration of l-carnitine is tightly regulated by an equilibrium between endogenous synthesis (from lysine and methionine), renal reabsorption, and dietary l-carnitine supply, the latter especially influencing the renal clearance rate (Evans and Fornasini 2003; Jeukendrup et al. 1998; Rebouche 2004 ).", [["body", "ANATOMY", 4, 8], ["renal", "ANATOMY", 136, 141], ["renal", "ANATOMY", 226, 231], ["l-carnitine", "CHEMICAL", 26, 37], ["lysine", "CHEMICAL", 112, 118], ["methionine", "CHEMICAL", 123, 133], ["l-carnitine", "CHEMICAL", 168, 179], ["l-carnitine", "CHEMICAL", 26, 37], ["lysine", "CHEMICAL", 112, 118], ["methionine", "CHEMICAL", 123, 133], ["l-carnitine", "CHEMICAL", 168, 179], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["l-carnitine", "SIMPLE_CHEMICAL", 26, 37], ["lysine", "SIMPLE_CHEMICAL", 112, 118], ["methionine", "SIMPLE_CHEMICAL", 123, 133], ["renal", "ORGAN", 136, 141], ["l-carnitine", "SIMPLE_CHEMICAL", 168, 179], ["renal", "ORGAN", 226, 231], ["The body concentration of l-carnitine", "TREATMENT", 0, 37], ["an equilibrium between endogenous synthesis", "PROBLEM", 62, 105], ["lysine and methionine", "TREATMENT", 112, 133], ["renal reabsorption", "TREATMENT", 136, 154], ["dietary l-carnitine supply", "TREATMENT", 160, 186], ["renal", "ANATOMY", 136, 141], ["reabsorption", "OBSERVATION", 142, 154], ["renal", "ANATOMY", 226, 231]]], ["Therefore, oral or intravenous dosages above a certain basal or physiological \"threshold\" level lead to an increased l-carnitine elimination and diminished uptake (Evans and Fornasini 2003; Rebouche and Seim 1998) .", [["oral", "ANATOMY", 11, 15], ["intravenous", "ANATOMY", 19, 30], ["l-carnitine", "CHEMICAL", 117, 128], ["l-carnitine", "CHEMICAL", 117, 128], ["oral", "ORGANISM_SUBDIVISION", 11, 15], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 30], ["l-carnitine", "SIMPLE_CHEMICAL", 117, 128], ["oral or intravenous dosages", "TREATMENT", 11, 38], ["an increased l-carnitine elimination", "PROBLEM", 104, 140], ["diminished uptake", "PROBLEM", 145, 162], ["diminished", "OBSERVATION_MODIFIER", 145, 155]]], ["Although the mechanisms of the intestinal absorption of l-carnitine have not yet been fully elucidated, they most likely involve carrier-mediated transport as well as passive diffusion, the latter being the more important intake route for non-dietary (i.e., high) carnitine concentrations (Evans and Fornasini 2003; Li et al. 1992) .", [["intestinal", "ANATOMY", 31, 41], ["l-carnitine", "CHEMICAL", 56, 67], ["carnitine", "CHEMICAL", 264, 273], ["l-carnitine", "CHEMICAL", 56, 67], ["carnitine", "CHEMICAL", 264, 273], ["intestinal", "ORGAN", 31, 41], ["l-carnitine", "SIMPLE_CHEMICAL", 56, 67], ["carnitine", "SIMPLE_CHEMICAL", 264, 273], ["l-carnitine", "TREATMENT", 56, 67], ["passive diffusion", "PROBLEM", 167, 184], ["non-dietary (i.e., high) carnitine concentrations", "TREATMENT", 239, 288], ["intestinal", "ANATOMY", 31, 41]]], ["Active renal reabsorption, intestinal uptake and tissue distribution of l-carnitine are mediated by so-called carnitine/organic cation transporters (OCTN), two of them (OCTN1 and OCTN2) having been identified in humans (Tamai 2013) .", [["renal", "ANATOMY", 7, 12], ["intestinal", "ANATOMY", 27, 37], ["tissue", "ANATOMY", 49, 55], ["l-carnitine", "CHEMICAL", 72, 83], ["carnitine", "CHEMICAL", 110, 119], ["l-carnitine", "CHEMICAL", 72, 83], ["carnitine", "CHEMICAL", 110, 119], ["renal", "MULTI-TISSUE_STRUCTURE", 7, 12], ["intestinal", "ORGAN", 27, 37], ["tissue", "TISSUE", 49, 55], ["l-carnitine", "SIMPLE_CHEMICAL", 72, 83], ["carnitine", "SIMPLE_CHEMICAL", 110, 119], ["organic cation transporters", "GENE_OR_GENE_PRODUCT", 120, 147], ["OCTN", "GENE_OR_GENE_PRODUCT", 149, 153], ["OCTN1", "GENE_OR_GENE_PRODUCT", 169, 174], ["OCTN2", "GENE_OR_GENE_PRODUCT", 179, 184], ["humans", "ORGANISM", 212, 218], ["organic cation transporters", "PROTEIN", 120, 147], ["OCTN", "PROTEIN", 149, 153], ["OCTN1", "PROTEIN", 169, 174], ["OCTN2", "PROTEIN", 179, 184], ["humans", "SPECIES", 212, 218], ["humans", "SPECIES", 212, 218], ["Active renal reabsorption", "PROBLEM", 0, 25], ["intestinal uptake and tissue distribution of l-carnitine", "PROBLEM", 27, 83], ["carnitine/organic cation transporters", "TREATMENT", 110, 147], ["renal", "ANATOMY", 7, 12], ["reabsorption", "OBSERVATION", 13, 25], ["intestinal", "ANATOMY", 27, 37], ["uptake", "OBSERVATION", 38, 44]]], ["Rare mutations in the SLC22A5 gene encoding for OCTN2 lead to systemic carnitine shortage and consequently to the development of a primary carnitine deficiency (PCD), which in most cases manifests itself clinically in form of a hypoketotic hypoglycemic encephalopathy as well as disorders of the heart and skeletal muscle (Erguven et al. 2007; Lahjouji et al. 2001) .", [["heart", "ANATOMY", 296, 301], ["skeletal muscle", "ANATOMY", 306, 321], ["carnitine", "CHEMICAL", 71, 80], ["carnitine", "CHEMICAL", 139, 148], ["PCD", "DISEASE", 161, 164], ["hypoglycemic encephalopathy", "DISEASE", 240, 267], ["disorders of the heart and skeletal muscle", "DISEASE", 279, 321], ["carnitine", "CHEMICAL", 71, 80], ["carnitine", "CHEMICAL", 139, 148], ["SLC22A5", "GENE_OR_GENE_PRODUCT", 22, 29], ["OCTN2", "GENE_OR_GENE_PRODUCT", 48, 53], ["carnitine", "SIMPLE_CHEMICAL", 71, 80], ["carnitine", "SIMPLE_CHEMICAL", 139, 148], ["heart", "ORGAN", 296, 301], ["skeletal muscle", "TISSUE", 306, 321], ["SLC22A5 gene", "DNA", 22, 34], ["OCTN2", "PROTEIN", 48, 53], ["Rare mutations", "PROBLEM", 0, 14], ["OCTN2", "PROBLEM", 48, 53], ["systemic carnitine shortage", "TREATMENT", 62, 89], ["a primary carnitine deficiency", "PROBLEM", 129, 159], ["a hypoketotic hypoglycemic encephalopathy", "PROBLEM", 226, 267], ["disorders of the heart and skeletal muscle", "PROBLEM", 279, 321], ["mutations", "OBSERVATION", 5, 14], ["carnitine deficiency", "OBSERVATION", 139, 159], ["hypoglycemic encephalopathy", "OBSERVATION", 240, 267], ["heart", "ANATOMY", 296, 301], ["skeletal muscle", "ANATOMY", 306, 321]]], ["In contrast, the clinically less severe secondary carnitine deficiency (SCD) is caused by organ (e.g., kidney or liver) or metabolic disorders (e.g., impaired fatty acid metabolism), carnitine malabsorption, malnutrition as well as pharmacological treatment (Erguven et al. 2007; Flanagan et al. 2010) .", [["organ", "ANATOMY", 90, 95], ["kidney", "ANATOMY", 103, 109], ["liver", "ANATOMY", 113, 118], ["carnitine", "CHEMICAL", 50, 59], ["SCD", "DISEASE", 72, 75], ["organ (e.g., kidney or liver) or metabolic disorders", "DISEASE", 90, 142], ["fatty acid", "CHEMICAL", 159, 169], ["carnitine", "CHEMICAL", 183, 192], ["malabsorption", "DISEASE", 193, 206], ["malnutrition", "DISEASE", 208, 220], ["carnitine", "CHEMICAL", 50, 59], ["fatty acid", "CHEMICAL", 159, 169], ["carnitine", "CHEMICAL", 183, 192], ["carnitine", "SIMPLE_CHEMICAL", 50, 59], ["organ", "ORGAN", 90, 95], ["kidney", "ORGAN", 103, 109], ["liver", "ORGAN", 113, 118], ["fatty acid", "SIMPLE_CHEMICAL", 159, 169], ["carnitine", "SIMPLE_CHEMICAL", 183, 192], ["carnitine deficiency (SCD)", "PROBLEM", 50, 76], ["organ (e.g., kidney or liver", "PROBLEM", 90, 118], ["metabolic disorders", "PROBLEM", 123, 142], ["impaired fatty acid metabolism", "PROBLEM", 150, 180], ["carnitine malabsorption", "PROBLEM", 183, 206], ["malnutrition", "PROBLEM", 208, 220], ["pharmacological treatment", "TREATMENT", 232, 257], ["carnitine deficiency", "OBSERVATION", 50, 70], ["kidney", "ANATOMY", 103, 109], ["liver", "ANATOMY", 113, 118], ["metabolic disorders", "OBSERVATION", 123, 142]]], ["The treatment of these disorders, especially in the case of PCD, consists in the daily supplementation of l-carnitine in doses (100-400 mg/kg bw or 990 mg 2-3 times/day) adapted to the patients' plasma level (Bain et al. 2006; Longo et al. 2006) .IntroductionSince the early 1980s, l-carnitine is also being extensively advertised and used by athletes, bodybuilders or even obese individuals as a nutritional supplement with allegedly \"fat burning\" and performance-enhancing properties (Jeukendrup et al. 1998 ), although to date there are no conclusive data supporting these claims neither in rats (Eder 2000; Melton et al. 2005; Saldanha Aoki et al. 2004 ) nor in humans (Barnett et al. 1994; Brass 2000; Cerretelli and Marconi 1990; Grunewald and Bailey 1993; Jeukendrup and Randell 2011; Jeukendrup et al. 1998; Vukovich et al. 1994) .", [["plasma", "ANATOMY", 195, 201], ["fat", "ANATOMY", 436, 439], ["PCD", "DISEASE", 60, 63], ["l-carnitine", "CHEMICAL", 106, 117], ["l-carnitine", "CHEMICAL", 282, 293], ["l-carnitine", "CHEMICAL", 106, 117], ["l-carnitine", "CHEMICAL", 282, 293], ["l-carnitine", "SIMPLE_CHEMICAL", 106, 117], ["patients", "ORGANISM", 185, 193], ["plasma", "ORGANISM_SUBSTANCE", 195, 201], ["l-carnitine", "SIMPLE_CHEMICAL", 282, 293], ["fat", "TISSUE", 436, 439], ["rats", "ORGANISM", 594, 598], ["humans", "ORGANISM", 666, 672], ["patients", "SPECIES", 185, 193], ["rats", "SPECIES", 594, 598], ["humans", "SPECIES", 666, 672], ["humans", "SPECIES", 666, 672], ["these disorders", "PROBLEM", 17, 32], ["PCD", "PROBLEM", 60, 63], ["l-carnitine in doses", "TREATMENT", 106, 126], ["l-carnitine", "TREATMENT", 282, 293], ["a nutritional supplement", "TREATMENT", 395, 419]]], ["Taking into account the inverse relationship between exogenous supplementation and bioavailability, one must conclude that, when fairly high oral doses are given, a significant amount of l-carnitine would remain in the gut.", [["oral", "ANATOMY", 141, 145], ["gut", "ANATOMY", 219, 222], ["l-carnitine", "CHEMICAL", 187, 198], ["l-carnitine", "CHEMICAL", 187, 198], ["oral", "ORGANISM_SUBDIVISION", 141, 145], ["l-carnitine", "SIMPLE_CHEMICAL", 187, 198], ["gut", "ORGANISM_SUBDIVISION", 219, 222], ["exogenous supplementation", "TREATMENT", 53, 78], ["l-carnitine", "TREATMENT", 187, 198], ["significant", "OBSERVATION_MODIFIER", 165, 176], ["amount", "OBSERVATION_MODIFIER", 177, 183], ["l-carnitine", "OBSERVATION", 187, 198], ["gut", "ANATOMY", 219, 222]]], ["The unabsorbed compound can be partially degraded to trimethylamine (TMA) or \u03b3-butyrobetaine by enterobacteria in the gut lumen of rats and, to a greater extent, humans (Koeth et al. 2013; Rebouche and Chenard 1991; Rebouche et al. 1984; Zhang et al. 1999) .", [["gut lumen", "ANATOMY", 118, 127], ["trimethylamine", "CHEMICAL", 53, 67], ["TMA", "CHEMICAL", 69, 72], ["\u03b3-butyrobetaine", "CHEMICAL", 77, 92], ["trimethylamine", "CHEMICAL", 53, 67], ["TMA", "CHEMICAL", 69, 72], ["\u03b3-butyrobetaine", "CHEMICAL", 77, 92], ["trimethylamine", "SIMPLE_CHEMICAL", 53, 67], ["TMA", "SIMPLE_CHEMICAL", 69, 72], ["\u03b3-butyrobetaine", "SIMPLE_CHEMICAL", 77, 92], ["gut lumen", "MULTI-TISSUE_STRUCTURE", 118, 127], ["rats", "ORGANISM", 131, 135], ["humans", "ORGANISM", 162, 168], ["rats", "SPECIES", 131, 135], ["humans", "SPECIES", 162, 168], ["humans", "SPECIES", 162, 168], ["trimethylamine (TMA)", "TREATMENT", 53, 73], ["\u03b3-butyrobetaine", "TREATMENT", 77, 92], ["enterobacteria", "PROBLEM", 96, 110], ["enterobacteria", "OBSERVATION", 96, 110], ["gut", "ANATOMY", 118, 121], ["lumen", "ANATOMY_MODIFIER", 122, 127], ["greater extent", "OBSERVATION_MODIFIER", 146, 160]]], ["After absorption, TMA is oxidized to trimethylamine-N-oxide (TMNO) by hepatic flavin monooxygenases (Baker and Chaykin 1962; Bennett et al. 2013; Koeth et al. 2013 ): In addition to that, and following l-carnitine supplementation, TMNO can be directly produced in the gut by the gastrointestinal microbiota (Koeth et al. 2013) .", [["gut", "ANATOMY", 268, 271], ["gastrointestinal", "ANATOMY", 279, 295], ["TMA", "DISEASE", 18, 21], ["trimethylamine-N-oxide", "CHEMICAL", 37, 59], ["TMNO", "CHEMICAL", 61, 65], ["l-carnitine", "CHEMICAL", 202, 213], ["TMNO", "CHEMICAL", 231, 235], ["TMA", "CHEMICAL", 18, 21], ["trimethylamine-N-oxide", "CHEMICAL", 37, 59], ["TMNO", "CHEMICAL", 61, 65], ["flavin", "CHEMICAL", 78, 84], ["l-carnitine", "CHEMICAL", 202, 213], ["TMA", "SIMPLE_CHEMICAL", 18, 21], ["trimethylamine-N-oxide", "SIMPLE_CHEMICAL", 37, 59], ["TMNO", "SIMPLE_CHEMICAL", 61, 65], ["hepatic flavin monooxygenases", "SIMPLE_CHEMICAL", 70, 99], ["l-carnitine", "SIMPLE_CHEMICAL", 202, 213], ["TMNO", "SIMPLE_CHEMICAL", 231, 235], ["gut", "ORGANISM_SUBDIVISION", 268, 271], ["gastrointestinal", "ORGAN", 279, 295], ["TMA", "TREATMENT", 18, 21], ["trimethylamine-N-oxide", "TREATMENT", 37, 59], ["l-carnitine supplementation", "TREATMENT", 202, 229], ["TMNO", "TREATMENT", 231, 235], ["hepatic", "ANATOMY", 70, 77], ["gastrointestinal microbiota", "ANATOMY", 279, 306]]], ["In an acidic environment and in the presence of nitrite ions, i.e., under conditions which prevail in the upper gastrointestinal tract, the known carcinogen N-nitrosodimethylamine (NDMA) can be formed from these amine precursors (Bain et al. 2005; Lijinsky et al. 1972; Loh et al. 2011; Tricker and Preussmann 1991) .", [["upper gastrointestinal tract", "ANATOMY", 106, 134], ["nitrite", "CHEMICAL", 48, 55], ["N-nitrosodimethylamine", "CHEMICAL", 157, 179], ["NDMA", "CHEMICAL", 181, 185], ["amine", "CHEMICAL", 212, 217], ["nitrite", "CHEMICAL", 48, 55], ["N-nitrosodimethylamine", "CHEMICAL", 157, 179], ["NDMA", "CHEMICAL", 181, 185], ["amine", "CHEMICAL", 212, 217], ["nitrite", "SIMPLE_CHEMICAL", 48, 55], ["upper gastrointestinal", "ORGANISM_SUBDIVISION", 106, 128], ["tract", "ORGANISM_SUBDIVISION", 129, 134], ["N-nitrosodimethylamine", "SIMPLE_CHEMICAL", 157, 179], ["NDMA", "SIMPLE_CHEMICAL", 181, 185], ["amine", "SIMPLE_CHEMICAL", 212, 217], ["nitrite ions", "TREATMENT", 48, 60], ["the known carcinogen N", "TREATMENT", 136, 158], ["nitrosodimethylamine (NDMA", "TREATMENT", 159, 185], ["acidic environment", "OBSERVATION", 6, 24], ["nitrite ions", "OBSERVATION", 48, 60], ["upper", "ANATOMY_MODIFIER", 106, 111], ["gastrointestinal tract", "ANATOMY", 112, 134]]], ["Additionally, bacterial metabolism can also lead to NDMA formation from amines such as TMA and dimethylamine (Maduagwu and Bassir 1979) .", [["NDMA", "CHEMICAL", 52, 56], ["amines", "CHEMICAL", 72, 78], ["TMA", "CHEMICAL", 87, 90], ["dimethylamine", "CHEMICAL", 95, 108], ["NDMA", "CHEMICAL", 52, 56], ["amines", "CHEMICAL", 72, 78], ["TMA", "CHEMICAL", 87, 90], ["dimethylamine", "CHEMICAL", 95, 108], ["NDMA", "SIMPLE_CHEMICAL", 52, 56], ["amines", "SIMPLE_CHEMICAL", 72, 78], ["TMA", "SIMPLE_CHEMICAL", 87, 90], ["dimethylamine", "SIMPLE_CHEMICAL", 95, 108], ["bacterial metabolism", "PROBLEM", 14, 34], ["NDMA formation", "PROBLEM", 52, 66], ["dimethylamine", "TREATMENT", 95, 108], ["bacterial metabolism", "OBSERVATION", 14, 34]]], ["Consumption of l-carnitine in doses that are not completely absorbed might thus enhance bacterial NDMA production in the colon and consequently contribute to colorectal tumor formation, as has been shown by Knekt et al. (1999) and Loh et al. (2011) for dietary NDMA.", [["colon", "ANATOMY", 121, 126], ["colorectal tumor", "ANATOMY", 158, 174], ["l-carnitine", "CHEMICAL", 15, 26], ["NDMA", "CHEMICAL", 98, 102], ["colorectal tumor", "DISEASE", 158, 174], ["NDMA", "CHEMICAL", 261, 265], ["l-carnitine", "CHEMICAL", 15, 26], ["NDMA", "CHEMICAL", 98, 102], ["NDMA", "CHEMICAL", 261, 265], ["l-carnitine", "SIMPLE_CHEMICAL", 15, 26], ["NDMA", "SIMPLE_CHEMICAL", 98, 102], ["colon", "ORGAN", 121, 126], ["colorectal tumor", "CANCER", 158, 174], ["NDMA", "SIMPLE_CHEMICAL", 261, 265], ["l-carnitine in doses", "TREATMENT", 15, 35], ["bacterial NDMA production in the colon", "PROBLEM", 88, 126], ["colorectal tumor formation", "PROBLEM", 158, 184], ["dietary NDMA", "PROBLEM", 253, 265], ["bacterial", "OBSERVATION_MODIFIER", 88, 97], ["NDMA", "OBSERVATION", 98, 102], ["colon", "ANATOMY", 121, 126], ["colorectal", "ANATOMY", 158, 168], ["tumor", "OBSERVATION", 169, 174], ["NDMA", "OBSERVATION", 261, 265]]], ["Therefore, we investigated whether a chronic administration of different l-carnitine concentrations via drinking water leads to an increased number of aberrant crypt foci (ACF), which are considered preneoplastic lesions associated with colorectal cancer formation (Bird 1995) , in the colon of male Fischer 344 rats.", [["crypt foci", "ANATOMY", 160, 170], ["ACF", "ANATOMY", 172, 175], ["preneoplastic lesions", "ANATOMY", 199, 220], ["colorectal cancer", "ANATOMY", 237, 254], ["colon", "ANATOMY", 286, 291], ["l-carnitine", "CHEMICAL", 73, 84], ["colorectal cancer", "DISEASE", 237, 254], ["l-carnitine", "CHEMICAL", 73, 84], ["l-carnitine", "SIMPLE_CHEMICAL", 73, 84], ["crypt foci", "CELLULAR_COMPONENT", 160, 170], ["ACF", "CANCER", 172, 175], ["preneoplastic lesions", "CANCER", 199, 220], ["colorectal cancer", "CANCER", 237, 254], ["colon", "ORGAN", 286, 291], ["Fischer 344 rats", "ORGANISM", 300, 316], ["rats", "SPECIES", 312, 316], ["a chronic administration of different l-carnitine concentrations", "TREATMENT", 35, 99], ["aberrant crypt foci", "PROBLEM", 151, 170], ["preneoplastic lesions", "PROBLEM", 199, 220], ["colorectal cancer formation", "PROBLEM", 237, 264], ["chronic", "OBSERVATION_MODIFIER", 37, 44], ["increased", "OBSERVATION_MODIFIER", 131, 140], ["number", "OBSERVATION_MODIFIER", 141, 147], ["aberrant", "OBSERVATION_MODIFIER", 151, 159], ["crypt foci", "OBSERVATION", 160, 170], ["preneoplastic", "OBSERVATION_MODIFIER", 199, 212], ["lesions", "OBSERVATION", 213, 220], ["colorectal cancer", "OBSERVATION", 237, 254], ["colon", "ANATOMY", 286, 291]]], ["As a recent study by Koeth et al. (2013) showed that TMNO resulting from l-carnitine supplementation promotes atherosclerosis in mice, we additionally examined its influence on the occurrence of atherosclerotic lesions in the aorta of the above-mentioned rats.Animals, housing and dietEighty male Fischer 344 DuCrl rats (F344 rats) were purchased at 5-6 weeks of age (100-120 g bw) from Charles River (Sulzfeld, Germany) and housed in type IV polycarbonate cages (EHRET, Emmendingen, Germany).", [["atherosclerotic lesions", "ANATOMY", 195, 218], ["aorta", "ANATOMY", 226, 231], ["TMNO", "CHEMICAL", 53, 57], ["l-carnitine", "CHEMICAL", 73, 84], ["atherosclerosis", "DISEASE", 110, 125], ["atherosclerotic lesions", "DISEASE", 195, 218], ["l-carnitine", "CHEMICAL", 73, 84], ["polycarbonate", "CHEMICAL", 443, 456], ["TMNO", "SIMPLE_CHEMICAL", 53, 57], ["l-carnitine", "SIMPLE_CHEMICAL", 73, 84], ["mice", "ORGANISM", 129, 133], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 195, 218], ["aorta", "MULTI-TISSUE_STRUCTURE", 226, 231], ["rats", "ORGANISM", 255, 259], ["Animals", "ORGANISM", 260, 267], ["Fischer 344 DuCrl rats", "ORGANISM", 297, 319], ["F344 rats", "ORGANISM", 321, 330], ["TMNO", "PROTEIN", 53, 57], ["mice", "SPECIES", 129, 133], ["rats", "SPECIES", 255, 259], ["rats", "SPECIES", 315, 319], ["rats", "SPECIES", 326, 330], ["mice", "SPECIES", 129, 133], ["a recent study", "TEST", 3, 17], ["TMNO", "PROBLEM", 53, 57], ["l-carnitine supplementation", "TREATMENT", 73, 100], ["atherosclerosis", "PROBLEM", 110, 125], ["atherosclerotic lesions", "PROBLEM", 195, 218], ["type IV polycarbonate cages", "TREATMENT", 435, 462], ["atherosclerosis", "OBSERVATION", 110, 125], ["atherosclerotic", "OBSERVATION_MODIFIER", 195, 210], ["lesions", "OBSERVATION", 211, 218], ["aorta", "ANATOMY", 226, 231]]], ["The cages were placed in airflow cabinets (Uni Protect; EHRET) operated in a positive pressure mode (50 Pa) and providing a temperature of 21-23 \u00b0C, a relative humidity of 50-60 %, a maximum light intensity of 45 lux, 15-20 air shifts per hour as well as a 12/12 h day and night cycle.", [["The cages", "TREATMENT", 0, 9], ["a positive pressure mode", "TREATMENT", 75, 99], ["a temperature", "TEST", 122, 135], ["a relative humidity", "TEST", 149, 168]]], ["The bedding consisted of poplar granules (LIGNOCEL \u00ae Select; JRS, Rosenberg, Germany), which were changed once a week, and the diet was a standard pelleted rodent maintenance diet (cat. nr.", [["granules", "ANATOMY", 32, 40], ["granules", "ORGANISM_SUBSTANCE", 32, 40], ["cat", "ORGANISM", 181, 184], ["poplar granules", "TREATMENT", 25, 40], ["a standard pelleted rodent maintenance diet", "TREATMENT", 136, 179], ["poplar granules", "OBSERVATION", 25, 40]]], ["1324; see online resource 1 \"Specifications of the animal feed\" for details on feed composition) purchased from Altromin (Lage, Germany).", [["Altromin", "SIMPLE_CHEMICAL", 112, 120]]], ["The animals in each cage had access to tunnel housing made of red polycarbonate (BIOSCAPE, Castrop-Rauxel, Germany) and certified carcinogen and toxicant-free aspen rods (ABEDD \u00ae Lab&Vet Service, Vienna, Austria) as enrichment.Animals, housing and dietExperimental design and procedure Upon arrival, littermates were randomly assigned to one of four test groups consisting of 20 animals each and housed pairwise in each cage to minimize distress during the whole experimental period of 58 weeks.", [["red polycarbonate", "CHEMICAL", 62, 79], ["polycarbonate", "CHEMICAL", 66, 79], ["red polycarbonate (BIOSCAPE", "TREATMENT", 62, 89], ["Castrop", "TREATMENT", 91, 98], ["free aspen rods", "TREATMENT", 154, 169], ["procedure", "TREATMENT", 276, 285], ["distress", "PROBLEM", 437, 445]]], ["Animals in the control group (group 1) received drinking (tap) water without any supplementation.", [["Animals", "ORGANISM", 0, 7], ["drinking (tap) water", "TREATMENT", 48, 68], ["any supplementation", "TREATMENT", 77, 96]]], ["Water for groups 2, 3 and 4 was supplemented with 1, 2 or 5 g l-carnitine/l for 52 weeks, respectively. l-Carnitine (Carnipure\u2122; Lonza, Basel, Switzerland) with a purity of 99.5-99.9 % was purchased from Denk Ingredients (Munich, Germany).", [["l-carnitine", "CHEMICAL", 62, 73], ["l-Carnitine", "CHEMICAL", 104, 115], ["Carnipure\u2122", "CHEMICAL", 117, 127], ["l-carnitine", "CHEMICAL", 62, 73], ["l-Carnitine", "CHEMICAL", 104, 115], ["Carnipure\u2122", "CHEMICAL", 117, 127], ["l-carnitine", "SIMPLE_CHEMICAL", 62, 73], ["l-Carnitine", "SIMPLE_CHEMICAL", 104, 115], ["Carnipure\u2122", "SIMPLE_CHEMICAL", 117, 127], ["a purity", "TEST", 161, 169], ["Carnitine", "ANATOMY", 106, 115]]], ["Because of a sialodacryoadenitis virus (SDAV) infection (see results), the l-carnitine treatment was started in week 6 upon arrival after an acclimatization and recovery period of 5 weeks.", [["sialodacryoadenitis virus (SDAV) infection", "DISEASE", 13, 55], ["l-carnitine", "CHEMICAL", 75, 86], ["l-carnitine", "CHEMICAL", 75, 86], ["sialodacryoadenitis virus", "ORGANISM", 13, 38], ["SDAV", "ORGANISM", 40, 44], ["l-carnitine", "SIMPLE_CHEMICAL", 75, 86], ["sialodacryoadenitis virus", "SPECIES", 13, 38], ["SDAV", "SPECIES", 40, 44], ["a sialodacryoadenitis virus (SDAV) infection", "PROBLEM", 11, 55], ["the l-carnitine treatment", "TREATMENT", 71, 96], ["sialodacryoadenitis", "OBSERVATION", 13, 32]]], ["To avoid microbial contamination, drinking water was autoclaved before carnitine supplementation and changed twice a week.", [["carnitine", "CHEMICAL", 71, 80], ["carnitine", "CHEMICAL", 71, 80], ["carnitine", "SIMPLE_CHEMICAL", 71, 80], ["microbial contamination", "PROBLEM", 9, 32], ["carnitine supplementation", "TREATMENT", 71, 96]]], ["In the course of water changes, water consumption was recorded, while the weight of the animals was assessed once a week.", [["water", "SIMPLE_CHEMICAL", 32, 37], ["water consumption", "TREATMENT", 32, 49]]], ["Moreover, the stability of l-carnitine in the water was assessed by liquid chromatography/mass spectrometry (LC-MS) for a period of 7 days under experimental conditions (see online resource 1 \"Assessment of l-carnitine stability\" for details).", [["l-carnitine", "CHEMICAL", 27, 38], ["l-carnitine", "CHEMICAL", 27, 38], ["l-carnitine", "SIMPLE_CHEMICAL", 27, 38], ["water", "SIMPLE_CHEMICAL", 46, 51], ["l-carnitine", "TREATMENT", 27, 38], ["liquid chromatography", "TEST", 68, 89], ["mass spectrometry", "TEST", 90, 107], ["stability", "OBSERVATION_MODIFIER", 14, 23]]], ["After the 52-week administration period, individual rats were anaesthetized by CO 2 (6 L/min flush) and decapitated.", [["CO 2", "CHEMICAL", 79, 83], ["rats", "ORGANISM", 52, 56], ["rats", "SPECIES", 52, 56]]], ["Blood was immediately collected for further analysis and the gastrointestinal tract entirely removed and processed as previously described (Nicken et al. 2012) .", [["Blood", "ANATOMY", 0, 5], ["gastrointestinal tract", "ANATOMY", 61, 83], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["gastrointestinal tract", "ORGAN", 61, 83], ["Blood", "TEST", 0, 5], ["further analysis", "TEST", 36, 52], ["gastrointestinal tract", "ANATOMY", 61, 83]]], ["Briefly, the colon was removed, washed with phosphate buffered saline (PBS) and opened longitudinally.", [["colon", "ANATOMY", 13, 18], ["phosphate", "CHEMICAL", 44, 53], ["phosphate", "CHEMICAL", 44, 53], ["colon", "ORGAN", 13, 18], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 44, 69], ["phosphate buffered saline (PBS", "TREATMENT", 44, 74], ["colon", "ANATOMY", 13, 18], ["removed", "OBSERVATION", 23, 30]]], ["Thereafter, the tissues were fixed in formalin (Roti \u00ae -Histofix 4 %; Carl Roth, Karlsruhe, Germany), stained with methylene blue solution (0.1 % w/v in PBS) and ACF formation was assessed using a stereomicroscope (SZX16; Olympus, Hamburg, Germany).", [["tissues", "ANATOMY", 16, 23], ["ACF", "ANATOMY", 162, 165], ["formalin", "CHEMICAL", 38, 46], ["methylene blue", "CHEMICAL", 115, 129], ["formalin", "CHEMICAL", 38, 46], ["methylene blue", "CHEMICAL", 115, 129], ["tissues", "TISSUE", 16, 23], ["formalin", "SIMPLE_CHEMICAL", 38, 46], ["methylene blue solution", "SIMPLE_CHEMICAL", 115, 138], ["ACF", "SIMPLE_CHEMICAL", 162, 165], ["formalin", "TEST", 38, 46], ["Roti", "TEST", 48, 52], ["Histofix", "TEST", 56, 64], ["methylene blue solution", "TREATMENT", 115, 138], ["v in PBS", "TREATMENT", 148, 156], ["ACF formation", "PROBLEM", 162, 175], ["a stereomicroscope", "TEST", 195, 213], ["tissues", "ANATOMY", 16, 23], ["ACF", "OBSERVATION", 162, 165]]], ["Additionally, the kidneys, liver and spleen were removed and weighed.", [["kidneys", "ANATOMY", 18, 25], ["liver", "ANATOMY", 27, 32], ["spleen", "ANATOMY", 37, 43], ["kidneys", "ORGAN", 18, 25], ["liver", "ORGAN", 27, 32], ["spleen", "ORGAN", 37, 43], ["kidneys", "ANATOMY", 18, 25], ["liver", "ANATOMY", 27, 32], ["spleen", "ANATOMY", 37, 43], ["removed", "OBSERVATION", 49, 56]]], ["For histopathologic examination, heart, thoracic aorta and liver were fixed in 10 % neutral buffered formalin.", [["heart", "ANATOMY", 33, 38], ["thoracic aorta", "ANATOMY", 40, 54], ["liver", "ANATOMY", 59, 64], ["formalin", "CHEMICAL", 101, 109], ["heart", "ORGAN", 33, 38], ["thoracic aorta", "MULTI-TISSUE_STRUCTURE", 40, 54], ["liver", "ORGAN", 59, 64], ["formalin", "SIMPLE_CHEMICAL", 101, 109], ["histopathologic examination", "TEST", 4, 31], ["heart", "ANATOMY", 33, 38], ["thoracic aorta", "ANATOMY", 40, 54], ["liver", "ANATOMY", 59, 64], ["fixed", "OBSERVATION_MODIFIER", 70, 75]]], ["Organ trimming was performed in accordance with the Registry of Industrial Toxicology Animal-data (RITA) and North American Control Animal Database (NACAD) guidelines for organ sampling and trimming in rats and mice (Morawietz et al. 2004; Ruehl-Fehlert et al. 2003) , followed by embedding in paraffin wax, sectioning at 2 \u00b5m thickness, and staining with hematoxylin and eosin (HE).Imaging and illustrationsMicrographs of representative lesions were obtained using an Olympus BX51 microscope equipped with a DP72 12.8 megapixel digital color camera and cellSens Standard v. 1.7.1 software (Olympus Corp., Tokyo, Japan).", [["Organ", "ANATOMY", 0, 5], ["organ", "ANATOMY", 171, 176], ["lesions", "ANATOMY", 438, 445], ["hematoxylin", "CHEMICAL", 356, 367], ["eosin", "CHEMICAL", 372, 377], ["organ", "ORGAN", 171, 176], ["rats", "ORGANISM", 202, 206], ["mice", "ORGANISM", 211, 215], ["hematoxylin", "SIMPLE_CHEMICAL", 356, 367], ["eosin", "SIMPLE_CHEMICAL", 372, 377], ["lesions", "CANCER", 438, 445], ["rats", "SPECIES", 202, 206], ["mice", "SPECIES", 211, 215], ["mice", "SPECIES", 211, 215], ["Organ trimming", "TREATMENT", 0, 14], ["Animal Database (NACAD)", "TREATMENT", 132, 155], ["organ sampling", "TREATMENT", 171, 185], ["trimming in rats", "TREATMENT", 190, 206], ["hematoxylin", "TREATMENT", 356, 367], ["Imaging", "TEST", 383, 390], ["representative lesions", "PROBLEM", 423, 445], ["an Olympus BX51 microscope", "TEST", 466, 492], ["a DP72", "TEST", 507, 513], ["lesions", "OBSERVATION", 438, 445]]], ["Figures were further processed with Adobe \u00ae Photoshop \u00ae v. 7.0 (Adobe Systems, Inc., San Jose, CA, USA), thereby adjusting contrast and brightness, if necessary.Imaging and illustrationsAssessment of the NDMA concentration in the urine of the experimental animals Urine was collected in the next-to-last week of the study by housing 16 animals (4 from each group) individually in metabolic cages (TECNIPLAST, Hohenpei\u00dfenberg, Germany) for 24 h.", [["urine", "ANATOMY", 230, 235], ["NDMA", "CHEMICAL", 204, 208], ["NDMA", "CHEMICAL", 204, 208], ["NDMA", "SIMPLE_CHEMICAL", 204, 208], ["urine", "ORGANISM_SUBSTANCE", 230, 235], ["Urine", "ORGANISM_SUBSTANCE", 264, 269], ["Imaging", "TEST", 161, 168], ["the NDMA concentration", "TEST", 200, 222], ["the urine", "TEST", 226, 235], ["the experimental animals Urine", "TEST", 239, 269], ["the study", "TEST", 312, 321]]], ["Gathered urine samples (5-10 ml) were stored in 50-ml tubes (Greiner Bio-One, Frickenhausen, Germany) protected from light at \u221280 \u00b0C until analysis.", [["urine samples", "ANATOMY", 9, 22], ["urine samples", "ORGANISM_SUBSTANCE", 9, 22], ["Gathered urine samples", "TEST", 0, 22]]], ["Sample extraction was performed using Supelclean coconut charcoal SPE tubes (Sigma-Aldrich, Schnelldorf, Germany) based on the U.S. Environmental Protection Agency method 521 for the detection of nitrosamines in drinking water (Munch and Bassett 2004) . d 6 -NDMA (Restek, Bad Homburg, Germany) was added to the urine samples as internal standard prior to sample preparation.", [["urine samples", "ANATOMY", 312, 325], ["sample", "ANATOMY", 356, 362], ["Supelclean coconut charcoal SPE", "CHEMICAL", 38, 69], ["nitrosamines", "CHEMICAL", 196, 208], ["d 6 -NDMA", "CHEMICAL", 254, 263], ["nitrosamines", "CHEMICAL", 196, 208], ["d 6 -NDMA", "CHEMICAL", 254, 263], ["Restek", "CHEMICAL", 265, 271], ["nitrosamines", "SIMPLE_CHEMICAL", 196, 208], ["d 6 -NDMA", "SIMPLE_CHEMICAL", 254, 263], ["Restek", "SIMPLE_CHEMICAL", 265, 271], ["urine samples", "ORGANISM_SUBSTANCE", 312, 325], ["Sample extraction", "TREATMENT", 0, 17], ["Supelclean coconut charcoal SPE tubes", "TREATMENT", 38, 75], ["nitrosamines", "TREATMENT", 196, 208], ["the urine samples", "TEST", 308, 325], ["sample preparation", "TREATMENT", 356, 374]]], ["The nitrosamines were eluted from the SPE tubes using methylene chloride (VWR, Leuven, Belgium) and concentrated under a gentle stream of nitrogen at 35 \u00b0C to a volume of approximately 0.5 ml.", [["nitrosamines", "CHEMICAL", 4, 16], ["methylene chloride", "CHEMICAL", 54, 72], ["nitrogen", "CHEMICAL", 138, 146], ["nitrosamines", "CHEMICAL", 4, 16], ["methylene chloride", "CHEMICAL", 54, 72], ["nitrogen", "CHEMICAL", 138, 146], ["nitrosamines", "SIMPLE_CHEMICAL", 4, 16], ["methylene chloride", "SIMPLE_CHEMICAL", 54, 72], ["nitrogen", "SIMPLE_CHEMICAL", 138, 146], ["The nitrosamines", "TREATMENT", 0, 16], ["the SPE tubes", "TREATMENT", 34, 47], ["methylene chloride", "TREATMENT", 54, 72], ["a gentle stream of nitrogen", "TREATMENT", 119, 146]]], ["An aliquot of 5 \u00b5l was injected into the GC-MS.", [["An aliquot of 5 \u00b5l", "TREATMENT", 0, 18]]], ["As residue-free urine was not available, the method validation was performed by using synthetic human urine (Synthetic Urine, Nussdorf, Germany) spiked with NDMA (Restek).", [["urine", "ANATOMY", 16, 21], ["urine", "ANATOMY", 102, 107], ["NDMA", "CHEMICAL", 157, 161], ["NDMA", "CHEMICAL", 157, 161], ["urine", "ORGANISM_SUBSTANCE", 16, 21], ["human", "ORGANISM", 96, 101], ["urine", "ORGANISM_SUBSTANCE", 102, 107], ["Urine", "ORGANISM_SUBSTANCE", 119, 124], ["NDMA", "SIMPLE_CHEMICAL", 157, 161], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["free urine", "TEST", 11, 21], ["the method validation", "TEST", 41, 62], ["synthetic human urine", "TEST", 86, 107]]], ["The samples were analyzed on an Agilent 7890A gas chromatograph (Waldbronn, Germany) coupled to an Agilent 5975C mass selective detector (MSD) applying the following parameters: column: Agilent DB-WAX (polyethylene glycol, 30 m; 0.25 mm i.d.; 0.5 \u00b5m film thickness); carrier gas: helium, 1.9 ml/min, constant flow; oven temperature program: 1 min 35 \u00b0C, +20 \u00b0C/min, 1 min 200 \u00b0C, backflush 3 min 200 \u00b0C; programmed temperature vaporization on an Agilent multimode inlet: inlet temperature program: 0.06 min 37 \u00b0C, +600 \u00b0C/min, 5 min 240 \u00b0C; vent flow 100 ml/min at 0.34 bar; ionization: 70 eV, EI, SIM mode (m/z: 80, 74, 42).Statistical analysisStatistical analysis of the data was performed with Prism v. 6.04 (GraphPad Software, Inc., La Jolla, CA, USA).", [["samples", "ANATOMY", 4, 11], ["polyethylene glycol", "CHEMICAL", 202, 221], ["polyethylene glycol", "CHEMICAL", 202, 221], ["helium", "CHEMICAL", 280, 286], ["polyethylene glycol", "SIMPLE_CHEMICAL", 202, 221], ["The samples", "TEST", 0, 11], ["an Agilent 7890A gas chromatograph", "TEST", 29, 63], ["an Agilent 5975C mass selective detector (MSD)", "TREATMENT", 96, 142], ["Agilent DB-WAX (polyethylene glycol", "TREATMENT", 186, 221], ["carrier gas", "TEST", 267, 278], ["programmed temperature vaporization", "TREATMENT", 404, 439], ["an Agilent multimode inlet: inlet temperature program", "TREATMENT", 443, 496], ["vent flow", "TEST", 541, 550], ["Statistical analysisStatistical analysis", "TEST", 625, 665], ["the data", "TEST", 669, 677], ["Prism v.", "TEST", 697, 705], ["GraphPad", "TEST", 712, 720], ["Software", "TEST", 721, 729]]], ["The Shapiro-Wilk normality test was used to assess probability distribution of the datasets.", [["The Shapiro-Wilk normality test", "TEST", 0, 31]]], ["Normally distributed sets were subjected to a one-way analysis of variance (ANOVA) followed by Tukey's post hoc test, while non-normally distributed data or data with too few independent experiments to perform a Shapiro-Wilk test (analysis of NDMA levels in rat urine) were subjected to a Kruskal-Wallis test followed by Dunn's post hoc comparison.", [["urine", "ANATOMY", 262, 267], ["NDMA", "CHEMICAL", 243, 247], ["NDMA", "CHEMICAL", 243, 247], ["NDMA", "SIMPLE_CHEMICAL", 243, 247], ["rat", "ORGANISM", 258, 261], ["urine", "ORGANISM_SUBSTANCE", 262, 267], ["rat", "SPECIES", 258, 261], ["rat", "SPECIES", 258, 261], ["Tukey's post hoc test", "TEST", 95, 116], ["a Shapiro-Wilk test", "TEST", 210, 229], ["NDMA levels in rat urine", "TEST", 243, 267], ["a Kruskal-Wallis test", "TEST", 287, 308]]], ["The relationship between the frequencies of pathohistological findings and l-carnitine treatment was analyzed by means of Pearson's chi-squared test.", [["l-carnitine", "CHEMICAL", 75, 86], ["l-carnitine", "CHEMICAL", 75, 86], ["l-carnitine", "SIMPLE_CHEMICAL", 75, 86], ["pathohistological findings", "TEST", 44, 70], ["l-carnitine treatment", "TREATMENT", 75, 96], ["Pearson's chi-squared test", "TEST", 122, 148]]], ["Statistical significance was considered if p \u2264 0.05.Clinical observationsIn the first week upon arrival, the animals showed signs of an SDAV infection.", [["infection", "DISEASE", 141, 150], ["animals", "ORGANISM", 109, 116], ["SDAV", "GENE_OR_GENE_PRODUCT", 136, 140], ["SDAV", "SPECIES", 136, 140], ["Clinical observations", "TEST", 52, 73], ["an SDAV infection", "PROBLEM", 133, 150], ["SDAV", "ANATOMY", 136, 140], ["infection", "OBSERVATION", 141, 150]]], ["SDAV is a relatively common and rat-specific coronavirus with high morbidity and very lowto-no mortality (Gaillard and Clifford 2000; Jacoby and Gaertner 2006) .", [["coronavirus", "DISEASE", 45, 56], ["SDAV", "GENE_OR_GENE_PRODUCT", 0, 4], ["SDAV", "SPECIES", 0, 4], ["high morbidity", "PROBLEM", 62, 76]]], ["The infection was relatively silent, the most prominent clinical symptom being sneezing followed by red-colored nasal discharge.Experimental findingsIn groups 1, 2 and 3, one animal had to be euthanized before the completion of the study.", [["nasal", "ANATOMY", 112, 117], ["infection", "DISEASE", 4, 13], ["sneezing", "DISEASE", 79, 87], ["nasal", "ORGANISM_SUBDIVISION", 112, 117], ["animal", "ORGANISM", 175, 181], ["The infection", "PROBLEM", 0, 13], ["sneezing", "PROBLEM", 79, 87], ["red-colored nasal discharge", "PROBLEM", 100, 127], ["Experimental findings", "PROBLEM", 128, 149], ["the study", "TEST", 228, 237], ["infection", "OBSERVATION", 4, 13], ["most prominent", "OBSERVATION_MODIFIER", 41, 55], ["nasal", "ANATOMY", 112, 117]]], ["All other animals completed the study in good general condition.", [["the study", "TEST", 28, 37]]], ["No statistically significant differences were observed between the groups regarding the final body weight, all animals weighing ~410 g at the end of the study (Table 1 , \"Final bw\").Experimental findingsSimilarly, the final weight of the various organs sampled from the different animals did not differ across the groups in a significant manner (Table 1 , \"Kidney, liver and spleen weight\").", [["body", "ANATOMY", 94, 98], ["organs", "ANATOMY", 246, 252], ["Kidney", "ANATOMY", 357, 363], ["liver", "ANATOMY", 365, 370], ["spleen", "ANATOMY", 375, 381], ["body", "ORGANISM_SUBDIVISION", 94, 98], ["organs", "ORGAN", 246, 252], ["Kidney", "ORGAN", 357, 363], ["liver", "ORGAN", 365, 370], ["spleen", "ORGAN", 375, 381], ["the study", "TEST", 149, 158], ["Experimental findingsSimilarly", "PROBLEM", 182, 212], ["statistically", "OBSERVATION_MODIFIER", 3, 16], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["differences", "OBSERVATION", 29, 40], ["Kidney", "ANATOMY", 357, 363], ["liver", "ANATOMY", 365, 370], ["spleen", "ANATOMY", 375, 381]]], ["Interestingly, the rats in the highest dose group (group 4) drank significantly more water than the animals in groups 1 (control) and 2 (lowest dose; Table 1 , \"Water uptake\").", [["rats", "ORGANISM", 19, 23], ["rats", "SPECIES", 19, 23]]], ["Based on average water consumption of 18.3 ml/ rat/day (Table 1 , \"Water uptake\") and an average body weight of 260 g/rat (Table 1; Regarding ACF formation and ACF multiplicity (crypts/ACF), there was no statistically significant difference between the four groups tested (Tables 2, 3) Histopathological alterations in the aorta were only seen in one animal of the control group, showing mild focal degenerative changes in the media accompanied by a mild infiltration of macrophages and mineralization ( Fig. 1a ; Table 3 ).", [["body", "ANATOMY", 97, 101], ["crypts", "ANATOMY", 178, 184], ["aorta", "ANATOMY", 323, 328], ["macrophages", "ANATOMY", 471, 482], ["rat", "ORGANISM", 47, 50], ["body", "ORGANISM_SUBDIVISION", 97, 101], ["rat", "ORGANISM", 118, 121], ["ACF", "MULTI-TISSUE_STRUCTURE", 142, 145], ["crypts", "MULTI-TISSUE_STRUCTURE", 178, 184], ["aorta", "MULTI-TISSUE_STRUCTURE", 323, 328], ["macrophages", "CELL", 471, 482], ["macrophages", "CELL_TYPE", 471, 482], ["rat", "SPECIES", 47, 50], ["rat", "SPECIES", 118, 121], ["an average body weight", "TEST", 86, 108], ["ACF formation", "TREATMENT", 142, 155], ["crypts/ACF", "TREATMENT", 178, 188], ["Histopathological alterations in the aorta", "PROBLEM", 286, 328], ["mild focal degenerative changes in the media", "PROBLEM", 388, 432], ["a mild infiltration of macrophages", "PROBLEM", 448, 482], ["no", "UNCERTAINTY", 201, 203], ["significant", "OBSERVATION_MODIFIER", 218, 229], ["difference", "OBSERVATION", 230, 240], ["aorta", "ANATOMY", 323, 328], ["mild", "OBSERVATION_MODIFIER", 388, 392], ["focal", "OBSERVATION_MODIFIER", 393, 398], ["degenerative", "OBSERVATION", 399, 411], ["media", "ANATOMY", 427, 432], ["mild", "OBSERVATION_MODIFIER", 450, 454], ["infiltration", "OBSERVATION", 455, 467], ["macrophages", "OBSERVATION", 471, 482], ["mineralization", "OBSERVATION_MODIFIER", 487, 501]]], ["Histopathological examination of the heart revealed a mild multifocal chronic lymphohistiocytic myocarditis with myocardial degeneration and fibrosis in about 50 % of the rats, but no statistically significant difference between the groups was observed ( Fig. 1b; Table 3 ).", [["heart", "ANATOMY", 37, 42], ["myocardial", "ANATOMY", 113, 123], ["myocarditis", "DISEASE", 96, 107], ["myocardial degeneration", "DISEASE", 113, 136], ["fibrosis", "DISEASE", 141, 149], ["heart", "ORGAN", 37, 42], ["myocardial", "MULTI-TISSUE_STRUCTURE", 113, 123], ["rats", "ORGANISM", 171, 175], ["rats", "SPECIES", 171, 175], ["Histopathological examination of the heart", "TEST", 0, 42], ["a mild multifocal chronic lymphohistiocytic myocarditis", "PROBLEM", 52, 107], ["myocardial degeneration", "PROBLEM", 113, 136], ["fibrosis", "PROBLEM", 141, 149], ["heart", "ANATOMY", 37, 42], ["mild", "OBSERVATION_MODIFIER", 54, 58], ["multifocal", "OBSERVATION_MODIFIER", 59, 69], ["chronic", "OBSERVATION_MODIFIER", 70, 77], ["lymphohistiocytic myocarditis", "OBSERVATION", 78, 107], ["myocardial", "ANATOMY", 113, 123], ["degeneration", "OBSERVATION", 124, 136], ["fibrosis", "OBSERVATION", 141, 149], ["no", "UNCERTAINTY", 181, 183], ["statistically", "OBSERVATION_MODIFIER", 184, 197], ["significant", "OBSERVATION_MODIFIER", 198, 209], ["difference", "OBSERVATION", 210, 220]]], ["Moreover, all animals displayed a variable degree of bile duct hyperplasia (Fig. 1c) , and a high number of animals showed a mild-to-moderate multifocal acute to subacute Table 1 Physiological data of the experimental animals Where applicable, values are shown as mean \u00b1 standard deviation * Weight of one kidney \u25b2 Calculated on the basis of the mean of the weekly water consumption of two animals/cage a Kruskal-Wallis test followed by Dunn's post hoc analysis b One-way ANOVA followed by Tukey's post hoc analysis \u03b1 Significantly different (p < 0.01) when compared to group 1 \u03b2 Significantly different (p < 0.001) when compared to group 2 Group 1 (0 g/l) Group 2 (1 g/l) Group 3 (2 g/l) Group 4 (5 g/l)Experimental findingsNumber of animals 19 19 19 20Experimental findingsStarting body weight (g) a 105.1 \u00b1 7.9 102.4 \u00b1 7.0 101.9 \u00b1 6.9 101.6 \u00b1 6.9Experimental findingsFinal body weight (g) a 410.5 \u00b1 19.6 408.5 \u00b1 14.6 413.2 \u00b1 14.1 414.5 \u00b1 18.3 Kidney weight (g)* ,a 1.27 \u00b1 0.08 1.26 \u00b1 0.07 1.28 \u00b1 0.1 1.30 \u00b1 0.09 Liver weight (g) b 11.4 \u00b1 1.0 11.4 \u00b1 0.9 11.6 \u00b1 0.8 11.9 \u00b1 0.9Experimental findingsSpleen weight (g) b 0.82 \u00b1 0.1 0.83 \u00b1 0.08 0.84 \u00b1 0.06 0.84 \u00b1 0.08Experimental findingsWater uptake (ml/day/animal) \u25b2,a 18.1 \u00b1 1.6 18.1 \u00b1 2.1 18.3 \u00b1 1.2 18.8 \u00b1 1.8 \u03b1,\u03b2 Table 3 Pathohistological findings in the aorta, heart and liver of the animals All pathohistological findings analyzed with Pearson's chi-squared test a Number of animals with the mentioned alteration/total number of animals analyzed, frequency (%) in parentheses Group 1 (0 g/l) Group 2 (1 g/l) Group 3 (2 g/l) Group 4 (5 g/l) (100) 20/20 (100) Fig. 1 a Aorta of a control animal: mild focal degenerative changes in the media accompanied by a mild infiltration of macrophages and mineralization (arrowheads; L lumen). b Heart of an animal of group 4: mild multifocal chronic lymphohistiocytic myocarditis with myocardial degeneration and fibrosis. c Liver of a control ani-mal: mild bile duct hyperplasia, associated with mild lymphohistiocytic infiltration. d Liver of a control animal: focal suppurative and necrotizing hepatitis.", [["bile duct", "ANATOMY", 53, 62], ["kidney", "ANATOMY", 306, 312], ["body", "ANATOMY", 784, 788], ["body", "ANATOMY", 876, 880], ["Kidney", "ANATOMY", 946, 952], ["Liver", "ANATOMY", 1015, 1020], ["Spleen", "ANATOMY", 1098, 1104], ["aorta", "ANATOMY", 1308, 1313], ["heart", "ANATOMY", 1315, 1320], ["liver", "ANATOMY", 1325, 1330], ["macrophages", "ANATOMY", 1732, 1743], ["L lumen", "ANATOMY", 1776, 1783], ["Heart", "ANATOMY", 1788, 1793], ["myocardial", "ANATOMY", 1878, 1888], ["Liver", "ANATOMY", 1918, 1923], ["bile duct", "ANATOMY", 1951, 1960], ["lymphohistiocytic", "ANATOMY", 1995, 2012], ["Liver", "ANATOMY", 2029, 2034], ["focal suppurative", "ANATOMY", 2056, 2073], ["bile duct hyperplasia", "DISEASE", 53, 74], ["myocarditis", "DISEASE", 1861, 1872], ["myocardial degeneration", "DISEASE", 1878, 1901], ["fibrosis", "DISEASE", 1906, 1914], ["bile duct hyperplasia", "DISEASE", 1951, 1972], ["necrotizing hepatitis", "DISEASE", 2078, 2099], ["bile duct", "MULTI-TISSUE_STRUCTURE", 53, 62], ["kidney", "ORGAN", 306, 312], ["body", "ORGANISM_SUBDIVISION", 784, 788], ["body", "ORGANISM_SUBDIVISION", 876, 880], ["Liver", "ORGAN", 1015, 1020], ["Spleen", "ORGAN", 1098, 1104], ["aorta", "MULTI-TISSUE_STRUCTURE", 1308, 1313], ["heart", "ORGAN", 1315, 1320], ["liver", "ORGAN", 1325, 1330], ["macrophages", "CELL", 1732, 1743], ["Heart", "ORGAN", 1788, 1793], ["myocardial", "MULTI-TISSUE_STRUCTURE", 1878, 1888], ["Liver", "ORGAN", 1918, 1923], ["ani-mal", "CANCER", 1937, 1944], ["bile duct", "MULTI-TISSUE_STRUCTURE", 1951, 1960], ["Liver", "ORGAN", 2029, 2034], ["macrophages", "CELL_TYPE", 1732, 1743], ["bile duct hyperplasia", "PROBLEM", 53, 74], ["a mild-to-moderate multifocal acute to subacute Table", "PROBLEM", 123, 176], ["Weight", "TEST", 292, 298], ["hoc analysis", "TEST", 503, 515], ["Group", "TEST", 657, 662], ["Group", "TEST", 673, 678], ["Experimental findings", "TEST", 704, 725], ["Experimental findings", "TEST", 754, 775], ["body weight", "TEST", 784, 795], ["g", "TEST", 797, 798], ["a", "TEST", 800, 801], ["\u00b1", "TEST", 832, 833], ["Experimental findings", "TEST", 849, 870], ["Final body weight", "TEST", 870, 887], ["Kidney weight", "TEST", 946, 959], ["g", "TEST", 961, 962], ["a", "TEST", 966, 967], ["Liver weight", "TEST", 1015, 1027], ["g", "TEST", 1029, 1030], ["b", "TEST", 1032, 1033], ["\u00b1", "TEST", 1039, 1040], ["\u00b1", "TEST", 1050, 1051], ["\u00b1", "TEST", 1061, 1062], ["Experimental findings", "PROBLEM", 1077, 1098], ["Spleen weight", "TEST", 1098, 1111], ["g", "TEST", 1113, 1114], ["b", "TEST", 1116, 1117], ["Experimental findings", "TEST", 1164, 1185], ["Water uptake", "TEST", 1185, 1197], ["All pathohistological findings", "TEST", 1346, 1376], ["Pearson's chi-squared test", "TEST", 1391, 1417], ["Group", "TEST", 1547, 1552], ["Group", "TEST", 1563, 1568], ["Group", "TEST", 1579, 1584], ["mild focal degenerative changes in the media", "PROBLEM", 1649, 1693], ["a mild infiltration of macrophages", "PROBLEM", 1709, 1743], ["mineralization (arrowheads", "PROBLEM", 1748, 1774], ["mild multifocal chronic lymphohistiocytic myocarditis", "PROBLEM", 1819, 1872], ["myocardial degeneration", "PROBLEM", 1878, 1901], ["fibrosis", "PROBLEM", 1906, 1914], ["mild bile duct hyperplasia", "PROBLEM", 1946, 1972], ["mild lymphohistiocytic infiltration", "PROBLEM", 1990, 2025], ["focal suppurative and necrotizing hepatitis", "PROBLEM", 2056, 2099], ["variable", "OBSERVATION_MODIFIER", 34, 42], ["degree", "OBSERVATION_MODIFIER", 43, 49], ["bile duct", "ANATOMY", 53, 62], ["hyperplasia", "OBSERVATION", 63, 74], ["mild", "OBSERVATION_MODIFIER", 125, 129], ["-to-moderate", "OBSERVATION_MODIFIER", 129, 141], ["multifocal", "OBSERVATION_MODIFIER", 142, 152], ["acute", "OBSERVATION_MODIFIER", 153, 158], ["subacute", "OBSERVATION_MODIFIER", 162, 170], ["kidney", "ANATOMY", 306, 312], ["Kidney", "ANATOMY", 946, 952], ["Liver", "ANATOMY", 1015, 1020], ["Pathohistological", "OBSERVATION", 1274, 1291], ["aorta", "ANATOMY", 1308, 1313], ["heart", "ANATOMY", 1315, 1320], ["liver", "ANATOMY", 1325, 1330], ["Aorta", "ANATOMY", 1622, 1627], ["mild", "OBSERVATION_MODIFIER", 1649, 1653], ["focal", "OBSERVATION_MODIFIER", 1654, 1659], ["degenerative", "OBSERVATION", 1660, 1672], ["media", "ANATOMY", 1688, 1693], ["mild", "OBSERVATION_MODIFIER", 1711, 1715], ["infiltration", "OBSERVATION", 1716, 1728], ["macrophages", "OBSERVATION", 1732, 1743], ["mineralization", "OBSERVATION_MODIFIER", 1748, 1762], ["lumen", "ANATOMY_MODIFIER", 1778, 1783], ["mild", "OBSERVATION_MODIFIER", 1819, 1823], ["multifocal", "OBSERVATION_MODIFIER", 1824, 1834], ["chronic", "OBSERVATION_MODIFIER", 1835, 1842], ["lymphohistiocytic myocarditis", "OBSERVATION", 1843, 1872], ["myocardial", "ANATOMY", 1878, 1888], ["degeneration", "OBSERVATION", 1889, 1901], ["fibrosis", "OBSERVATION", 1906, 1914], ["Liver", "ANATOMY", 1918, 1923], ["mild", "OBSERVATION_MODIFIER", 1946, 1950], ["bile duct", "ANATOMY", 1951, 1960], ["hyperplasia", "OBSERVATION", 1961, 1972], ["mild", "OBSERVATION_MODIFIER", 1990, 1994], ["lymphohistiocytic infiltration", "OBSERVATION", 1995, 2025], ["Liver", "ANATOMY", 2029, 2034], ["focal", "OBSERVATION_MODIFIER", 2056, 2061], ["suppurative", "OBSERVATION_MODIFIER", 2062, 2073], ["necrotizing", "OBSERVATION_MODIFIER", 2078, 2089], ["hepatitis", "OBSERVATION", 2090, 2099]]], ["Scale bars a, b, d 100 \u00b5m, scale bar c 50 \u00b5m suppurative and necrotizing hepatitis (Fig. 1d) , without statistically significant differences between the groups (Table 3) .", [["suppurative", "DISEASE", 45, 56], ["necrotizing hepatitis", "DISEASE", 61, 82], ["suppurative", "PROBLEM", 45, 56], ["necrotizing hepatitis", "PROBLEM", 61, 82], ["suppurative", "OBSERVATION", 45, 56], ["necrotizing", "OBSERVATION_MODIFIER", 61, 72], ["hepatitis", "OBSERVATION", 73, 82], ["without", "UNCERTAINTY", 95, 102], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["differences", "OBSERVATION", 129, 140]]], ["Except for a hepatocellular carcinoma in one animal of group 1, no tumors were observed within the livers of the remaining animals.", [["hepatocellular carcinoma", "ANATOMY", 13, 37], ["tumors", "ANATOMY", 67, 73], ["livers", "ANATOMY", 99, 105], ["hepatocellular carcinoma", "DISEASE", 13, 37], ["tumors", "DISEASE", 67, 73], ["hepatocellular carcinoma", "CANCER", 13, 37], ["tumors", "CANCER", 67, 73], ["livers", "ORGAN", 99, 105], ["a hepatocellular carcinoma", "PROBLEM", 11, 37], ["tumors", "PROBLEM", 67, 73], ["hepatocellular", "ANATOMY", 13, 27], ["carcinoma", "OBSERVATION", 28, 37], ["no", "UNCERTAINTY", 64, 66], ["tumors", "OBSERVATION", 67, 73], ["livers", "ANATOMY", 99, 105]]], ["No significant differences regarding the NDMA content in the urine of the animals was observed between the test groups (Fig. 2) .", [["urine", "ANATOMY", 61, 66], ["NDMA", "CHEMICAL", 41, 45], ["NDMA", "CHEMICAL", 41, 45], ["NDMA", "SIMPLE_CHEMICAL", 41, 45], ["urine", "ORGANISM_SUBSTANCE", 61, 66], ["the NDMA content", "PROBLEM", 37, 53], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["NDMA", "OBSERVATION", 41, 45]]], ["Interestingly, animals receiving 2 or 5 g/l l-carnitine (groups 3 and 4) seem to excrete the lowest amount of NDMA, median concentrations reaching 281.9 ng/ml and 267.6 ng/ml, respectively (group 1: 314.2 ng/ml; group 2: 348.8 ng/ml).", [["l-carnitine", "CHEMICAL", 44, 55], ["NDMA", "CHEMICAL", 110, 114], ["l-carnitine", "CHEMICAL", 44, 55], ["NDMA", "CHEMICAL", 110, 114], ["l-carnitine", "SIMPLE_CHEMICAL", 44, 55], ["NDMA", "SIMPLE_CHEMICAL", 110, 114], ["5 g/l l-carnitine (groups", "TREATMENT", 38, 63]]], ["However, it has to be noted that the differences are not statistically significant and that the amount of urinary NDMA strongly varies between the animals tested in each group (Fig. 2 ).DiscussionThe final mean body weights of the rats recorded during the course of this study correspond to weights measured in untreated F344 rats of the same age (Solleveld et al. 1984) .", [["urinary", "ANATOMY", 106, 113], ["body", "ANATOMY", 211, 215], ["NDMA", "CHEMICAL", 114, 118], ["NDMA", "CHEMICAL", 114, 118], ["urinary", "ORGANISM_SUBSTANCE", 106, 113], ["NDMA", "SIMPLE_CHEMICAL", 114, 118], ["body", "ORGANISM_SUBDIVISION", 211, 215], ["rats", "ORGANISM", 231, 235], ["F344 rats", "ORGANISM", 321, 330], ["rats", "SPECIES", 231, 235], ["rats", "SPECIES", 326, 330], ["urinary NDMA", "PROBLEM", 106, 118], ["this study", "TEST", 266, 276], ["weights", "TEST", 291, 298], ["amount", "OBSERVATION_MODIFIER", 96, 102], ["urinary", "ANATOMY", 106, 113], ["NDMA", "OBSERVATION", 114, 118]]], ["In contrast, the water uptake of the rats in this study was somewhat reduced when compared to the water uptake of laboratory rats in general (Hofstetter et al. 2006 ).", [["water", "SIMPLE_CHEMICAL", 17, 22], ["rats", "ORGANISM", 37, 41], ["water", "SIMPLE_CHEMICAL", 98, 103], ["rats", "ORGANISM", 125, 129], ["rats", "SPECIES", 37, 41], ["rats", "SPECIES", 125, 129], ["the water uptake", "TEST", 13, 29], ["this study", "TEST", 45, 55], ["reduced", "OBSERVATION_MODIFIER", 69, 76]]], ["Although rats administered 5 g/l l-carnitine drank significantly more water than animals in groups 1 and 2, this finding can be considered as biologically irrelevant, and it is questionable whether it is actually related to l-carnitine supplementation.", [["carnitine", "CHEMICAL", 35, 44], ["l-carnitine", "CHEMICAL", 224, 235], ["carnitine", "CHEMICAL", 35, 44], ["l-carnitine", "CHEMICAL", 224, 235], ["rats", "ORGANISM", 9, 13], ["l-carnitine", "SIMPLE_CHEMICAL", 33, 44], ["l-carnitine", "SIMPLE_CHEMICAL", 224, 235], ["rats", "SPECIES", 9, 13], ["l-carnitine supplementation", "TREATMENT", 224, 251]]], ["F344 rats have extensively been used in longterm (i.e., 2 years-long) carcinogenicity studies (Dinse et al. 2010; Solleveld et al. 1984) and are characterized by an extremely low spontaneous incidence rate (0.1-0.6 %) of neoplasms of the small and large intestine (Haseman et al. 1998) , rendering them particularly useful for the investigation of putative colon carcinogens.", [["neoplasms", "ANATOMY", 221, 230], ["intestine", "ANATOMY", 254, 263], ["colon", "ANATOMY", 357, 362], ["neoplasms", "DISEASE", 221, 230], ["colon carcinogens", "DISEASE", 357, 374], ["F344 rats", "ORGANISM", 0, 9], ["neoplasms", "CANCER", 221, 230], ["intestine", "ORGAN", 254, 263], ["colon", "ORGAN", 357, 362], ["rats", "SPECIES", 5, 9], ["F344", "SPECIES", 0, 4], ["carcinogenicity studies", "TEST", 70, 93], ["an extremely low spontaneous incidence rate", "PROBLEM", 162, 205], ["neoplasms of the small and large intestine", "PROBLEM", 221, 263], ["putative colon carcinogens", "PROBLEM", 348, 374], ["extremely", "OBSERVATION_MODIFIER", 165, 174], ["low", "OBSERVATION_MODIFIER", 175, 178], ["neoplasms", "OBSERVATION", 221, 230], ["small", "OBSERVATION_MODIFIER", 238, 243], ["large", "ANATOMY_MODIFIER", 248, 253], ["intestine", "ANATOMY", 254, 263], ["colon", "ANATOMY", 357, 362], ["carcinogens", "OBSERVATION", 363, 374]]], ["However, ACFs seem to spontaneously develop in the colon of F344 rats with a fairly high incidence (40-60 %), even in animals killed at an earlier age than those in the present study (Furukawa et al. 2002; Tanakamaru et al. 2001) .", [["ACFs", "ANATOMY", 9, 13], ["colon", "ANATOMY", 51, 56], ["ACFs", "GENE_OR_GENE_PRODUCT", 9, 13], ["colon", "ORGAN", 51, 56], ["F344 rats", "ORGANISM", 60, 69], ["rats", "SPECIES", 65, 69], ["ACFs", "PROBLEM", 9, 13], ["colon", "ANATOMY", 51, 56]]], ["With an overall frequency of 7.7 % and no statistically significant difference in the number of ACFs/animal between the testing groups, ACF formation in this study is considered to be spontaneous and not related to l-carnitine supplementation.", [["ACF", "CHEMICAL", 136, 139], ["l-carnitine", "CHEMICAL", 215, 226], ["l-carnitine", "CHEMICAL", 215, 226], ["ACF", "SIMPLE_CHEMICAL", 136, 139], ["l-carnitine", "SIMPLE_CHEMICAL", 215, 226], ["an overall frequency", "TEST", 5, 25], ["the testing groups", "TEST", 116, 134], ["ACF formation", "PROBLEM", 136, 149], ["this study", "TEST", 153, 163], ["l-carnitine supplementation", "TREATMENT", 215, 242], ["no", "UNCERTAINTY", 39, 41], ["statistically", "OBSERVATION_MODIFIER", 42, 55], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["difference", "OBSERVATION_MODIFIER", 68, 78], ["ACF", "OBSERVATION", 136, 139]]], ["In addition, the data obtained in the course of this study show that the administration of different l-carnitine dosages does not lead to increased amounts of NDMA being excreted via the urine when compared to untreated animals, a fact which might furthermore explain the low ACF incidence.", [["urine", "ANATOMY", 187, 192], ["l-carnitine", "CHEMICAL", 101, 112], ["NDMA", "CHEMICAL", 159, 163], ["ACF", "DISEASE", 276, 279], ["l-carnitine", "CHEMICAL", 101, 112], ["NDMA", "CHEMICAL", 159, 163], ["l-carnitine", "SIMPLE_CHEMICAL", 101, 112], ["NDMA", "SIMPLE_CHEMICAL", 159, 163], ["urine", "ORGANISM_SUBSTANCE", 187, 192], ["ACF", "CANCER", 276, 279], ["the data", "TEST", 13, 21], ["this study", "TEST", 48, 58], ["different l-carnitine dosages", "TREATMENT", 91, 120], ["increased amounts of NDMA", "PROBLEM", 138, 163], ["the urine", "TEST", 183, 192], ["the low ACF incidence", "PROBLEM", 268, 289], ["increased", "OBSERVATION_MODIFIER", 138, 147], ["amounts", "OBSERVATION_MODIFIER", 148, 155], ["NDMA", "OBSERVATION", 159, 163], ["low", "OBSERVATION_MODIFIER", 272, 275], ["ACF", "OBSERVATION", 276, 279]]], ["Even though there was no difference between the test groups, it should be noted that a \"basal\" NDMA level (376.2 \u00b1 169.8 ng/ml on average) was nevertheless observable in the urine of the animals in group 1.", [["urine", "ANATOMY", 174, 179], ["NDMA", "CHEMICAL", 95, 99], ["NDMA", "CHEMICAL", 95, 99], ["NDMA", "SIMPLE_CHEMICAL", 95, 99], ["urine", "ORGANISM_SUBSTANCE", 174, 179], ["the test groups", "TEST", 44, 59], ["a \"basal\" NDMA level", "PROBLEM", 85, 105]]], ["This might be the result of its endogenous formation or of a contamination of unknown etiology (Kraft et al. 1981; Tricker and Preussmann 1991; Vermeer et al. 1998) .DiscussionRegarding the possible influence of the SDAV infection on the outcome of the study at hand, it should be mentioned that the repair processes in the affected tissues (respiratory tract, eye, salivary and lacrimal glands) begin 5-7 days post infection and in the case of the salivary and lacrimal glands are completed after about 21 days (Jacoby and Gaertner 2006; Percy et al. 1988 ).", [["tissues", "ANATOMY", 333, 340], ["respiratory tract", "ANATOMY", 342, 359], ["eye", "ANATOMY", 361, 364], ["salivary", "ANATOMY", 366, 374], ["lacrimal glands", "ANATOMY", 379, 394], ["salivary", "ANATOMY", 449, 457], ["lacrimal glands", "ANATOMY", 462, 477], ["infection", "DISEASE", 221, 230], ["infection", "DISEASE", 416, 425], ["SDAV", "GENE_OR_GENE_PRODUCT", 216, 220], ["hand", "ORGANISM_SUBDIVISION", 262, 266], ["tissues", "TISSUE", 333, 340], ["respiratory tract", "ORGANISM_SUBDIVISION", 342, 359], ["eye", "ORGAN", 361, 364], ["salivary", "ORGAN", 366, 374], ["lacrimal glands", "ORGAN", 379, 394], ["salivary", "ORGAN", 449, 457], ["lacrimal glands", "ORGAN", 462, 477], ["its endogenous formation", "PROBLEM", 28, 52], ["a contamination", "PROBLEM", 59, 74], ["the SDAV infection", "PROBLEM", 212, 230], ["the study", "TEST", 249, 258], ["the repair processes", "TREATMENT", 296, 316], ["the affected tissues (respiratory tract, eye, salivary and lacrimal glands)", "PROBLEM", 320, 395], ["infection", "PROBLEM", 416, 425], ["the salivary and lacrimal glands", "PROBLEM", 445, 477], ["endogenous formation", "OBSERVATION", 32, 52], ["contamination", "OBSERVATION", 61, 74], ["infection", "OBSERVATION", 221, 230], ["repair", "OBSERVATION", 300, 306], ["affected tissues", "ANATOMY", 324, 340], ["respiratory tract", "ANATOMY", 342, 359], ["eye", "ANATOMY", 361, 364], ["salivary", "ANATOMY", 366, 374], ["lacrimal glands", "ANATOMY", 379, 394], ["infection", "OBSERVATION", 416, 425], ["salivary", "ANATOMY", 449, 457], ["lacrimal glands", "ANATOMY", 462, 477]]], ["Since SDAV infection occurred at the very beginning of the study and the animals had 3-4 weeks to recover, we do not suspect any major effect of the virus on the outcome of this study, especially since SDAV is not known to interfere with colon tumorigenesis or heart-related pathologies (Jacoby and Gaertner 2006) .", [["colon", "ANATOMY", 238, 243], ["heart", "ANATOMY", 261, 266], ["infection", "DISEASE", 11, 20], ["colon tumorigenesis", "DISEASE", 238, 257], ["heart-related pathologies", "DISEASE", 261, 286], ["SDAV", "GENE_OR_GENE_PRODUCT", 6, 10], ["SDAV", "GENE_OR_GENE_PRODUCT", 202, 206], ["colon", "ORGAN", 238, 243], ["heart", "ORGAN", 261, 266], ["SDAV infection", "PROBLEM", 6, 20], ["the study", "TEST", 55, 64], ["the virus", "PROBLEM", 145, 154], ["this study", "TEST", 173, 183], ["colon tumorigenesis", "PROBLEM", 238, 257], ["heart-related pathologies", "PROBLEM", 261, 286], ["infection", "OBSERVATION", 11, 20], ["virus", "OBSERVATION", 149, 154], ["colon", "ANATOMY", 238, 243], ["tumorigenesis", "OBSERVATION", 244, 257], ["heart", "ANATOMY", 261, 266]]], ["The latter statement as well as the fact that immunocompetent animals develop immunity and recover relatively fast with barely any sequelae (Jacoby and Gaertner 2006) led to the decision, not to kill the entire colony and to continue the experiment.DiscussionParticularly, male rats develop a plethora of pathologic changes with increasing age, the most common being spontaneous tumors, chronic nephropathy and lesions of the cardiovascular system (Coleman et al. 1977; King and Russell 2006) .", [["colony", "ANATOMY", 211, 217], ["tumors", "ANATOMY", 379, 385], ["lesions", "ANATOMY", 411, 418], ["cardiovascular system", "ANATOMY", 426, 447], ["tumors", "DISEASE", 379, 385], ["nephropathy", "DISEASE", 395, 406], ["lesions of the cardiovascular system", "DISEASE", 411, 447], ["animals", "ORGANISM", 62, 69], ["rats", "ORGANISM", 278, 282], ["tumors", "CANCER", 379, 385], ["lesions", "PATHOLOGICAL_FORMATION", 411, 418], ["cardiovascular", "ANATOMICAL_SYSTEM", 426, 440], ["system", "ANATOMICAL_SYSTEM", 441, 447], ["rats", "SPECIES", 278, 282], ["pathologic changes", "PROBLEM", 305, 323], ["spontaneous tumors", "PROBLEM", 367, 385], ["chronic nephropathy", "PROBLEM", 387, 406], ["lesions of the cardiovascular system", "PROBLEM", 411, 447], ["pathologic", "OBSERVATION", 305, 315], ["increasing", "OBSERVATION_MODIFIER", 329, 339], ["most common", "OBSERVATION_MODIFIER", 349, 360], ["spontaneous", "OBSERVATION_MODIFIER", 367, 378], ["tumors", "OBSERVATION", 379, 385], ["chronic", "OBSERVATION_MODIFIER", 387, 394], ["nephropathy", "OBSERVATION", 395, 406], ["lesions", "OBSERVATION", 411, 418], ["cardiovascular system", "ANATOMY", 426, 447]]], ["The pathologic findings related to the cardiovascular system described in this study clearly fall in this category.", [["cardiovascular system", "ANATOMY", 39, 60], ["cardiovascular", "ANATOMICAL_SYSTEM", 39, 53], ["The pathologic findings", "PROBLEM", 0, 23], ["the cardiovascular system", "PROBLEM", 35, 60], ["this study", "TEST", 74, 84], ["pathologic", "OBSERVATION", 4, 14], ["cardiovascular system", "ANATOMY", 39, 60]]], ["Focal myocardial degeneration in conjunction with inflammation (lymphohistiocytic infiltrations) followed by myocardial fibrosis have been described in aged F344 rats as well as other rat strains in incidences comparable to the ones reported herein, especially when the animals were fed ad libitum (Blankenship and Skaggs 2013; Coleman et al. 1977; Goodman et al. 1979; Hall et al. 1992; Keenan et al. 1995a, b; Maeda et al. 1985) .", [["myocardial", "ANATOMY", 6, 16], ["lymphohistiocytic", "ANATOMY", 64, 81], ["myocardial", "ANATOMY", 109, 119], ["myocardial degeneration", "DISEASE", 6, 29], ["inflammation", "DISEASE", 50, 62], ["myocardial fibrosis", "DISEASE", 109, 128], ["myocardial", "MULTI-TISSUE_STRUCTURE", 6, 16], ["myocardial", "MULTI-TISSUE_STRUCTURE", 109, 119], ["F344 rats", "ORGANISM", 157, 166], ["rat", "ORGANISM", 184, 187], ["animals", "ORGANISM", 270, 277], ["rats", "SPECIES", 162, 166], ["rat", "SPECIES", 184, 187], ["rat", "SPECIES", 184, 187], ["Focal myocardial degeneration", "PROBLEM", 0, 29], ["inflammation", "PROBLEM", 50, 62], ["lymphohistiocytic infiltrations", "PROBLEM", 64, 95], ["myocardial fibrosis", "PROBLEM", 109, 128], ["other rat strains", "PROBLEM", 178, 195], ["myocardial", "ANATOMY", 6, 16], ["degeneration", "OBSERVATION", 17, 29], ["inflammation", "OBSERVATION", 50, 62], ["lymphohistiocytic infiltrations", "OBSERVATION", 64, 95], ["myocardial", "ANATOMY", 109, 119], ["fibrosis", "OBSERVATION", 120, 128]]], ["In this context, the left ventricular papillary muscle, which was the primarily affected Fig. 2 NDMA concentrations in the urine of the experimental animals collected in the next-to-last week of the study.", [["left ventricular papillary muscle", "ANATOMY", 21, 54], ["urine", "ANATOMY", 123, 128], ["NDMA", "CHEMICAL", 96, 100], ["NDMA", "CHEMICAL", 96, 100], ["left ventricular papillary muscle", "TISSUE", 21, 54], ["NDMA", "SIMPLE_CHEMICAL", 96, 100], ["urine", "ORGANISM_SUBSTANCE", 123, 128], ["NDMA concentrations", "TEST", 96, 115], ["the urine", "TEST", 119, 128], ["the study", "TEST", 195, 204], ["left ventricular", "ANATOMY", 21, 37], ["papillary muscle", "ANATOMY", 38, 54], ["urine", "OBSERVATION", 123, 128]]], ["Shown is the median as well as NDMA levels of each individual animal/group (mean of three measurements/sample).", [["NDMA", "CHEMICAL", 31, 35], ["NDMA", "CHEMICAL", 31, 35], ["NDMA", "SIMPLE_CHEMICAL", 31, 35], ["NDMA levels", "TEST", 31, 42], ["NDMA", "OBSERVATION", 31, 35]]], ["The dataset was subjected to a Kruskal-Wallis test followed by Dunn's post hoc comparison location in numerous animals (data not shown), is reported to be a preferred site for these lesions (Percy and Barthold 2008) .", [["lesions", "ANATOMY", 182, 189], ["lesions", "PATHOLOGICAL_FORMATION", 182, 189], ["a Kruskal-Wallis test", "TEST", 29, 50], ["these lesions", "PROBLEM", 176, 189], ["lesions", "OBSERVATION", 182, 189]]], ["Additionally, aging rats commonly exhibit hyperplastic bile ducts (King and Russell 2006) .", [["hyperplastic bile ducts", "ANATOMY", 42, 65], ["hyperplastic bile ducts", "DISEASE", 42, 65], ["rats", "ORGANISM", 20, 24], ["hyperplastic bile ducts", "MULTI-TISSUE_STRUCTURE", 42, 65], ["rats", "SPECIES", 20, 24], ["hyperplastic bile ducts", "PROBLEM", 42, 65], ["hyperplastic", "OBSERVATION", 42, 54], ["bile ducts", "ANATOMY", 55, 65]]], ["According to Coleman et al. (1977) , 75 % of approximately 12-month old F344 rats show bile duct hyperplasia, a finding which contrasts the incidence of 100 % reported in this study, although, still in accordance with the same source, similar incidences were reported in significantly older animals (>18 months).", [["bile duct", "ANATOMY", 87, 96], ["bile duct hyperplasia", "DISEASE", 87, 108], ["F344 rats", "ORGANISM", 72, 81], ["bile duct hyperplasia", "PATHOLOGICAL_FORMATION", 87, 108], ["rats", "SPECIES", 77, 81], ["bile duct hyperplasia", "PROBLEM", 87, 108], ["this study", "TEST", 171, 181], ["bile duct", "ANATOMY", 87, 96], ["hyperplasia", "OBSERVATION", 97, 108]]], ["In contrast, control F344 rats used in 2-year carcinogenicity studies of the U.S. National Institutes of Health Carcinogenesis Testing Program only marginally suffered from bile duct hyperplasia, 24.5 % of male and 12.5 % of female F344 rats being affected (Goodman et al. 1979) .", [["bile duct", "ANATOMY", 173, 182], ["bile duct hyperplasia", "DISEASE", 173, 194], ["F344 rats", "ORGANISM", 21, 30], ["bile duct", "MULTI-TISSUE_STRUCTURE", 173, 182], ["F344 rats", "ORGANISM", 232, 241], ["rats", "SPECIES", 26, 30], ["rats", "SPECIES", 237, 241], ["F344", "SPECIES", 21, 25], ["F344", "SPECIES", 232, 236], ["bile duct hyperplasia", "PROBLEM", 173, 194], ["bile duct", "ANATOMY", 173, 182], ["hyperplasia", "OBSERVATION", 183, 194]]], ["The frequency of multifocal suppurative and necrotizing liver lesions observed in this study (68.4-90.0 %) was distinctly above the relatively low incidence of spontaneous necrotizing processes previously described in aged male F344 rats (approx.", [["suppurative", "ANATOMY", 28, 39], ["liver lesions", "ANATOMY", 56, 69], ["necrotizing liver lesions", "DISEASE", 44, 69], ["multifocal suppurative", "PATHOLOGICAL_FORMATION", 17, 39], ["liver lesions", "PATHOLOGICAL_FORMATION", 56, 69], ["F344 rats", "ORGANISM", 228, 237], ["rats", "SPECIES", 233, 237], ["multifocal suppurative and necrotizing liver lesions", "PROBLEM", 17, 69], ["this study", "TEST", 82, 92], ["spontaneous necrotizing processes", "PROBLEM", 160, 193], ["multifocal", "OBSERVATION_MODIFIER", 17, 27], ["suppurative", "OBSERVATION_MODIFIER", 28, 39], ["necrotizing", "OBSERVATION_MODIFIER", 44, 55], ["liver", "ANATOMY", 56, 61], ["lesions", "OBSERVATION", 62, 69], ["relatively", "OBSERVATION_MODIFIER", 132, 142], ["low incidence", "OBSERVATION_MODIFIER", 143, 156], ["spontaneous", "OBSERVATION_MODIFIER", 160, 171], ["necrotizing", "OBSERVATION", 172, 183]]], ["Although we were unable to identify characteristic viral, bacterial, mycotic or parasitic structures within the liver lesions employing routine and special histological staining methods (Gram stain, periodic acid Schiff-reaction, and Groccott silver stain; data not shown), we cannot rule out the possibility that the animals were infected with agents such as Clostridium piliforme (Tyzzer's disease), Salmonella spp. or Corynebacterium kutscheri (Percy and Barthold 2008; Thoolen et al. 2010) .", [["liver lesions", "ANATOMY", 112, 125], ["Clostridium piliforme", "DISEASE", 360, 381], ["Tyzzer's disease", "DISEASE", 383, 399], ["Salmonella spp.", "DISEASE", 402, 417], ["silver", "CHEMICAL", 243, 249], ["parasitic structures", "PATHOLOGICAL_FORMATION", 80, 100], ["liver lesions", "PATHOLOGICAL_FORMATION", 112, 125], ["animals", "ORGANISM", 318, 325], ["Clostridium piliforme", "ORGANISM", 360, 381], ["Tyzzer's disease", "ORGANISM", 383, 399], ["Salmonella spp.", "ORGANISM", 402, 417], ["Corynebacterium kutscheri", "ORGANISM", 421, 446], ["Clostridium piliforme", "SPECIES", 360, 381], ["Salmonella spp.", "SPECIES", 402, 417], ["Corynebacterium kutscheri", "SPECIES", 421, 446], ["Clostridium piliforme", "SPECIES", 360, 381], ["Salmonella spp.", "SPECIES", 402, 417], ["Corynebacterium kutscheri (Percy and Barthold 2008; Thoolen et al. 2010", "SPECIES", 421, 492], ["characteristic viral, bacterial, mycotic or parasitic structures", "PROBLEM", 36, 100], ["the liver lesions", "PROBLEM", 108, 125], ["special histological staining methods", "TEST", 148, 185], ["Gram stain", "TEST", 187, 197], ["periodic acid Schiff", "TEST", 199, 219], ["reaction", "PROBLEM", 220, 228], ["Groccott silver stain", "TEST", 234, 255], ["agents", "TREATMENT", 345, 351], ["Clostridium piliforme (Tyzzer's disease", "PROBLEM", 360, 399], ["Salmonella spp.", "TREATMENT", 402, 417], ["Corynebacterium", "PROBLEM", 421, 436], ["bacterial", "OBSERVATION_MODIFIER", 58, 67], ["mycotic", "OBSERVATION", 69, 76], ["parasitic", "OBSERVATION_MODIFIER", 80, 89], ["liver", "ANATOMY", 112, 117], ["lesions", "OBSERVATION", 118, 125]]], ["However, since all test groups were equally affected, this finding is clearly not related to the l-carnitine treatment.", [["l-carnitine", "CHEMICAL", 97, 108], ["l-carnitine", "CHEMICAL", 97, 108], ["l-carnitine", "SIMPLE_CHEMICAL", 97, 108], ["all test groups", "TEST", 15, 30], ["the l-carnitine treatment", "TREATMENT", 93, 118]]], ["Additionally, it should be considered that these lesions were mainly of mild, subclinical grade and acute in character and therefore might have developed only in the last days (or the last week) of the study, thus rendering an influence on ACF formation or the onset of cardiovascular lesions unlikely.DiscussionNo definitive (sub-)intimal atherosclerotic lesions were observed in the aortas of the animals.", [["lesions", "ANATOMY", 49, 56], ["ACF", "ANATOMY", 240, 243], ["cardiovascular lesions", "ANATOMY", 270, 292], ["intimal atherosclerotic lesions", "ANATOMY", 332, 363], ["aortas", "ANATOMY", 385, 391], ["cardiovascular lesions", "DISEASE", 270, 292], ["atherosclerotic", "DISEASE", 340, 355], ["lesions", "PATHOLOGICAL_FORMATION", 49, 56], ["ACF", "CANCER", 240, 243], ["cardiovascular lesions", "PATHOLOGICAL_FORMATION", 270, 292], ["intimal atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 332, 363], ["aortas", "MULTI-TISSUE_STRUCTURE", 385, 391], ["these lesions", "PROBLEM", 43, 56], ["mild, subclinical grade and acute in character", "PROBLEM", 72, 118], ["the study", "TEST", 198, 207], ["ACF formation", "PROBLEM", 240, 253], ["cardiovascular lesions", "PROBLEM", 270, 292], ["definitive (sub-)intimal atherosclerotic lesions", "PROBLEM", 315, 363], ["lesions", "OBSERVATION", 49, 56], ["mild", "OBSERVATION_MODIFIER", 72, 76], ["subclinical grade", "OBSERVATION_MODIFIER", 78, 95], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["ACF", "OBSERVATION", 240, 243], ["cardiovascular", "ANATOMY", 270, 284], ["lesions", "OBSERVATION", 285, 292], ["sub", "OBSERVATION_MODIFIER", 327, 330], ["intimal", "OBSERVATION_MODIFIER", 332, 339], ["atherosclerotic", "OBSERVATION_MODIFIER", 340, 355], ["lesions", "OBSERVATION", 356, 363], ["aortas", "ANATOMY", 385, 391]]], ["The degenerative changes observed in the aorta of one control rat were interpreted as an incidental finding of unknown etiology and are in agreement with the previously reported rare spontaneous lesions described in old F344 rats (King and Russell 2006) .", [["aorta", "ANATOMY", 41, 46], ["lesions", "ANATOMY", 195, 202], ["aorta", "MULTI-TISSUE_STRUCTURE", 41, 46], ["rat", "ORGANISM", 62, 65], ["lesions", "PATHOLOGICAL_FORMATION", 195, 202], ["F344 rats", "ORGANISM", 220, 229], ["rat", "SPECIES", 62, 65], ["rats", "SPECIES", 225, 229], ["The degenerative changes", "PROBLEM", 0, 24], ["rare spontaneous lesions", "PROBLEM", 178, 202], ["degenerative", "OBSERVATION", 4, 16], ["aorta", "ANATOMY", 41, 46], ["incidental", "OBSERVATION", 89, 99], ["spontaneous", "OBSERVATION_MODIFIER", 183, 194], ["lesions", "OBSERVATION", 195, 202]]], ["Since this finding concerns only one animal in the control group, a carnitine-related cause can be excluded.", [["carnitine", "CHEMICAL", 68, 77], ["carnitine", "CHEMICAL", 68, 77], ["carnitine", "SIMPLE_CHEMICAL", 68, 77], ["can be excluded", "UNCERTAINTY", 92, 107]]], ["Additionally, it should be noted that rats, except for specially bred strains, generally do not develop atherosclerosis (King and Russell 2006; Moghadasian 2002) .", [["atherosclerosis", "DISEASE", 104, 119], ["rats", "ORGANISM", 38, 42], ["rats", "SPECIES", 38, 42], ["specially bred strains", "PROBLEM", 55, 77], ["atherosclerosis", "PROBLEM", 104, 119], ["atherosclerosis", "OBSERVATION", 104, 119]]], ["This fact together with differences in the composition of the gut microbiota, the metabolism of l-carnitine as well as the amount (1.3 g/l) of l-carnitine given to the apolipoprotein E-knockout mice might explain the divergent results of the study at hand to that conducted by Koeth et al. (2013) regarding the formation of atherosclerotic lesions.DiscussionIn conclusion, this study provides evidence that the daily administration of l-carnitine in concentrations of 70.4, 140.8 and 351.9 mg/kg bw/day for 1 year does not lead to an adverse effect in the colon or cardiovascular system of male F344 rats.", [["gut microbiota", "ANATOMY", 62, 76], ["atherosclerotic lesions", "ANATOMY", 324, 347], ["colon", "ANATOMY", 556, 561], ["cardiovascular system", "ANATOMY", 565, 586], ["l-carnitine", "CHEMICAL", 96, 107], ["l-carnitine", "CHEMICAL", 143, 154], ["atherosclerotic lesions", "DISEASE", 324, 347], ["l-carnitine", "CHEMICAL", 435, 446], ["l-carnitine", "CHEMICAL", 96, 107], ["l-carnitine", "CHEMICAL", 143, 154], ["l-carnitine", "CHEMICAL", 435, 446], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 62, 76], ["l-carnitine", "SIMPLE_CHEMICAL", 96, 107], ["l-carnitine", "SIMPLE_CHEMICAL", 143, 154], ["apolipoprotein E", "GENE_OR_GENE_PRODUCT", 168, 184], ["mice", "ORGANISM", 194, 198], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 324, 347], ["l-carnitine", "SIMPLE_CHEMICAL", 435, 446], ["colon", "ORGAN", 556, 561], ["cardiovascular", "ANATOMICAL_SYSTEM", 565, 579], ["system", "ANATOMICAL_SYSTEM", 580, 586], ["F344 rats", "ORGANISM", 595, 604], ["apolipoprotein E", "PROTEIN", 168, 184], ["mice", "SPECIES", 194, 198], ["rats", "SPECIES", 600, 604], ["l-carnitine", "TREATMENT", 96, 107], ["l-carnitine", "TREATMENT", 143, 154], ["the apolipoprotein E-knockout mice", "TREATMENT", 164, 198], ["the study", "TEST", 238, 247], ["atherosclerotic lesions", "PROBLEM", 324, 347], ["this study", "TEST", 373, 383], ["l-carnitine", "TREATMENT", 435, 446], ["an adverse effect in the colon", "PROBLEM", 531, 561], ["atherosclerotic", "OBSERVATION_MODIFIER", 324, 339], ["lesions", "OBSERVATION", 340, 347], ["colon", "ANATOMY", 556, 561]]]], "PMC7167749": [["Study subjects ::: MethodsOne hundred children, aged 1\u201323 months, were admitted to hospital due to respiratory infection\u2010related wheezing in 1992\u20131993, as described earlier in detail.12", [["respiratory", "ANATOMY", 99, 110], ["respiratory infection\u2010related wheezing", "DISEASE", 99, 137], ["children", "ORGANISM", 38, 46], ["children", "SPECIES", 38, 46], ["Methods", "TREATMENT", 19, 26], ["respiratory infection\u2010related wheezing", "PROBLEM", 99, 137], ["respiratory", "ANATOMY", 99, 110], ["wheezing", "OBSERVATION", 129, 137]]]], "d586f2bf78df2e4475a635bd2cdaaa85309afe3e": [["IntroductionAs the new emerging coronavirus, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV 2), spreads all over the world, new features of this coronavirus disease 2019 (COVID-19) is being reported.", [["coronavirus", "DISEASE", 32, 43], ["acute respiratory syndrome-coronavirus", "DISEASE", 52, 90], ["coronavirus disease", "DISEASE", 156, 175], ["coronavirus", "ORGANISM", 32, 43], ["severe acute respiratory syndrome-coronavirus 2", "ORGANISM", 45, 92], ["SARS-CoV 2", "ORGANISM", 94, 104], ["coronavirus", "ORGANISM", 156, 167], ["coronavirus", "SPECIES", 32, 43], ["-coronavirus", "SPECIES", 78, 90], ["severe acute respiratory syndrome-coronavirus", "SPECIES", 45, 90], ["SARS-CoV", "SPECIES", 94, 102], ["the new emerging coronavirus", "PROBLEM", 15, 43], ["severe acute respiratory syndrome", "PROBLEM", 45, 78], ["coronavirus", "PROBLEM", 79, 90], ["this coronavirus disease", "PROBLEM", 151, 175], ["COVID", "TEST", 182, 187], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["respiratory syndrome", "OBSERVATION", 58, 78], ["coronavirus disease", "OBSERVATION", 156, 175]]], ["It is reported that there might be some mechanisms by which the disease can affect the central nervous system (CNS) (1) .", [["central nervous system", "ANATOMY", 87, 109], ["CNS", "ANATOMY", 111, 114], ["central nervous system", "ANATOMICAL_SYSTEM", 87, 109], ["CNS", "ANATOMICAL_SYSTEM", 111, 114], ["the disease", "PROBLEM", 60, 71], ["disease", "OBSERVATION", 64, 71], ["central", "ANATOMY_MODIFIER", 87, 94], ["nervous system", "ANATOMY", 95, 109]]], ["Despite various neurological signs and symptoms, which have been reported (2) , there are only a few reported cases with documented specific neurological processes to explain the CNS signs (3) .", [["neurological", "ANATOMY", 16, 28], ["neurological", "ANATOMY", 141, 153], ["CNS", "ANATOMY", 179, 182], ["CNS", "ANATOMICAL_SYSTEM", 179, 182], ["various neurological signs", "PROBLEM", 8, 34], ["symptoms", "PROBLEM", 39, 47], ["documented specific neurological processes", "PROBLEM", 121, 163], ["CNS", "ANATOMY", 179, 182]]], ["To our knowledge, no cases of post infectious encephalitis (PIE) and its close follow up have been reported.", [["infectious encephalitis", "DISEASE", 35, 58], ["PIE", "DISEASE", 60, 63], ["post infectious encephalitis", "PROBLEM", 30, 58], ["infectious", "OBSERVATION_MODIFIER", 35, 45], ["encephalitis", "OBSERVATION", 46, 58]]], ["Herein we report a case with clinical (including respiratory and neurological), laboratory, chest Computed Tomography and Brain Magnetic Resonance Imaging (B-MRI) findings during evolution and convalescence phase which can illuminate the natural history of similar cases.Case reportA 39-year-old female presented to emergency department (ED) with fever, myalgias, anorexia, drowsiness and dry cough.", [["respiratory", "ANATOMY", 49, 60], ["neurological", "ANATOMY", 65, 77], ["fever", "DISEASE", 347, 352], ["myalgias", "DISEASE", 354, 362], ["anorexia", "DISEASE", 364, 372], ["drowsiness", "DISEASE", 374, 384], ["dry cough", "DISEASE", 389, 398], ["female", "ORGANISM", 296, 302], ["chest Computed Tomography", "TEST", 92, 117], ["Brain Magnetic Resonance Imaging", "TEST", 122, 154], ["convalescence phase", "TEST", 193, 212], ["fever", "PROBLEM", 347, 352], ["myalgias", "PROBLEM", 354, 362], ["anorexia", "PROBLEM", 364, 372], ["drowsiness", "PROBLEM", 374, 384], ["dry cough", "PROBLEM", 389, 398], ["chest", "ANATOMY", 92, 97], ["fever", "OBSERVATION", 347, 352], ["myalgias", "OBSERVATION", 354, 362], ["anorexia", "OBSERVATION", 364, 372], ["cough", "OBSERVATION", 393, 398]]], ["Fever and myalgias had been present for nine days; she did not experience any improvement with rest and anti-inflammatory drug (NSAIDS).", [["Fever", "DISEASE", 0, 5], ["myalgias", "DISEASE", 10, 18], ["Fever", "PROBLEM", 0, 5], ["myalgias", "PROBLEM", 10, 18], ["rest", "TREATMENT", 95, 99], ["anti-inflammatory drug (NSAIDS", "TREATMENT", 104, 134], ["myalgias", "OBSERVATION", 10, 18]]], ["She had prolonged exposure to a covid-19 patient for prior 2 weeks.", [["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48]]], ["Past medical history was otherwise insignificant.Case reportAfter presentation to ED (day 10), she demonstrated a decline in consciousness along with respiratory distress, ultimately needed endotracheal intubation.", [["respiratory", "ANATOMY", 150, 161], ["endotracheal", "ANATOMY", 190, 202], ["decline in consciousness", "DISEASE", 114, 138], ["respiratory distress", "DISEASE", 150, 170], ["a decline in consciousness", "PROBLEM", 112, 138], ["respiratory distress", "PROBLEM", 150, 170], ["endotracheal intubation", "TREATMENT", 190, 213], ["insignificant", "OBSERVATION_MODIFIER", 35, 48], ["respiratory", "ANATOMY", 150, 161], ["distress", "OBSERVATION", 162, 170], ["endotracheal intubation", "OBSERVATION", 190, 213]]], ["Chest CT showed multiple peripheral patchy ground-glass opacities with typical covid-19 distribution (day 10); these opacities later formed bilateral peripheral consolidation (day 22) (figure 1).", [["opacities", "DISEASE", 117, 126], ["Chest CT", "TEST", 0, 8], ["multiple peripheral patchy ground-glass opacities", "PROBLEM", 16, 65], ["these opacities", "PROBLEM", 111, 126], ["bilateral peripheral consolidation", "PROBLEM", 140, 174], ["multiple", "OBSERVATION_MODIFIER", 16, 24], ["peripheral", "ANATOMY_MODIFIER", 25, 35], ["patchy", "OBSERVATION_MODIFIER", 36, 42], ["ground-glass opacities", "OBSERVATION", 43, 65], ["typical", "OBSERVATION_MODIFIER", 71, 78], ["covid", "OBSERVATION_MODIFIER", 79, 84], ["19 distribution", "OBSERVATION_MODIFIER", 85, 100], ["opacities", "OBSERVATION", 117, 126], ["bilateral", "ANATOMY_MODIFIER", 140, 149], ["peripheral", "ANATOMY_MODIFIER", 150, 160], ["consolidation", "OBSERVATION", 161, 174]]], ["She was transferred to intensive care unit (ICU) and treated with broad-spectrum IV antibiotics (meropenem 1g tid, levofloxacin 750 mg daily, linezolide 600 bid), hydroxychloroqine 400 mg bid for the first day, then 200 mg bid, atazanavir 400 mg daily and immunoglobulin (IVIg) 25 g/day for 3days.", [["meropenem 1g tid", "CHEMICAL", 97, 113], ["levofloxacin", "CHEMICAL", 115, 127], ["linezolide", "CHEMICAL", 142, 152], ["hydroxychloroqine", "CHEMICAL", 163, 180], ["atazanavir", "CHEMICAL", 228, 238], ["IVIg", "CHEMICAL", 272, 276], ["meropenem", "CHEMICAL", 97, 106], ["levofloxacin", "CHEMICAL", 115, 127], ["linezolide", "CHEMICAL", 142, 152], ["hydroxychloroqine", "CHEMICAL", 163, 180], ["atazanavir", "CHEMICAL", 228, 238], ["meropenem 1g", "SIMPLE_CHEMICAL", 97, 109], ["tid", "SIMPLE_CHEMICAL", 110, 113], ["levofloxacin", "SIMPLE_CHEMICAL", 115, 127], ["linezolide", "SIMPLE_CHEMICAL", 142, 152], ["hydroxychloroqine", "SIMPLE_CHEMICAL", 163, 180], ["atazanavir", "SIMPLE_CHEMICAL", 228, 238], ["immunoglobulin", "SIMPLE_CHEMICAL", 256, 270], ["IVIg", "SIMPLE_CHEMICAL", 272, 276], ["immunoglobulin", "PROTEIN", 256, 270], ["broad-spectrum IV antibiotics", "TREATMENT", 66, 95], ["meropenem", "TREATMENT", 97, 106], ["levofloxacin", "TREATMENT", 115, 127], ["linezolide", "TREATMENT", 142, 152], ["hydroxychloroqine", "TREATMENT", 163, 180], ["atazanavir", "TREATMENT", 228, 238], ["immunoglobulin (IVIg)", "TREATMENT", 256, 277]]], ["RT-polymerase chain reaction (PCR) of a nasopharyngeal swab was negative for SARS-CoV2 yet she was admitted with a diagnosis of Covid-19, based on clinical history and chest CT scan findings.Case reportThe patient experienced an episode of self-limited generalized tonic-clonic seizure (GTCS) on the following day (day 11) treated with intravenous (IV) levetiracetam 500 mg bid.", [["nasopharyngeal swab", "ANATOMY", 40, 59], ["intravenous", "ANATOMY", 336, 347], ["tonic-clonic seizure", "DISEASE", 265, 285], ["GTCS", "DISEASE", 287, 291], ["levetiracetam", "CHEMICAL", 353, 366], ["levetiracetam", "CHEMICAL", 353, 366], ["nasopharyngeal swab", "CANCER", 40, 59], ["patient", "ORGANISM", 206, 213], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 336, 347], ["levetiracetam", "SIMPLE_CHEMICAL", 353, 366], ["patient", "SPECIES", 206, 213], ["RT-polymerase chain reaction", "TEST", 0, 28], ["PCR", "TEST", 30, 33], ["a nasopharyngeal swab", "TEST", 38, 59], ["SARS", "PROBLEM", 77, 81], ["Covid", "TEST", 128, 133], ["chest CT scan findings", "TEST", 168, 190], ["self-limited generalized tonic-clonic seizure (GTCS", "PROBLEM", 240, 291], ["intravenous (IV) levetiracetam", "TREATMENT", 336, 366], ["chain reaction", "OBSERVATION", 14, 28], ["nasopharyngeal", "ANATOMY", 40, 54], ["chest", "ANATOMY", 168, 173]]], ["She experienced another episode of GTCS on the same day, managed with increment in levetiracetam dosage (500 mg tid).", [["GTCS", "DISEASE", 35, 39], ["levetiracetam", "CHEMICAL", 83, 96], ["levetiracetam", "CHEMICAL", 83, 96], ["levetiracetam", "SIMPLE_CHEMICAL", 83, 96], ["GTCS", "PROBLEM", 35, 39], ["increment in levetiracetam dosage", "TREATMENT", 70, 103]]], ["After improvement of respiratory function, she was extubated (day 15).", [["respiratory", "ANATOMY", 21, 32], ["respiratory function", "OBSERVATION", 21, 41]]], ["Despite improvement in inflammatory and metabolic tests, she had a fluctuating level of consciousness.", [["inflammatory and metabolic tests", "TEST", 23, 55], ["a fluctuating level of consciousness", "PROBLEM", 65, 101], ["improvement", "OBSERVATION_MODIFIER", 8, 19], ["inflammatory", "OBSERVATION_MODIFIER", 23, 35]]], ["During investigation for decreased level of consciousness, B-MRI revealed T2-fluid attenuated inversion recovery (FLAIR) high signal intensities in bilateral thalami, medial temporal and pons (figure 2).", [["thalami", "ANATOMY", 158, 165], ["medial temporal", "ANATOMY", 167, 182], ["pons", "ANATOMY", 187, 191], ["thalami", "MULTI-TISSUE_STRUCTURE", 158, 165], ["medial temporal", "MULTI-TISSUE_STRUCTURE", 167, 182], ["pons", "MULTI-TISSUE_STRUCTURE", 187, 191], ["decreased level of consciousness", "PROBLEM", 25, 57], ["B-MRI", "TEST", 59, 64], ["T2-fluid attenuated inversion recovery (FLAIR) high signal intensities in bilateral thalami, medial temporal and pons", "PROBLEM", 74, 191], ["fluid attenuated", "OBSERVATION_MODIFIER", 77, 93], ["high signal", "OBSERVATION", 121, 132], ["bilateral", "ANATOMY_MODIFIER", 148, 157], ["thalami", "ANATOMY", 158, 165], ["medial", "ANATOMY_MODIFIER", 167, 173], ["temporal", "ANATOMY_MODIFIER", 174, 182], ["pons", "ANATOMY", 187, 191]]], ["Corresponding areas in T1 images were hypo-signal and without gadolinium enhancement or restriction on T1 post-contrast and diffusion weighted imaging (DWI) sequences, respectively.", [["gadolinium", "CHEMICAL", 62, 72], ["gadolinium", "CHEMICAL", 62, 72], ["diffusion weighted imaging (DWI) sequences", "DNA", 124, 166], ["Corresponding areas in T1 images", "TEST", 0, 32], ["gadolinium enhancement", "PROBLEM", 62, 84], ["diffusion weighted imaging", "TEST", 124, 150]]], ["Cerebrospinal fluid (CSF) analysis showed normal protein (19 mg/dl) and glucose (61 mg/dl) levels with no white or red blood cells.", [["Cerebrospinal fluid", "ANATOMY", 0, 19], ["red blood cells", "ANATOMY", 115, 130], ["glucose", "CHEMICAL", 72, 79], ["glucose", "CHEMICAL", 72, 79], ["Cerebrospinal fluid", "ORGANISM_SUBSTANCE", 0, 19], ["CSF", "ORGANISM_SUBSTANCE", 21, 24], ["glucose", "SIMPLE_CHEMICAL", 72, 79], ["red blood cells", "CELL", 115, 130], ["red blood cells", "CELL_TYPE", 115, 130], ["Cerebrospinal fluid (CSF) analysis", "TEST", 0, 34], ["glucose", "TEST", 72, 79], ["levels", "TEST", 91, 97], ["white or red blood cells", "PROBLEM", 106, 130], ["fluid", "OBSERVATION", 14, 19], ["no", "UNCERTAINTY", 103, 105], ["blood cells", "ANATOMY", 119, 130]]], ["PCR tests for detecting viruses including SARS-CoV 2 and herpes simplex virus in CSF were negative.", [["herpes simplex virus", "DISEASE", 57, 77], ["SARS-CoV 2", "ORGANISM", 42, 52], ["herpes simplex virus", "ORGANISM", 57, 77], ["CSF", "GENE_OR_GENE_PRODUCT", 81, 84], ["SARS-CoV 2", "SPECIES", 42, 52], ["herpes simplex virus", "SPECIES", 57, 77], ["SARS-CoV", "SPECIES", 42, 50], ["herpes simplex virus", "SPECIES", 57, 77], ["PCR tests", "TEST", 0, 9], ["viruses", "PROBLEM", 24, 31], ["SARS", "TEST", 42, 46], ["CoV", "TEST", 47, 50], ["herpes simplex virus in CSF", "TEST", 57, 84]]], ["No oligoclonal bands (OCB) was detected.", [["oligoclonal bands (OCB)", "PROBLEM", 3, 26], ["oligoclonal bands", "OBSERVATION", 3, 20]]], ["Autoimmune serologic markers including SS-A/SS-B and Anti-phospholipid antibodies were unremarkable.", [["SS-A", "GENE_OR_GENE_PRODUCT", 39, 43], ["SS-B", "GENE_OR_GENE_PRODUCT", 44, 48], ["Anti-phospholipid antibodies", "GENE_OR_GENE_PRODUCT", 53, 81], ["Autoimmune serologic markers", "PROTEIN", 0, 28], ["Anti-phospholipid antibodies", "PROTEIN", 53, 81], ["Autoimmune serologic markers", "TEST", 0, 28], ["SS", "TEST", 39, 41], ["A/SS", "TEST", 42, 46], ["Anti-phospholipid antibodies", "TEST", 53, 81], ["unremarkable", "OBSERVATION", 87, 99]]], ["There was a borderline positive anti-nuclear antibody (ANA=2.7, positive>1.2) result.", [["anti-nuclear antibody", "PROTEIN", 32, 53], ["a borderline positive anti-nuclear antibody", "PROBLEM", 10, 53], ["ANA", "TEST", 55, 58], ["borderline", "OBSERVATION_MODIFIER", 12, 22], ["positive", "OBSERVATION_MODIFIER", 23, 31], ["anti-nuclear antibody", "OBSERVATION", 32, 53]]], ["Other laboratory tests and their changes during disease course are listed in table 1.", [["Other laboratory tests", "TEST", 0, 22]]], ["These results led to the diagnosis of para-infectious encephalitis associated with COVID-19 and treatment with IVIg continued to a total dosage of 3g/kg of body weight (250g total) which resulted in considerable improvement in consciousness, but discontinued because of headaches (day 28).", [["body", "ANATOMY", 156, 160], ["encephalitis", "DISEASE", 54, 66], ["COVID-19", "CHEMICAL", 83, 91], ["IVIg", "CHEMICAL", 111, 115], ["headaches", "DISEASE", 270, 279], ["IVIg", "SIMPLE_CHEMICAL", 111, 115], ["body", "ORGANISM_SUBDIVISION", 156, 160], ["para-infectious encephalitis", "PROBLEM", 38, 66], ["COVID", "TEST", 83, 88], ["treatment", "TREATMENT", 96, 105], ["IVIg", "TREATMENT", 111, 115], ["body weight", "TREATMENT", 156, 167], ["consciousness", "PROBLEM", 227, 240], ["headaches", "PROBLEM", 270, 279], ["para-infectious", "OBSERVATION_MODIFIER", 38, 53], ["encephalitis", "OBSERVATION", 54, 66], ["considerable", "OBSERVATION_MODIFIER", 199, 211], ["improvement", "OBSERVATION_MODIFIER", 212, 223]]], ["She complained of diplopia and was drowsy, even though the orientation seemed fully recovered (day 28).", [["diplopia", "DISEASE", 18, 26], ["diplopia", "PROBLEM", 18, 26], ["drowsy", "PROBLEM", 35, 41], ["diplopia", "OBSERVATION", 18, 26]]], ["At this point, we continued the treatment with high dose methylprednisolone (500mg/day) IV for 6 days, after which the diplopia resolved and she regained complete consciousness.", [["methylprednisolone", "CHEMICAL", 57, 75], ["diplopia", "DISEASE", 119, 127], ["methylprednisolone", "CHEMICAL", 57, 75], ["methylprednisolone", "SIMPLE_CHEMICAL", 57, 75], ["the treatment", "TREATMENT", 28, 41], ["high dose methylprednisolone", "TREATMENT", 47, 75], ["the diplopia", "PROBLEM", 115, 127]]], ["Subsequent B-MRIs (figure 2) showed marked resolution of medial temporal and thalami involvements as well as partial improvement in pontine lesions after reinstitution of IVIg (day 22) and administration of methylprednisolone (day 33).", [["medial temporal", "ANATOMY", 57, 72], ["thalami", "ANATOMY", 77, 84], ["pontine lesions", "ANATOMY", 132, 147], ["medial temporal and thalami involvements", "DISEASE", 57, 97], ["methylprednisolone", "CHEMICAL", 207, 225], ["methylprednisolone", "CHEMICAL", 207, 225], ["medial temporal", "MULTI-TISSUE_STRUCTURE", 57, 72], ["thalami", "ORGAN", 77, 84], ["pontine lesions", "PATHOLOGICAL_FORMATION", 132, 147], ["IVIg", "SIMPLE_CHEMICAL", 171, 175], ["methylprednisolone", "SIMPLE_CHEMICAL", 207, 225], ["Subsequent B-MRIs (figure", "TEST", 0, 25], ["medial temporal and thalami involvements", "PROBLEM", 57, 97], ["pontine lesions", "PROBLEM", 132, 147], ["IVIg", "TREATMENT", 171, 175], ["methylprednisolone", "TREATMENT", 207, 225], ["marked", "OBSERVATION_MODIFIER", 36, 42], ["resolution", "OBSERVATION_MODIFIER", 43, 53], ["medial", "ANATOMY_MODIFIER", 57, 63], ["temporal", "ANATOMY_MODIFIER", 64, 72], ["thalami", "ANATOMY", 77, 84], ["partial", "OBSERVATION_MODIFIER", 109, 116], ["improvement", "OBSERVATION_MODIFIER", 117, 128], ["pontine", "ANATOMY", 132, 139], ["lesions", "OBSERVATION", 140, 147]]], ["Results of SARS-CoV2 serology tests taken during admission became available after discharge and were positive for both IgG and IgM.DiscussionBrain involvement during COVID-19 pandemic has been reported in various forms, but the prevalence and proportion of each type of involvement is unknown (2, 3) .", [["Brain", "ANATOMY", 141, 146], ["IgG", "GENE_OR_GENE_PRODUCT", 119, 122], ["Brain", "ORGAN", 141, 146], ["IgG", "PROTEIN", 119, 122], ["SARS-CoV2 serology tests", "TEST", 11, 35], ["IgG", "TEST", 119, 122], ["COVID", "TEST", 166, 171], ["pandemic", "PROBLEM", 175, 183], ["involvement", "OBSERVATION", 270, 281]]], ["Stroke and encephalitis are specific CNS disorders reported in COVID-19 but there are many reports of neurological findings without obvious pathophysiologic explanations.", [["CNS", "ANATOMY", 37, 40], ["neurological", "ANATOMY", 102, 114], ["Stroke", "DISEASE", 0, 6], ["encephalitis", "DISEASE", 11, 23], ["CNS disorders", "DISEASE", 37, 50], ["CNS", "ANATOMICAL_SYSTEM", 37, 40], ["Stroke", "PROBLEM", 0, 6], ["encephalitis", "PROBLEM", 11, 23], ["specific CNS disorders", "PROBLEM", 28, 50], ["COVID", "TEST", 63, 68], ["neurological findings", "PROBLEM", 102, 123], ["encephalitis", "OBSERVATION", 11, 23], ["without obvious", "UNCERTAINTY", 124, 139]]], ["The most common reported neurological manifestations have been headache, dizziness, encephalopathy and delirium.", [["neurological", "ANATOMY", 25, 37], ["headache", "DISEASE", 63, 71], ["dizziness", "DISEASE", 73, 82], ["encephalopathy", "DISEASE", 84, 98], ["delirium", "DISEASE", 103, 111], ["headache", "PROBLEM", 63, 71], ["dizziness", "PROBLEM", 73, 82], ["encephalopathy", "PROBLEM", 84, 98], ["delirium", "PROBLEM", 103, 111], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["headache", "OBSERVATION", 63, 71], ["encephalopathy", "OBSERVATION", 84, 98], ["delirium", "OBSERVATION", 103, 111]]], ["Some of these patients have been undergone a neurological workup, yet despite reports of CNS symptoms in up to 40% of these patients, there are only few cases where distinct etiology has been discovered (3).", [["neurological", "ANATOMY", 45, 57], ["CNS", "ANATOMY", 89, 92], ["patients", "ORGANISM", 14, 22], ["CNS", "ANATOMICAL_SYSTEM", 89, 92], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 124, 132], ["a neurological workup", "TEST", 43, 64], ["CNS symptoms", "PROBLEM", 89, 101], ["CNS", "ANATOMY", 89, 92]]], ["Among these there is only one established cases of encephalitis with evidence of virus in CNS (4) and another case with acute necrotizing encephalitis (ANE) but without evidence for direct viral invasion (5) .", [["CNS", "ANATOMY", 90, 93], ["encephalitis", "DISEASE", 51, 63], ["acute necrotizing encephalitis", "DISEASE", 120, 150], ["ANE", "DISEASE", 152, 155], ["CNS", "ANATOMICAL_SYSTEM", 90, 93], ["ANE", "CANCER", 152, 155], ["encephalitis", "PROBLEM", 51, 63], ["virus in CNS", "PROBLEM", 81, 93], ["acute necrotizing encephalitis", "PROBLEM", 120, 150], ["direct viral invasion", "PROBLEM", 182, 203], ["encephalitis", "OBSERVATION", 51, 63], ["evidence of", "UNCERTAINTY", 69, 80], ["virus", "OBSERVATION", 81, 86], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["necrotizing", "OBSERVATION_MODIFIER", 126, 137], ["encephalitis", "OBSERVATION", 138, 150], ["without evidence for", "UNCERTAINTY", 161, 181], ["viral", "OBSERVATION_MODIFIER", 189, 194], ["invasion", "OBSERVATION", 195, 203]]], ["The distribution of cerebral lesions in MRI for our patient was similar to both aforementioned cases but with more extensive and symmetrical involvement of thalami and medial temporal lobes.", [["cerebral lesions", "ANATOMY", 20, 36], ["thalami", "ANATOMY", 156, 163], ["medial temporal lobes", "ANATOMY", 168, 189], ["cerebral lesions", "DISEASE", 20, 36], ["cerebral lesions", "PATHOLOGICAL_FORMATION", 20, 36], ["patient", "ORGANISM", 52, 59], ["thalami", "CANCER", 156, 163], ["medial temporal lobes", "CANCER", 168, 189], ["patient", "SPECIES", 52, 59], ["cerebral lesions", "PROBLEM", 20, 36], ["MRI", "TEST", 40, 43], ["more extensive and symmetrical involvement of thalami and medial temporal lobes", "PROBLEM", 110, 189], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["cerebral", "ANATOMY", 20, 28], ["lesions", "OBSERVATION", 29, 36], ["extensive", "OBSERVATION_MODIFIER", 115, 124], ["symmetrical", "OBSERVATION_MODIFIER", 129, 140], ["involvement", "OBSERVATION", 141, 152], ["thalami", "ANATOMY", 156, 163], ["medial", "ANATOMY_MODIFIER", 168, 174], ["temporal lobes", "ANATOMY", 175, 189]]], ["The involvement of pons has not been present in previous reported cases.", [["pons", "ANATOMY", 19, 23], ["pons", "MULTI-TISSUE_STRUCTURE", 19, 23], ["The involvement of pons", "PROBLEM", 0, 23], ["pons", "ANATOMY", 19, 23]]], ["Contrary to the ANE case, in our patient there was no evidence for hemorrhage or necrosis in serial B-MRIs.", [["hemorrhage", "DISEASE", 67, 77], ["necrosis", "DISEASE", 81, 89], ["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["hemorrhage", "PROBLEM", 67, 77], ["necrosis", "PROBLEM", 81, 89], ["serial B-MRIs", "TEST", 93, 106], ["no evidence for", "UNCERTAINTY", 51, 66], ["hemorrhage", "OBSERVATION", 67, 77], ["necrosis", "OBSERVATION", 81, 89]]], ["A recent paper has described a number of B-MRI changes in COVID-19 patients, but none of them have been the same as those in our patient (6) .", [["patients", "ORGANISM", 67, 75], ["patient", "ORGANISM", 129, 136], ["patients", "SPECIES", 67, 75], ["patient", "SPECIES", 129, 136]]], ["Although in ANE the authors mentioned treatment with IVIg, but exact dosage, protocol and response to treatment has not been described.", [["IVIg", "SIMPLE_CHEMICAL", 53, 57], ["treatment", "TREATMENT", 38, 47], ["IVIg", "TREATMENT", 53, 57], ["protocol", "TREATMENT", 77, 85], ["treatment", "TREATMENT", 102, 111]]], ["Our patient before diagnosis of neurologic involvement had received IVIg (25 g/day for three days) as a part of treatment for COVID-19 severe pulmonary involvement; and after the CNS lesions were established, it was reinstituted and due to very good clinical and radiological response, we decided to continue IVIg therapy until complete recovery, unless there is a complication.", [["neurologic", "ANATOMY", 32, 42], ["pulmonary", "ANATOMY", 142, 151], ["CNS lesions", "ANATOMY", 179, 190], ["IVIg", "CHEMICAL", 68, 72], ["patient", "ORGANISM", 4, 11], ["IVIg", "SIMPLE_CHEMICAL", 68, 72], ["pulmonary", "ORGAN", 142, 151], ["CNS lesions", "CANCER", 179, 190], ["IVIg", "SIMPLE_CHEMICAL", 309, 313], ["patient", "SPECIES", 4, 11], ["neurologic involvement", "PROBLEM", 32, 54], ["IVIg", "TREATMENT", 68, 72], ["treatment", "TREATMENT", 112, 121], ["COVID-19 severe pulmonary involvement", "PROBLEM", 126, 163], ["the CNS lesions", "PROBLEM", 175, 190], ["IVIg therapy", "TREATMENT", 309, 321], ["a complication", "PROBLEM", 363, 377], ["severe", "OBSERVATION_MODIFIER", 135, 141], ["pulmonary", "ANATOMY", 142, 151], ["involvement", "OBSERVATION", 152, 163], ["CNS", "ANATOMY", 179, 182], ["lesions", "OBSERVATION", 183, 190]]], ["After administration of a total 250 g (3 g/kg) IVIg, it was stopped due to occurrence of headaches that seemed related to drug infusion.", [["IVIg", "CHEMICAL", 47, 51], ["headaches", "DISEASE", 89, 98], ["IVIg", "SIMPLE_CHEMICAL", 47, 51], ["IVIg", "TREATMENT", 47, 51], ["headaches", "PROBLEM", 89, 98], ["drug infusion", "TREATMENT", 122, 135], ["headaches", "OBSERVATION", 89, 98]]], ["After discontinuation of IVIg, the headaches resolved completely and due to presence of diplopia and drowsiness treatment was then continued with methylprednisolone (500 mg/day for six days), which led to complete resolution of neurological symptoms.", [["neurological", "ANATOMY", 228, 240], ["IVIg", "CHEMICAL", 25, 29], ["headaches", "DISEASE", 35, 44], ["diplopia", "DISEASE", 88, 96], ["methylprednisolone", "CHEMICAL", 146, 164], ["methylprednisolone", "CHEMICAL", 146, 164], ["IVIg", "SIMPLE_CHEMICAL", 25, 29], ["methylprednisolone", "SIMPLE_CHEMICAL", 146, 164], ["IVIg", "TREATMENT", 25, 29], ["the headaches", "PROBLEM", 31, 44], ["diplopia", "PROBLEM", 88, 96], ["drowsiness treatment", "PROBLEM", 101, 121], ["methylprednisolone", "TREATMENT", 146, 164], ["neurological symptoms", "PROBLEM", 228, 249], ["diplopia", "OBSERVATION", 88, 96]]], ["Upon discharge from the hospital, the patient was completely asymptomatic.", [["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["asymptomatic", "PROBLEM", 61, 73], ["asymptomatic", "OBSERVATION", 61, 73]]], ["We consider this type of brain involvement, a para-infectious autoimmune encephalitis, as we believe was the case for ANE patient, and recommend prompt immunotherapy upon diagnosis of similar cases.", [["brain", "ANATOMY", 25, 30], ["autoimmune encephalitis", "DISEASE", 62, 85], ["brain", "ORGAN", 25, 30], ["patient", "ORGANISM", 122, 129], ["patient", "SPECIES", 122, 129], ["brain involvement", "PROBLEM", 25, 42], ["a para-infectious autoimmune encephalitis", "PROBLEM", 44, 85], ["prompt immunotherapy", "TREATMENT", 145, 165], ["brain", "ANATOMY", 25, 30], ["autoimmune encephalitis", "OBSERVATION", 62, 85]]], ["The use of IVIg in severe COVID-19 patients may prevent or ameliorate CNS involvement, as seem to happen for our patient compared to ANE case.ConclusionNeurological involvement in COVID-19 is increasingly reported and the investigations regarding etiology, natural history and appropriate treatment are essential.", [["CNS", "ANATOMY", 70, 73], ["IVIg", "CHEMICAL", 11, 15], ["COVID", "DISEASE", 26, 31], ["IVIg", "SIMPLE_CHEMICAL", 11, 15], ["patients", "ORGANISM", 35, 43], ["CNS", "ANATOMICAL_SYSTEM", 70, 73], ["patient", "ORGANISM", 113, 120], ["ANE", "CANCER", 133, 136], ["patients", "SPECIES", 35, 43], ["patient", "SPECIES", 113, 120], ["IVIg", "TREATMENT", 11, 15], ["severe COVID", "TREATMENT", 19, 31], ["COVID", "TEST", 180, 185], ["appropriate treatment", "TREATMENT", 277, 298]]], ["As for our patient, neurological symptoms not correlated with respiratory and metabolic conditions should be an alarm for the possibility of CNS involvement.", [["neurological", "ANATOMY", 20, 32], ["respiratory", "ANATOMY", 62, 73], ["CNS", "ANATOMY", 141, 144], ["patient", "ORGANISM", 11, 18], ["CNS", "ANATOMICAL_SYSTEM", 141, 144], ["patient", "SPECIES", 11, 18], ["neurological symptoms", "PROBLEM", 20, 41], ["respiratory and metabolic conditions", "PROBLEM", 62, 98], ["CNS involvement", "PROBLEM", 141, 156]]], ["Similar to many other viral agents, SARS-CoV 2 seems capable of causing encephalitis.", [["SARS", "DISEASE", 36, 40], ["encephalitis", "DISEASE", 72, 84], ["SARS-CoV 2", "ORGANISM", 36, 46], ["SARS-CoV", "SPECIES", 36, 44], ["SARS", "PROBLEM", 36, 40], ["encephalitis", "PROBLEM", 72, 84], ["viral agents", "OBSERVATION", 22, 34], ["encephalitis", "OBSERVATION", 72, 84]]], ["The nature of etiology regarding encephalitis remains the matter of debate as both direct invasion and parainfectious mechanisms seem possible.", [["encephalitis", "DISEASE", 33, 45], ["encephalitis", "PROBLEM", 33, 45], ["direct invasion and parainfectious mechanisms", "PROBLEM", 83, 128], ["encephalitis", "OBSERVATION", 33, 45], ["invasion", "OBSERVATION", 90, 98]]], ["We recommend prompt assessment of CSF for overt signs of viral infection (marked cellular reaction, increased protein and positive PCR test) and considering immunotherapy with IVIg in cases compatible with para-infectious origin.", [["cellular", "ANATOMY", 81, 89], ["viral infection", "DISEASE", 57, 72], ["IVIg", "CHEMICAL", 176, 180], ["CSF", "ORGANISM_SUBSTANCE", 34, 37], ["cellular", "CELL", 81, 89], ["IVIg", "SIMPLE_CHEMICAL", 176, 180], ["prompt assessment of CSF", "TEST", 13, 37], ["viral infection", "PROBLEM", 57, 72], ["marked cellular reaction", "PROBLEM", 74, 98], ["increased protein", "PROBLEM", 100, 117], ["positive PCR test", "TEST", 122, 139], ["immunotherapy", "TREATMENT", 157, 170], ["IVIg", "TREATMENT", 176, 180], ["para-infectious origin", "PROBLEM", 206, 228], ["viral", "OBSERVATION_MODIFIER", 57, 62], ["infection", "OBSERVATION", 63, 72], ["marked", "OBSERVATION_MODIFIER", 74, 80], ["cellular reaction", "OBSERVATION", 81, 98], ["compatible with", "UNCERTAINTY", 190, 205], ["para-infectious origin", "OBSERVATION", 206, 228]]], ["The usefulness of prophylactic IVIg in severe COVID-19 and the role of serology in CSF for diagnosing neuroinvasion, remain interesting discussions that we are unable to comment about at this moment.DisclosuresFunding sources: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. ; PRO-BNP: pro b-type natriuretic peptide (pg/ml, abnormal>125); PCT: Procalcitonin (ng/ml, normal<0.5); Tn=troponin-n (ng/ml, normal<19);VBG: venous blood gas; WBC: white blood cells (per mm 3 ); ?: unknown because of decreased consciousness", [["venous blood", "ANATOMY", 495, 507], ["WBC", "ANATOMY", 513, 516], ["white blood cells", "ANATOMY", 518, 535], ["IVIg", "CHEMICAL", 31, 35], ["neuroinvasion", "DISEASE", 102, 115], ["decreased consciousness", "DISEASE", 571, 594], ["PRO", "CHEMICAL", 354, 357], ["IVIg", "SIMPLE_CHEMICAL", 31, 35], ["CSF", "ORGANISM_SUBSTANCE", 83, 86], ["PRO-BNP", "GENE_OR_GENE_PRODUCT", 354, 361], ["pro b-type natriuretic peptide", "GENE_OR_GENE_PRODUCT", 363, 393], ["Procalcitonin", "GENE_OR_GENE_PRODUCT", 422, 435], ["Tn", "GENE_OR_GENE_PRODUCT", 457, 459], ["troponin", "GENE_OR_GENE_PRODUCT", 460, 468], ["venous", "ORGANISM_SUBSTANCE", 495, 501], ["blood", "ORGANISM_SUBSTANCE", 502, 507], ["WBC", "CELL", 513, 516], ["white blood cells", "CELL", 518, 535], ["Tn", "PROTEIN", 457, 459], ["troponin", "PROTEIN", 460, 468], ["WBC", "CELL_TYPE", 513, 516], ["white blood cells", "CELL_TYPE", 518, 535], ["prophylactic IVIg", "TREATMENT", 18, 35], ["severe COVID", "PROBLEM", 39, 51], ["serology in CSF", "TEST", 71, 86], ["neuroinvasion", "PROBLEM", 102, 115], ["BNP", "TEST", 358, 361], ["type natriuretic peptide", "PROBLEM", 369, 393], ["PCT", "TEST", 417, 420], ["Procalcitonin", "TEST", 422, 435], ["Tn", "TEST", 457, 459], ["troponin-n (ng/ml", "TEST", 460, 477], ["VBG", "TEST", 490, 493], ["venous blood gas", "TEST", 495, 511], ["WBC", "TEST", 513, 516], ["white blood cells", "TEST", 518, 535], ["decreased consciousness", "PROBLEM", 571, 594], ["venous", "ANATOMY", 495, 501]]]]}